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CHAPTER 1 
Introduction 
 
1.1 Overview and Objectives 
Oral inhalation (OI) is a promising route for the administration of therapeutics 
including small molecules and biomacromolecules, such as nucleotides, peptides, and 
proteins, to (regionally) and through (systemically) the lungs.1, 2  The large surface area 
of the lungs, good epithelial permeability, and small aqueous volume at the absorptive 
surface are some advantages of systemic delivery via the pulmonary route.1  OI is 
especially attractive for the delivery of nucleic acids (deoxyribonucleic acid – DNA, and 
small interfering ribonucleic acid – siRNA, for example) as it provides for a direct and 
non-invasive means of targeting different regions of the lungs.  Fewer side effects are 
expected compared to intravenous (i.v.) administration, which is an indirect way of 
targeting the lungs, as lower dosages may be required due to enhanced local 
bioavailability.2 
However, despite all potential advantages, the use of OI to deliver nucleic acids 
for the treatment of medically relevant pulmonary diseases such as lung cancer, cystic 
fibrosis, and asthma, still remains relatively unexploited.3  The progress of OI 
formulations for the delivery of nucleic acids to the lungs has been hampered largely by 
the lack of efficient carriers capable of overcoming the lung architecture, the extra and 
intracellular barriers present in the lung tissue,4, 5 and formulation challenges.6, 7  We 
attempt to address some of these challenges in this work. 
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Polymeric nanocarriers (PNCs) have great potential when combined with OI 
therapies for the delivery of nucleic acids.  PNCs can be applied to condense, 
encapsulate or conjugate nucleic acids, so as to enhance their cellular internalization.  
Moreover, PNCs can protect nucleic acids from degradation, promote sustainable 
release, and offer versatility in terms of cellular internalization and targeting through 
conjugation of ligands.8  Ligand conjugation to PNCs have been shown to improve 
cellular uptake and specificity in cell binding.9  Reductive, pH-, and thermo-responsive 
polymers can be used as a strategy for escaping lysosomal degradation, and improving 
the release of the therapeutics.9, 10  Therefore, PNCs may offer unique opportunities to 
overcome extra and intracellular barriers to improve the delivery of therapeutics 
(including nucleic acids) to and through the lungs. 
Inhaled delivery systems can be divided in three categories: nebulizers, 
pressurized metered dose inhalers (pMDIs), and dry powder inhalers (DPIs).11  
Nebulizers are used mostly in hospitals and usually are not preferred by patients with 
pulmonary diseases because they are large, inconvenient,12 and have low delivery 
efficiency.13  pMDIs and DPIs are the two most commonly used OI devices for treatment 
of lung diseases,13 accounting for approximately 67% of the total sales in the respiratory 
market in 2007 – US, France, Germany, Italy, Spain, and UK.14  pMDIs are the most 
widely used OI devices because they are compact, portable, inexpensive, provide 
multiple and reproducible doses, and the environment is sealed – no degradation of the 
therapeutic.15, 16  DPIs also offer advantages – e.g. portability, compact, breath 
actuation, and no hand-mouth co-ordination is required – but humidity may cause 
powder aggregation and capsules to soften, and the respirable dose depends on the 
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inspiratory flow rate.15  On the other hand, pMDIs also can be used by patients with 
diseased lungs, because it is propellant-based and not respiratory driven,16, 17  and thus, 
they may be more suitable for children and elderly.  pMDIs are thus very strong 
candidates for the delivery of nucleic acids to and through the lungs.18  
Formulation Challenges.  In order to efficiently deliver DNA and siRNA to the 
lungs using pMDIs, several formulation challenges need to be overcome.  The first one 
is related to the aerodynamic particle size distribution, which needs to be between 1 and 
5 m for optimal lung deposition,1, 19, 20 although some published works have mentioned 
the range of 0.5 - 5 m.13, 21  The rationale is that particles having aerodynamic size >   
5 m trend to be deposited in the oropharynx and large conducting airways due to 
inertial impaction, those between 1 and 5 m are subject to gravitational sedimentation 
that occurs in the respiratory bronchioles and smaller airways, and those ≤ 0.5 m are 
deposited by diffusion (Brownian motion).22  Secondly, the particles need also to be well 
dispersed in the propellant to provide good aerosol performance,23, 24 that is, they must 
have a surface chemistry able to be well-solvated by the propellant to prevent particle 
aggregation.24-26  Finally, the effect of ethanol – the most used co-solvent in pMDIs to 
enhance solubility of therapeutics and excipients in propellant hydrofluoroalkanes 
(HFAs)27, 28 – on solvation of surfactant tail groups in HFAs needs to be better 
understood, since good solvation is pre-requisite for particle stabilization upon 
surfactant adsorption.26, 27, 29 
Nucleic Acid Delivery.  While traditional routes for the delivery of nucleic acids 
(i.v.,30-36 oral,36-40 and intranasal41-44) have been extensively discussed in literature, 
much less attention has been given to OI.  Nebulization is the most prominent OI 
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strategy that has been proposed so far for the delivery of nucleic acids to the lungs.6, 45-
53  However, current approaches (jet, ultrasonic, and mesh nebulizers)45 are still 
inefficient due to shearing forces causing degradation/denaturation of the nucleic acid,11 
adhesion to the device components,11 large residual dead volume, and evaporation.6, 54-
56  On DNA formulated in DPIs, some studies have demonstrated the potential of DNA-
based lipoplexes dry powders,57-59 and DNA-based polyplexes dry powders prepared by 
supercritical CO2 using chitosan (CS) as cationic PNC.
60, 61  Literature on the formulation 
of DNA in pMDIs has been fairly limited.54, 62  A single work discussing delivery of DNA 
applying HFA-based pMDI has been found up-to-date,54 and it consists in the use of 
surfactant-coated DNA particles prepared by reverse microemulsion.  On siRNA 
delivered to the lungs via DPIs, there are few reports describing preparation of siRNA-
based dry powders using supercritical CO2 and sugars,
63 particle replication in non-
wetting templates (PRINT),64 spray drying of siRNA encapsulated in poly(D,L-lactic-co-
glycolic acid) nanoparticles (PLGA NPs)65 and in cationic lipid-modified PLGA NPs.66  
To the best of our knowledge, no work has been reported about siRNA delivered to the 
lungs via pMDIs to date, and most of the in vivo studies use either intratracheal or 
intranasal routes.41, 67, 68 
Within this context, the objectives of this dissertation are: 
 
Objective # 01: Design PNCs capable of efficiently delivering nucleic acids to the 
lung epithelium.  Gene therapy is a promising approach for the treatment of genetic 
and chronic diseases, and its application to treat pulmonary disorders that affect both 
the alveoli and airways is of great relevance.69  In spite of the tremendous potential in 
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targeting DNA and siRNA to the lungs,70, 71 there several barriers that need to 
overcome.  Extracellular barriers include:4, 72-74 lung architecture, mucociliary and cough 
clearance processes, macrophages, neutrophils, mucus layer and lung surfactant.  
Intracellular barriers include:75-78 internalization, endolysosomal escape, nuclease 
degradation, release from the carrier, nuclear import and assembly into the RNA-
induced silencing complex (RISC) – these latter two for DNA and siRNA, respectively.  
Since administration of free DNA and siRNA does not lead to the desired therapeutic 
effect,76, 79 current research has focused on natural or synthetic carriers (viruses, lipids, 
peptides, and polymers) engineered to pack, protect, and deliver the nucleic acid to 
target cells.79, 80  In this work, cationic polymers were chosen as PNCs for DNA and 
siRNA because they provide an attractive alternative to viruses and lipids – the 
complexes formed between cationic polymers and nucleic acids are more stable and 
less toxic.36  Cationic polymers condense large genes into nanoparticles (NPs), protect 
them during cellular uptake and traffic, and provide flexibility since their physicochemical 
properties can be modulated by varying the polymer composition, molecular weight, 
architecture (linear, branched, dendrimer, block and graft copolymer), and chemistry 
(introduction of side chains and target-specific ligands).81  In addition, their biological 
responses can be regulated by their size, surface charge, polymer degradation rate, 
and the mechanism of nucleic acid release, all characteristics that  can be modulated.81  
We studied complexes formed between chitosan (CS) and DNA (CS-DNA polyplexes), 
and generation-four amine-terminated poly(amidoamine) dendrimer (PAMAM G4NH2) 
and siRNA (siRNA-G4NH2 dendriplexes).  The studies were initiated with DNA, but 
switched to siRNA because DNA-based therapies have a key disadvantage – in order to 
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be properly expressed, the DNA must enter into the nucleus of the target cell.  However, 
since such nuclear entry is a very inefficient process, this step has been faced as the 
biggest barrier to the success of DNA delivery.67  The delivery of double-stranded RNA 
(small interfering RNA – siRNA – typically consisting of 20-27 base pairs in length)82 
which targets the RISC located in the cell cytoplasm is a very promising approach with 
great therapeutic potential to treat many diseases.67  Moreover, there are also 
disadvantages associated with polyplexes and dendriplexes – (i) the sizes vary widely 
from as low as 50 nm to ca. 750 nm, with high polydispersity and variable shapes83-85 
which can affect the cellular uptake;86 (ii) the highly positive charges can be cytotoxic 
due to non-specific interactions with the cellular components,81, 87 and (iii) cause 
aggregation in negatively charged fluids (e.g. serum, bronchoalveolar lavage, mucus 
and lung surfactant);81, 83, 87  in addition, (iv) polyplexes and dendriplexes can be 
entrapped by the negatively charged mucus layer and lung surfactant components, and 
have reduced transport and cellular uptake.72  However, it has been demonstrated that 
charge is necessary, but not sufficient enough for cellular uptake.88  Direct conjugation 
of molecules to siRNA is an alternative that has demonstrated to increase the delivery 
efficiency to the target tissue, while maintaining the gene silencing activity.89  Therefore, 
in order to address these issues and have a PNC capable to overcome extra and 
intracellular barriers involved in pulmonary gene delivery, we designed and tested 
siRNA-PNC conjugates.  We used PAMAM G4NH2 as PNC, synthesized G4NH2-
siRNA conjugates, and tested their ability to deliver siRNA to the lung epithelium as a 
gene silencing strategy.  Details about the design and studies involving the CS-DNA 
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polyplexes, siRNA-G4NH2 dendriplexes, and G4NH2-siRNA conjugates will be further 
described in the following chapters. 
 
Objective # 02:  Develop oral inhalation formulations of PNCs containing DNA and 
siRNA in propellant-based metered-dose inhalers.  As discussed earlier, the direct 
targeting of DNA and siRNA to the lungs via OI administration has tremendous 
potential.70, 71  However, the use of pMDIs in pulmonary delivery of nucleic acids is still 
relatively unexploited, mainly due to challenges related to formulation – particles in 
suitable aerodynamic size for deep lung deposition,1, 13, 19 and containing an appropriate 
surface chemistry for solvation in propellant HFAs.24-26  In order to address these 
issues, we first developed a general platform for the delivery of nucleic acids to the 
lungs via pMDIs based on the engineering of core-shell particles.  Micron-sized core-
shell particles (polyplexes or dendriplexes as core, and a biodegradable water soluble 
co-oligomer as shell) were prepared by emulsification diffusion, which allows particle 
size modulation by changing the parameters.24  The shell was made from oligo(lactide)-
grafted-CS (OLA-g-CS) co-oligomer which is designed to be HFA-philic, and thus 
provides the appropriate surface chemistry for colloidal stability to the pMDI 
formulation.24  We tested this general platform to deliver two different types of DNA (CS-
DNA polyplexes) and siRNA (siRNA-G4NH2 dendriplexes) to the lung epithelium via 
pMDIs.  We also engineered mannitol spray-dried micron-sized particles to aid in the 
delivery of siRNA via OI pMDIs.  Mannitol is a sugar alcohol that is FDA approved for 
OI,15 it is clinically used for airway hydration,90 it has high aqueous solubility, and is 
generally recognized as safe (GRAS) excipient widely used as bulking agent and non-
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active carrier in DPIs.91, 92  It has been shown that micron-sized mannitol particles 
demonstrated less adhesion/cohesion in propellant HFA-134a, slower sedimentation 
rate, and superior aerosol performance than lactose ones.93  Moreover, since solvation 
is a pre-requisite for particle stabilization upon surfactant adsorption in suspension-
based pMDI formulations,26, 27, 29 the effect of ethanol as cosolvent in solvation is an 
important factor to be considered during the development of the pMDI formulation.  
Thus, in order to address this issue, we performed a study to evaluate the ability of 
ethanol mixed with propellant HFA to improve solvation of moieties of relevance to 
pMDIs.  We applied chemical force microscopy (CFM) to measure the adhesion force 
(Fad) between various moieties in 2H,3H-perﬂuoropentane (HPFP) mixed with ethanol. 
HPFP is a liquid at ambient conditions that mimics propellant HFAs.94  The Fad results 
were thus a measure of solvation in HFAs. Johnson-Kendall-Roberts (JKR) theory was 
used to model the experimental results.  Details about the design and studies involving 
the engineering of core-shell particles, the use of mannitol spray-dried particles, and the 
effect of ethanol in solvation will be further described in the following chapters. 
 
In Chapter 2 we present the literature review about carriers for pulmonary gene 
delivery, siRNA conjugates, extra and intracellular barriers to pulmonary delivery of 
nucleic acids, and pMDIs for the delivery of nucleic acids via OI administration. 
In Chapter 3 we discuss the effect of ethanol cosolvent in solvation forces in 
hydrofluoroalkanes.  The goal of this work was to evaluate the ability of ethanol added 
to propellant HFA to improve solvation of moieties of relevance in pMDIs.  Chemical 
force microscopy (CFM) was used to measure the adhesion force (Fad) between alkyl-, 
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ether- and ester-based moieties (C8/C8, COC/COC and COOC/COOC interactions) in 
liquid mixtures of HPFP and ethanol.  The C8 moiety was selected as baseline, as it 
represents the tail groups of surfactants currently used in commercial pMDI 
formulations, e.g. oleic acid and sorbitan trioleate,27, 95  which have very low solubility in 
HFAs,95 and are poorly solvated by HFAs alone, being unable to stabilize drug 
suspensions in HFAs.26, 27, 96  The COC and COOC moieties contain more polar groups, 
which provide possible sites to form strong polar interactions with the HFAs.28  The 
substrates and AFM cantilevers were surface-modified via solution deposition, and the 
CFM measurements were performed in a liquid cell.  Since there is no propellant HFA 
which is liquid at ambient conditions, HPFP was used because it is very well known to 
mimic HFAs.94  The Fad values were thus a measure of solvation in HFAs, and the 
Johnson-Kendall-Roberts (JKR) theory was used to model the experimental results.  
This chapter is based on the published manuscript: Conti, D. S.; Grashik, J.; Yang, L.; 
Wu, L.; da Rocha, S. R. P.  Solvation in hydrofluoroalkanes: How can ethanol help? 
Journal of Pharmacy and Pharmacology 2011, 64, (9), 1236-1244. 
In Chapter 4 we discuss the use of CS as PNC for DNA delivery (CS-DNA 
polyplexes) to the lung epithelium, and their formulation in pMDIs using engineered 
core-shell particles.  CS was selected as cationic PNC because it is biodegradable, 
biocompatible, and has shown low cytotoxicity in relevant epithelial models.36, 97  CS 
with molecular weight (Mw) varying between 10 and 100 kDa,98 when considered in 
combination with other relevant parameters such as degree of deacetylation (DDA), 
nitrogen/phosphate (N/P) ratio, pH and serum content of the culture medium, and cell 
type,36 seems to optimize the in vitro gene expression of the DNA.  Thus, large Mw CS 
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(100 - 300 kDa and 80% DDA) was depolymerized,99 and the Mw was characterized by 
viscometry.100  Calf Thymus DNA (18,940 bp) and a plasmid DNA (pDNA, 5,757 bp) 
encoding for green fluorescent protein (GFP) were chosen as models of nucleic acid.  
The use of two different DNAs (plasmid vs. linear) is relevant to demonstrate the 
applicability of the proposed approach for the delivery of a broad range of nucleic acids 
to the lungs.  CS-DNA polyplexes were characterized according to size, morphology, 
surface charge, complexation efficiency, and DNA protection against nuclease 
degradation.  Oligo(lactide)-grafted-CS (OLA-g-CS, the co-oligomer shell) was 
synthesized according to a modified method from literature,24, 101 and characterized by 
1H-NMR, FTIR and MALDI-TOF.  Emulsification diffusion was used to prepare the core-
shell particles (CS-DNA polyplexes as core and OLA-g-CS as shell) and the resulting 
micron-sized particles were characterized according to size, morphology, and DNA 
loading efficiency.  These microparticles were then formulated in propellant HFA-227, 
and the suspension-based pMDIs were evaluated according to their physical stability 
and aerosol performance using Andersen Cascade Impactor (ACI).  The biological 
functionality and integrity of the pDNA were demonstrated via in vitro gene transfection 
in A549 cell line (human lung adenocarcinoma cell line, an in vitro model of Type II 
alveolar epithelium)102 and gel electrophoresis, respectively.  In vitro cytotoxicity studies 
of CS and OLA-g-CS were performed in A549 cell line as well.  This chapter is based on 
the published manuscript: Conti, D. S.; Bharatwaj, B.; Brewer, D.; da Rocha, S. R. P.  
Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation. 
Journal of Controlled Release 2012, 157, (3), 406-417. 
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In Chapter 5 we discuss the use of PAMAM G4NH2 as PNC to deliver siRNA 
(siRNA-G4NH2 dendriplexes) to the lung epithelium, and their formulation in pMDIs 
using mannitol spray-dried micron-sized and core-shell particles.  PAMAM dendrimers 
are highly branched polymers with low polydispersity, high functionality, and provide an 
ideal structure for construction of effective drug carriers, gene transfer vehicles, and 
imaging of biological systems.103, 104  There has been a growing interest in the use of 
PAMAM with low generation (≤ G4) due to their low cytotoxicity at relevant 
concentrations.105  Dendriplexes were prepared and fully characterized according to 
size, morphology, surface charge, and siRNA complexation efficiency.  Their ability to 
protect the siRNA against nuclease degradation, and to release the siRNA at pH-
dependent in vitro conditions was evaluated according to different N/P ratios.  The in 
vitro gene knockdown of eGFP (enhanced green fluorescent protein) in A549 cell line 
(stably expressing eGFP) was demonstrated using siRNA before and after a long-term 
exposure in propellant HFA-227.  In vitro cytotoxicity studies of G4NH2 (pure and as 
dendriplexes) were performed in A549 cell line as well.  The siRNA-G4NH2 
dendriplexes were formulated in pMDIs using two strategies – mannitol spray-dried and 
core-shell particles.  The microparticles containing dendriplexes were characterized 
according to size, morphology, siRNA loading efficiency and integrity, and the 
suspension-based pMDIs were evaluated according to their physical stability and 
aerosol characteristics using ACI.  This chapter is based on the manuscript:  Conti, D. 
S.; Brewer, D.; Grashik, J.; Avasarala, S.; da Rocha, S. R. P. Dendrimer Nanocarriers 
and their Aerosol Formulations for siRNA Delivery to the Lung Epithelium. To be 
submitted to Molecular Pharmaceutics, 2013. 
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In Chapter 6 we discuss synthesis, characterization, and gene knockdown 
efficiency of G4NH2-siRNA conjugates.  As discussed earlier, free siRNA being 
delivered to lung cells is very susceptible to degradation, and it has poor cellular 
internalization.76  Current strategies (polyplexes, dendriplexes, and polyesteres NPs) for 
delivering siRNA have demonstrated limitations, and thus, a PNC with conjugated 
siRNA may offer unique opportunities to overcome extra and intracellular barriers 
encountered in the pulmonary epithelia.  In terms of conjugation, PAMAM dendrimers 
are very attractive as PNCs due to their very small size (c.a. 4.5 nm), molecular 
uniformity, and abundance of functional groups, which allows for chemical modification 
and linkage of different compounds, including imaging agents and ligands along with the 
therapeutic molecules.106  PAMAM G4NH2 and siRNA were conjugated via N-
succinimidyl 3-(2-pyridyldithio) propionate (SPDP) crosslinker, which allows a reducible 
disulfide bond between the dendrimer and siRNA, and it is expected to be cleaved 
preferentially in the reductive space of the cytosol, thus releasing the siRNA in its target 
site.89  G4NH2 was firstly reacted with SPDP crosslinker, and this intermediate 
conjugate was characterized using 1H-NMR, MALDI-TOF, UV-Vis Spectroscopy, and 
DLS.  Next, the G4NH2-PDP was reacted with siRNA, and the final G4NH2-siRNA 
conjugate was characterized via DLS, UV-Vis Spectroscopy, and non-denaturing 
agarose gel electrophoresis.  The ability of G4NH2-siRNA conjugates to deliver siRNA 
to the lung epithelium was tested using in vitro gene knockdown experiments in A549 
cells stably expressing eGFP.  This chapter is based on the manuscript: Conti, D. S.; 
Zhong, Q.; Patel, A. M.; da Rocha, S. R. P. siRNA-Dendrimer Conjugates for the Lung 
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Epithelium: Synthesis, Characterization, and Gene Silencing. To be submitted to 
Journal of the American Chemical Society, 2013. 
In Chapter 7 we discuss conclusions and future directions. 
 
1.2 Relevance and Innovation 
This research is innovative in several aspects.  Since gene knockdown or 
expression is relevant in the treatment of many lung diseases, the use of DNA and 
siRNA as therapeutics is very attractive.107  This is the first time that DNA and siRNA as 
polyplexes and dendriplexes are formulated and tested in pMDIs.  In addition, several 
reports describe the conjugation of siRNA with other compounds, e.g. hyaluronic acid 
(HA),108 PLGA,109 poly(ethylene glycol) (PEG),110-117 polylysine(PLL)-PEG-peptide,118 
gold119, 120 and magnetic NPs,121 quantum dots (QD),122, 123 -tocopherol,124 poly(PEG 
acrylate),125 amphipathic poly(vinyl ether),126 and cell penetrating peptides.127-129  
However, there is no literature reporting siRNA-dendrimer conjugates.  This research is 
also relevant as pMDIs are commonly used as OI devices for treatment of pulmonary 
diseases.13, 14  Therefore, this work contributes to the development of new gene-based 
therapies that may be employed in the treatment of medically relevant pulmonary 
diseases such as cystic fibrosis, lung cancer, tuberculosis, and asthma, among others, 
and aid in their further formulation in such inexpensive OI devices. 
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CHAPTER 2 
Literature Review 
 
2.1  Carriers for Pulmonary Gene Delivery 
Gene therapy is a broad term that involves any approach to treat diseases using 
intracellular transfer of nucleic acids (e.g. DNA and siRNA) to modulate cellular 
functions by expressing proteins, or inhibiting induction of specific genes.1, 2  Gene 
therapy has attracted attention in the fields of medicine, pharmacy, and 
bionanotechnology due to its potential for treating a large number of relevant diseases.3 
Exogenous gene transfer to the lungs provides an important strategy for the 
treatment of several heritable and acquired lung diseases.  Treatment of airway 
diseases, such as cystic fibrosis (CF), asthma, reactive airways dysfunction syndrome 
(RADS), primary pulmonary hypertension, bronchitis, and bronchiectasis, requires 
delivery of relevant genes to the airway epithelium.4-7  In contrast, the alveolar region is 
the target for diseases such as 1-antitrypsin deficiency, emphysema, chronic 
pulmonary microlithiasis, idiopathic pulmonary fibrosis (IPF), pulmonary alveolar 
proteinosis (PAP), acute respiratory distress syndrome (ARDS), interstitial lung disease 
(ILD), and respiratory syncytial virus (RSV) infection.4, 8-11  Chronic obstructive 
pulmonary disease (COPD) refers to two lung diseases, chronic bronchitis and 
emphysema, and it requires gene delivery to airways and alveoli.12  In addition, most 
types of lung cancer arise from the small bronchi/bronchioles and alveoli.13  While the 
promise in gene delivery to treat lung diseases is great, there are many challenges to 
overcome for the development of effective gene therapies to the lung tissue. 
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Due to the structural similarity between DNA and siRNA,14 the barriers to their 
delivery are somewhat similar.  Both nucleic acids must overcome the extracellular 
barriers present in the airways and alveolar epithelia, be internalized by the cell, and 
escape from lysosomal degradation.  However, while DNA needs to enter into the 
nucleus for initiation of transcription of the encoded gene, siRNA functions in the 
cytoplasm – this is a determinant advantage of siRNA over DNA15 especially for non-
mitotic cells, where nuclear internalization is significantly challenging.15, 16  RNA 
interference (RNAi, Figure 2.1) is a natural gene silencing pathway in eukaryotic cells by 
which sequence-specific siRNA is able to target and cleave complementary messenger 
RNA (mRNA).17  However, the lack of safe and effective siRNA and DNA carriers and 
effective portable OI formulations have hindered the clinical progress of lung gene 
therapy.18 
 
Figure 2.1.  Mechanism of RNAi in mammalian cells.
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Administration of free DNA, in most cases, results in insufficient quantities of 
intact coding sequences reaching the nucleus of the target cell.18  Similarly, free siRNA 
is readily degraded by nucleases, and does not cross the cell membrane through 
passive diffusion due to its large molecular weight (Mw ~ 13 kDa) and negative charge.  
Thus, administration of free siRNA usually fails to produce therapeutic effects as well.16  
Current research has focused on the use natural or synthetic carriers (viruses, lipids, 
peptides, and polymers) engineered to pack, protect, and deliver DNA and siRNA to 
target cells.18, 20 
Cationic polymers provide an attractive alternative to viruses and lipids, since 
they are able to form ionic complexes with DNA and siRNA, which are more stable and 
less toxic.21  Cationic polymers condense large genes into nanoparticles (NPs) and 
protect the nucleic acid during cellular uptake.  The use of cationic polymers provides 
flexibility since the chemical and physical properties of polyplexes (Figure 2.2) can be 
modulated by varying the polymer composition, Mw, architecture (linear, branched, 
dendrimer, block and graft copolymer) and chemistry (conjugation of side chains and 
target-specific ligands).22, 23  In addition, the biological response of the polyplexes can 
be regulated by their size, surface charge and polymer degradation rate.  The 
mechanism of DNA/siRNA release can be modulated as well.22  Several cationic 
polymers have been studied as carriers for DNA to the lungs, in vitro and in vivo, such 
as poly-L-lysine (PLL), poly-L-arginine (PLR), poly-L-ornithine (PLO), polyethylenimine 
(PEI), chitosan (CS) and poly(amidoamine) (PAMAM) dendrimers.24-33  Similarly, 
CS/siRNA, PEI/siRNA, folate-CS-g-PEI/siRNA, CS-g-PEI/siRNA, and PEG-PEI/siRNA 
polyplexes have shown gene knockdown in lung cells in vitro34-36 and in vivo.34, 35, 37-40 
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Figure 2.2.  Polyplexes are formed by electrostatic interactions between cationic polymer and negatively 
charged DNA/siRNA.
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However, the delivery of nucleic acids using polyplexes has some 
disadvantages.  Since the complexation process is electrostatic and entropically 
driven,41 attaining reproducible particles is extremely cumbersome,22 and the sizes vary 
widely from as low as ca. 50 to 500 nm, with high polydispersity and variable shapes42, 
43 which could affect the cellular uptake.44  Nevertheless, the size of DNA-based NPs  
needs to be maintained between 25 and 30 nm to facilitate nuclear transport.45, 46  
Moreover, siRNA is a stiffer molecule than DNA, and thus, a 21 bp siRNA is not likely to 
further condense.14  Disorderly interactions between siRNA and cationic polymers may 
result in low complexation efficiency and large NPs.14  siRNA-based polyplexes are also 
expected to be less stable due to the lower number of negative charges compared to 
DNA.47 
The highly positively charged polyplexes can also be cytotoxic due to non-
specific interactions with the cellular components.22, 48  Moreover, polyplexes may 
aggregate in negatively charged fluids (e.g. serum, BALF, mucus and lung 
surfactant).22, 40, 48  This aggregation reduces the number of positive charges or causes 
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charge reversal, increasing the size of the polyplexes49 which may have reduced 
cellular uptake and transfection efficiency.44  Moreover, positively charged polyplexes 
can be entrapped by the negative charged mucus layer and lung surfactant 
components, and thus have reduced transport and cellular uptake.50  Thus, the design 
of polyplexes with balanced cationicity level seems to be a plausible alternative to 
overcome the aforementioned hindrances. 
Another alternative for delivering genes to cells and tissues is the encapsulation 
of the nucleic acid within a biodegradable polymer matrix, usually polyesters such as 
poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and poly(D,L-lactic-co-glycolic acid) 
(PLGA).51, 52  Using this approach, the gene can be protected from degradation in a 
physiological environment, and such particles have enhanced cellular uptake compared 
to free nucleic acids.52  DNA/PLGA and siRNA/PLGA NPs have shown in vitro 
controlled-release ability over an extended period of time (> 30 days)43, 52, 53 and 
prolonged gene expression in vivo.29 
However, there are also disadvantages associated with gene delivery from 
biodegradable polymeric matrices: degradation of the nucleic acid during 
encapsulation,49, 54, 55 poor gene loading,48, 49 and reproducibility in size.51  Hydrolysis of 
PLA, PGA, and PLGA releases acidic moieties and produces low pH environment, 
which potentially can result in DNA/siRNA degradation.55, 56  Size and shape of the NPs 
are influenced by stabilizer and solvents used during their preparation.51  Most 
stabilizers lead to negatively charged NPs, and thus, the nucleic acid encapsulation is 
achieved by double emulsion technique, which results in low gene loading.48  The 
involvement of the nucleic acid with organic solvents can also impact its stability and 
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biological activity.48, 51, 54  The negative surface charges of PLA, PGA, and PLGA NPs 
may limit their interaction with the cell membrane, leading to poor internalization.43, 51  
Thus, surface modification of the polyester NPs with different chemistries, such as 
cationic polymers (e.g. PLA and PLGA NPs coated with cationic surfactant55 and 
chitosan43, 51) and PEG (e.g. PLA-PEG copolymer57) have been proposed as an 
alternative.  Different strategies for particle preparation also have been proposed 
(solvent diffusion,58 double- and single-emulsion, and spray-drying112,114,115,119,122). 
The development of therapies for gene regulation in the lungs requires the 
efficient delivery of the nucleic acid to the target site of action.59  siRNA has tremendous 
potential for the treatment of several pulmonary disorders, and clinical trials are already 
ongoing15, 60-62 – aerosolization (phase IIa) and nasal spray (phases I and II) of siRNA to 
treat RVS,63 inhalation to treat asthma (phase II),64 and intravenous (i.v.) for metastatic 
lung cancer (phase I).65  However, the delivery of stable and active siRNA to the lungs 
at high enough concentrations involves challenges in every step of the process.66  The 
biggest hindrance to siRNA therapy is its effective delivery to the intracellular milieu 
within region of interest.67  Viruses, complexation, and encapsulation in biodegradable 
polyesters NPs have been exploited in vitro and in vivo,19, 60 but still present 
disadvantages.  Thus, siRNA conjugated directly to the PNCs may be an interesting 
approach to overcome those limitations towards the success of the siRNA delivery. 
 
2.2 siRNA Conjugates 
Direct conjugation of molecules (e.g., antibodies, peptides and polymers) to 
siRNA is a potential alternative which can improve in vivo pharmacokinetic behavior of 
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the siRNA, enhance its biological half-life, increase its delivery efficiency to the targeted 
cell population, while maintaining the gene silencing activity,68 and hence is a viable 
strategy to overcome the extra and intracellular barriers present in the lungs.  Several 
reports have described the conjugation of siRNA with different compounds, e.g. 
hyaluronic acid (HA),69 PLGA,70 PEG,71-78 PLL-PEG-peptide,47 gold79, 80 and magnetic 
NPs,81 quantum dots (QD),82, 83 -tocopherol,84 poly(PEG acrylate),85 amphipathic 
poly(vinyl ether),86 and cell penetrating peptides.87-89  Thus, siRNA has a great 
versatility to be conjugated to several different molecules. 
Since siRNA is a hybridized molecule of two complementary strands (sense and 
antisense) there are four terminal ends as potential conjugation sites.  It has been 
observed that the integrity of the 5’-end of the antisense strand is important for the 
initiation of the RNAi mechanism.90  Therefore, the 3’- and 5’-ends of the sense strand, 
and the 3’-end of the antisense strand (Figure 2.3a), are considered potential sites for 
conjugation with minimal influence on RNAi activity.  In addition, most conjugates use 
cleavable linkages between siRNA and the conjugated molecule to facilitate the release 
of siRNA in the cell cytosol, such as acid-labile or reducible bonds (Figure 2.3b).68  
Disulfide bonds (S-S) are relatively stable in oxidizing environment, but can be easily 
cleaved by a reducing agent, forming two thiols (SH).  In a polymeric backbone, the S-S 
bonds are readily reduced in the intracellular environment by small redox molecules, 
such as glutathione (GSH) and thioredoxin, either alone or with the aid of a enzymatic 
machinery.91  GSH is very abundant in the cell cytoplasm, which functions as natural 
oxidant and the major reducing agent.92  The intracellular concentration of GSH ranges 
from 0.5 to 20 mM, which makes the cell cytosol more reductive than the extracellular 
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environment72 – e.g. 2 M GSH in plasma.92  Thus, the strategy of using disulfide bonds 
between the siRNA and the conjugated molecule provides a great opportunity for 
intracellular delivery of the siRNA as therapeutic.92 
 
 
Figure 2.3.  (a) Sites for conjugation onto siRNA (dashed circles), while the 5’-end of the antisense strand 
(solid circle line) is suggested to be free in order to keep the efficiency of the RNAi.
68
 (b) Disulfide bond 
(S-S) between the siRNA and the conjugated molecule (R) is reduced (2 HS-) due to the redox molecules 
(e.g. glutathione) present in the cytoplasm.
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Independent on the gene carrier, the critical issue in delivering siRNA to the 
lungs via OI administration is the modulation of the interaction of formulation/nanocarrier 
with the biological extra and intracellular barriers,93 which will be discussed next. 
 
2.3 Extra and Intracellular Barriers to Pulmonary Delivery of Nucleic Acids 
2.3.1  Lung physiology, mucus layer, and lung surfactant 
Some of the extracellular barriers present in the lungs (Figures 2.4 and 2.5) 
include the branched pulmonary architecture, clearance processes (mucociliary and 
cough) and immune responses mediated by macrophages and neutrophils.61, 94  In 
addition, mucus in the upper airways and surfactant in the lower airways represent the 
major barriers to cellular delivery of DNA and siRNA by entrapping the gene carriers 
and slowing down their diffusion.61 
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Figure 2.4.  Bifurcations of the lungs from trachea to alveolar sacs.
95
 
 
 
Figure 2.5.  Physical and immune barriers to successful lung nucleic acid transfer.
95, 96
 
 
The respiratory mucus lines the epithelium from the nose to the terminal 
bronchioles, and is mainly composed of a 3D network of cross-linked mucin chains 
(Figure 2.6a) which gives its viscoelastic properties.97  Inhaled materials are entrapped 
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by the mucus and continuously transported by the cilia to the esophagus (mucociliary 
escalator).  The location in the airways and the presence of pathologic conditions 
determine the thickness of the mucus layer (Figure 2.5).  In non-pathological conditions, 
the mucus thickness is between 10 - 30 µm in the trachea, and between 2 - 5 µm in the 
bronchi, but some reports suggest that its thickness can vary from 5 to 260 µm.50  
However, under pathological condition, such as CF, the thickness of the mucus layer 
can be even higher,50 and the viscosity and the composition of the mucus can also vary 
as well.50 
 
 
Figure 2.6.  (a) The mucus layer, a mixture of carbohydrates, glycoproteins and polysaccharides, resides 
on the surface of the airways epithelium and forms a barrier for nanocarriers.
97
 (b) Pulmonary surfactant, 
alveolar fluid and macrophages as barriers in the alveolus.
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Nanocarriers trying to cross the mucus layer will face three barriers: (i) the 
biopolymer network may block the diffusion of NPs by steric obstruction or by binding to 
the nanocarriers (function of the size and surface characteristics); (ii) macromolecules 
may also bind to the surface of the NPs, leading to aggregation; (iii) the removal of the 
mucus via mucociliary transport.50  Thus, nanocarriers would be ideally small (100 nm in 
diameter or smaller) so as to allow free and fast passive diffusion through the mucus 
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network.  In addition, the cationic surface of the NPs should be shielded by neutral and 
hydrophilic molecules to prevent strong interactions with the negatively charged 
biomolecules present in mucus.50 
Lung surfactant (composed by phospholipids and specific surfactant-associated 
proteins) covers the alveolar epithelium (Figure 2.6b)50, 98 and it is only ca. 50 - 80 nm 
thick.94  The major function of the lung surfactant is to diminish the surface tension at 
the air-water interface of the terminal airways.50, 98  Lung surfactant does represent a 
critical barrier to lipoplexes,99 but polyplexes (e.g. DNA-PEI and DNA-PAMAM) have 
been demonstrated to be more resistant in vitro100 and in vivo.101  However, the effect of 
the lung surfactant on the properties of the gene carriers and transfection efficiency has 
received little attention.99, 100, 102 
 
2.3.2 Cellular internalization 
Once inside the cell, the nucleic acid has to be carried across several other 
barriers in order to reach the desired target and exert its therapeutic effect.103  Even 
before that, however, the nanocarrier must first cross the cellular membrane which is 
composed of lipid bilayer, proteins (glycoproteins, proteoglycans and 
glycerolphosphates) and has a negative surface charge (Figure 2.7).  Phagocytosis, 
macropinocytosis, and endocytosis are the main internalization pathways in mammalian 
cells.104  Phagocytosis is performed by specialized cells (e.g. macrophages and 
neutrophils) on particles ca. 500 nm.104  In macropinocytosis, the large endocytic 
vesicles (1 - 5 m) acidify and shrink (Figure 2.7a).104  Clathrin-mediated endocytosis 
(CME) is the predominant endocytic mechanism in most of the cells – it can be 
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receptor-dependent (endocytic vesicles ca. 100 - 120 nm) or receptor-independent 
(fluid-phase endocytosis).104  CME leads to formation of early and late endosomes, and 
finally the lysosomes (the acidic and enzyme-rich environment ready for degradation of 
the NPs – Figure 2.7b).104  Caveolae-mediated endocytosis (CvME) is slower than 
CME, and gives rise to caveolar vesicles (ca. 50 - 100 nm) that can be delivered to 
caveosomes, avoiding the degradative acidic enzyme-rich environment from lysosomes 
(Figure 2.7c).104 
 
Figure 2.7.  Most common mechanisms of internalization and intracellular trafficking found in mammalian 
cells.
104
 
 
PNCs possess certain traits that can influence internalization and intracellular 
trafficking.  Size is important, but its impact may vary according to the cell type, surface 
charge, and presence of ligands.104  It has been observed that NPs < 200 nm are 
preferentially internalized by CME, while increasing the size (up to ca. 500 nm) alters 
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the mechanism to CvME.104  The surface charge of the NPs impacts the interaction with 
the cell membrane, endosomes, lysosomes, mucus and lung surfactant, and usually 
positively charged NPs display better association and internalization rates,104 but can 
stick in negatively charged components.50  PEGylation is a strategy to shield the surface 
charges of NPs, but can prevent endosomal/lysosomal escape50 and decrease cellular 
uptake.105  Ligands (e.g. cholesterol, folic acid, and lauroyl) onto NPs can promote 
delivery to a specific cell population and/or control the endocytosis pathway and 
intracellular trafficking.104  Folic acid (FA) is usually used as target ligand, since it has 
high affinity and specificity for folate receptors (FR)106 which are over expressed in 
several types of epithelial cells.107  FA is a ligand known to be internalized by CvME.104  
After FA receptor-mediated endocytosis, the FA-based conjugate is released into the 
cytosol for further metabolic processes, avoiding endolysosomal degradation.108  On the 
other hand, PAMAM G3NH2-lauroyl conjugates have been shown to be internalized at a 
higher rate by CME in HT-29 human colon adenocarcinoma cell line compared to 
G3NH2 alone, which was internalized by CvME.109  Therefore, understanding the 
mechanism of uptake and intracellular trafficking is of great relevance as both are 
influenced by the properties of the PNCs.104 
 
2.3.3 Endolysosomal escape 
Another obstacle to be addressed is the release of PNCs (and their cargo) from 
the endosomes (pH ca. 5.5 - 6) and lysosomes (pH ca. 4.5 - 5) into the cytoplasm.110  
The proton sponge effect (Figure 2.8)103 is thought to be the predominant mechanism 
utilized by synthetic cationic polymers to help the cargo to escape endolysosomal 
degradation.  Based on this hypothesis, the secondary and tertiary amines can exhibit 
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high buffering capacity in the pH range of 5 - 7, leading to the increase of protons and 
chloride ion influx during the endosome acidification, and thus, increase the osmotic 
pressure in the vesicle.  As consequence, the passive diffusion of water also increases, 
resulting in the swelling and rupture of the endosome, releasing the gene-based 
complexes to the cytoplasm.111 
 
Figure 2.8.  Proton-sponge hypothesis.  Protonation of the amine-based cationic polymer causes influx of 
protons and counter-ions into endocytic vesicles, increasing the osmotic pressure, and leading the vesicle 
to swell and rupture.
103
 
 
2.3.4 Degradation by nucleases in the cytoplasm 
The cell cytoplasm is a critical region to the stability of DNA and siRNA, which 
needs to be protected from degradation.  The majority of DNA enters into the nucleus 
during cell division, and thus, it must remain stable until the next disassembly of the 
nuclear envelope.111  Another factor that plays an important role in the nucleic acid 
transit through the cytoplasm is its rate of mobility.111  Large molecules such as free 
DNA have extremely low mobility in the cytoplasm, and thus, the formation of small and 
spherical NPs via complexation helps to increase the cytosolic mobility.111  On the order 
hand, siRNA is more prone to degradation than DNA due to the extra hydroxyl group in 
the siRNA backbone, which makes it more susceptible to hydrolysis by serum 
nucleases.14  Chemical modifications on the sugar-phosphate backbone of the siRNA 
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(e.g. 2’-fluoro and 2’-O-methyl)112 increases its stability, while complexation, 
encapsulation, and/or shielding provide additional protection.14 
 
2.3.5  Nucleic acid release from the carrier 
The process of nucleic acid dissociation from complexes is attributed to anionic 
molecules present in the cytoplasm which replace the anionic DNA or siRNA.111  
However, the DNA dissociation can also take place in the nucleus,111 the final 
intracellular barrier for DNA transfection.  Since the nuclear membrane disassembles 
during mitosis, even large DNA-based complexes can gain access to the nucleus.  
However, during interphase, the sole pathway to enter into the nucleus is through the 
nuclear membrane, and just very small molecules (ca. 50 kDa, ca. 10 nm) or ions are 
able to diffuse passively through the nuclear pores.  Since the upper size limit for this 
pathway of entry is ca. 25 - 30 nm,45, 46 it is extremely important to have DNA-based 
complexes as small as possible.111  In the case of siRNA delivery, the final intracellular 
barrier is its release into the cytoplasm followed by its assembly into the RISC.67  Most 
siRNA-based conjugates use cleavable linkages between the siRNA and the conjugated 
molecule, such as acid-labile (to be cleaved in the endosomes) or reducible bonds (to 
be cleaved in the cytosol) to facilitate the release of siRNA from the carrier.68 
 
2.4 PEGylation as Alternative to Overcome Extracellular Barriers in Gene 
Therapy to the Lungs 
One strategy to avoid interaction of NPs containing nucleic acids with mucus and 
lung surfactant is to modify them with biocompatible, hydrophilic, and biologically inert 
polymers, such as PEG50, so as to shield them from the external milieu.  This approach 
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may also reduce clearance by alveolar macrophages.50  The incorporation of PEG to 
complexes increases their aqueous solubility, reduces their serum protein coating, and 
prevents their aggregation.113  PEG may be covalently coupled to cationic polymers 
used to prepare polyplexes, and during the complexation process, the cationic polymer 
and the nucleic acid interact with each other, creating a hydrophobic core that is 
surrounded by a shield of hydrophilic molecules.  PEG can be also linked to the nucleic 
acid, e.g. siRNA-PEG conjugates,71-74, 76 and those can be used to prepare lipoplexes71, 
72 and polyplexes,72-74, 76 and the final NPs are surrounding by PEG molecules.  It has 
been demonstrated that PEGylated lipoplexes and polyplexes are able to achieve 
efficient nucleic acid delivery even in presence of CF mucus components at 
concentrations similar to the ones observed in vivo.50  PEGylation of PEI-DNA76,104 and 
PEI-siRNA110 polyplexes not only prevent aggregation of the NPs, but also provide 
shielding against charged anions, keeping their size stable and constant.50  In addition, 
PEG-PEI-siRNA polyplexes have showed better lung transfection in vivo.39  However, 
PEG chains at the surface of the nanocarriers can prevent endolysosomal escape.50  
PEGylated nanocarriers are also known to be less efficiently taken up by the cells.105  
Therefore, a balance between the positive charges from the cationic polymer, the size 
of PEG chains, and the PEG density on the complexes surface must be determined in 
order to achieve maximum gene delivery efficiency, or alternative strategies must be 
combined to overcome the PEGylation issues. 
 
2.5  pMDIs for the Delivery of Nucleic Acids via OI Administration 
Current routes for the regional delivery of nucleic acids to airway and alveolar 
epithelia include intranasal, intratracheal and oral inhalation (OI).45  OI of aerosolized 
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formulations is a non-invasive approach that may result in increased nucleic acid 
distribution to distal airways and alveoli.  pMDIs and DPIs are the OI devices commonly 
used for treatment of lung diseases,114 accounting for approximately 67% of the total 
sales in the respiratory market in 2007 – US, France, Germany, Italy, Spain, and UK.115  
pMDIs are of great relevance, as they are widely used because they are compact, 
portable, inexpensive, provide multiple and reproducible doses, and the environment is 
sealed – no degradation of the therapeutic.116, 117  pMDIs also can be used by patients 
with diseased lungs, because it is propellant-based and not respiratory driven,117, 118  
and thus, they may be more suitable for children and elderly.  Therefore, pMDIs may be 
preferred over DPIs,119 and become very strong candidates for the delivery of nucleic 
acids to and through the lungs.120  
A typical pMDI is composed by a canister sealed with a metering valve, 
positioned upside down in an actuator (Figure 2.9).  The compressed liquid propellant  
(> 98% of the formulation) is housed in the canister and in equilibrium with its vapor 
phase under saturation pressure.121  pMDIs can be formulated as solution (therapeutics 
dissolved in the propellant, usually with the aid of a co-solvent) or suspension 
(therapeutics dispersed in the propellant with or without excipients).  By pressing the 
actuator, the propellant and the ingredients are exposed to atmospheric pressure, 
forming an aerosol cloud containing the active therapeutic (with potentially other 
excipients) which is inhaled by the patient.121, 122 
In order to overcome solubility limitations, the industry has resorted to a large 
extent to the use of cosolvents, especially ethanol,123 not only as a solubility enhancer 
for drugs in solution formulations, but also as solubility enhancer for other excipients 
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(e.g. surfactants) in both solution and suspension formulations.121, 123  However, there 
are also many issues associated with the use of ethanol.118, 121, 123-125 
 
 
Figure 2.9.  Schematic diagram of a typical pMDI (adapted from 3M Pharmaceuticals). 
 
In solution-based formulations, ethanol may reduce the chemical stability, and 
depending on its concentration, it can adversely impact the aerosol performance.123, 126, 
127  In suspension-based formulations, ethanol may also affect the colloidal stability and 
aerosol characteristics.118, 128  While the enhancement of the solubility of surfactants in 
propellant HFAs upon the addition of ethanol is understood and well described in 
literature,120, 128, 129 the ability of ethanol to enhance the solvation of surfactant tail 
groups in HFAs, a pre-requisite for particle stabilization upon surfactant adsorption,123, 
130, 131 is less clear. 
Formulation of nucleic acids in pMDIs has received very little attention.  Only one 
work132 has reported the formulation of surfactant-coated DNA particles in pMDIs using 
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propellant HFA, which is approved by FDA.123  In that study, excipients and liposomes 
were used for improvement of colloidal stability, and in vitro transfection efficiency, 
respectively – however, addition of transfecting agent separately from the gene does 
not seem such a feasible strategy for commercial applications.  With respect to siRNA-
based propellant formulations, to the best of our knowledge, no work has been reported 
on pMDIs, and most in vivo studies have used either intratracheal or intranasal routes.67 
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CHAPTER 3 
Solvation in Hydrofluoroalkanes: How can Ethanol Help? 
 
3.1   Introduction 
Pressurized metered dose inhalers (pMDIs) are the most widely used portable 
oral inhalation (OI) devices,1, 2 and are usually associated with high compliance.3, 4  
pMDIs also offer an efficacious and convenient way of delivering drugs to the lungs for 
cases where repeated administration is necessary,5 and in disease states where 
moderate to high inspiratory flows cannot be achieved by the patient,6 as the aerosol 
formation in pMDIs is independent of inhalation effort.2  In a typical pMDI, the 
compressed liquid propellant, which is in equilibrium with its vapor, makes up 98% of 
the formulation.  pMDI formulations contain drugs either in solution, where the 
therapeutic is dissolved in the liquid propellant, usually with the help of a cosolvent, or in 
suspension, where drug crystals or amorphous drug particles are dispersed in the liquid 
propellant, usually with the aid of excipients including surfactants and cosolvents.2, 7 
Hydrofluoroalkanes (HFAs) are fluorinated short-chain alkanes with low degree 
of hydrogen substitution,8 which were introduced as propellants in pMDIs in the late 80’s 
due to the phasing out of chlorofluorocarbons (CFCs).9  HFAs are significantly less 
environmentally damaging than the fully halogenated CFCs.10  HFA-227 (1,1,1,2,3,3,3-
heptafluoropropane) and HFA-134a (1,1,1,2-tetrafluoroethane) are the two propellants 
currently used in commercial pMDIs.8, 11  They have been selected based on several 
criteria, including biological compatibility and inertness.12  However, due to their unique 
chemistry,10 HFAs have significantly different solvent properties compared to CFCs,8 
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including larger dielectric constant and dipole moment.13   HFAs have a dual character, 
being somewhat lipophobic, and at the same time hydrophobic.11, 14  Thus, most 
therapeutics of interest, and excipients used in previous CFC formulations have very 
low solubility in HFAs.10, 12 
In order to overcome solubility limitations, the industry has resorted to a large 
extent to the use of cosolvents, especially ethanol,12 not only as a solubility enhancer for 
drugs in the development of solution formulations, but also as solubility enhancer for 
other excipients, for both solution and suspension formulations.12, 15  However, there are 
also many issues associated with the use of ethanol.1, 7, 12, 15, 16  In solution-based 
formulations, ethanol may reduce the chemical stability of the system, and depending 
on its concentration, the presence of such low volatile compound mixed with the 
propellant can adversely impact the aerosol characteristics of the formulation.12, 13, 17  In 
suspension-based formulations, ethanol may also affect its physical stability and aerosol 
performance of the device.1, 18  In spite of these challenges, ethanol is still widely 
employed in suspension-based formulations so as to help enhancing the solubility of 
surfactant molecules, which are required to improve the physical stability of drug 
particles dispersed in the propellants,17 and thus the quality of the corresponding 
aerosol.3, 7 
While the enhancement of the solubility of surfactants in HFAs upon the addition 
of ethanol is understood, and well documented,2, 18, 19 the ability of ethanol to enhance 
the solvation of surfactant tail groups in HFAs, a pre-requisite for particle stabilization 
upon surfactant adsorption,12, 20, 21 is less clear. 
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The goal of this work was thus to investigate the ability of cosolvent ethanol to 
enhance the solvation of HFAs towards moieties relevant to pMDI formulations, such as 
those containing alkyl, ether, and ester groups.  In order to achieve this objective, the 
cohesive the force between candidate moieties was measured using chemical force 
microscopy (CFM) in mixtures of 2H, 3H-perfluoropentane (HPFP) – an excellent model 
for propellant HFAs, which is a liquid at ambient conditions8, 10 – and ethanol, at 
different volume fractions.  Johnson-Kendall-Roberts (JKR) theory was used to model 
the CFM results, and to gain insight on the contribution of ethanol as a solvation 
enhancer.  This work is novel because, for the first time, the enhancement in solvent 
capacity of HFAs upon the addition of cosolvent ethanol is being addressed 
quantitatively and systematically.  This is of importance as ethanol is a commonly used 
cosolvent in HFA-based pMDI formulations.  The results obtained from this work as a 
function of the chemistry of the moieties (alkyl, ether, and ester groups) are also novel 
and of relevance as they can help in the design of HFA-philic compounds, including 
surfactants and stabilizers, which may be used in the development of more efficient 
suspension-based pMDI formulations.  Finally, the results from this work help us 
evaluate the potential and limitations of predictive tools in understanding solvation in 
such novel and challenging fluids, the HFAs. 
 
3.2  Experimental Section 
3.2.1  Materials 
n-Octyltrichlorosilane (C8TS, > 95%), 3-Methoxypropyltrimethoxysilane (COCTS, 
> 95%), and Acetoxypropyltrimethoxysilane (COOCTS, >95%) were purchased from 
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Gelest Inc.  The molecular structures of these silanes that contain tail groups (alkyl, 
ether, and ester moieties) relevant to pMDIs are shown as insets in Figure 3.1.  Ethanol 
(100%, 200 proof) was purchased from Decon Labs.  2H, 3H-perfluoropentane (HPFP, 
98%) was purchased from DuPontTM TMC Ind. Inc.  Sulfuric acid (H2SO4, 95.8%) and 
toluene (HPLC grade, < 40 ppm of water, 99.9%) were purchased from Fisher Scientific.  
Hydrogen peroxide (H2O2, 30% solution) was purchased from EMD Chemicals Inc.  
Hydrochloric acid (HCl, 37%) was purchased from Mallinckrodt Chemicals.  Deionized 
water (DI-water, resistivity of 18.2 M.cm) was obtained from a NANOpure® 
DIamondTM UV ultrapure water system (Barnstead International).  Silicon nitride (Si3N4) 
triangular soft contact mode cantilevers with wedged tips were purchased from Budget 
Sensors (Model: SiNi).  The spring constant and the tip radius reported by the 
manufacturer are 0.06 N.m-1 and < 15 nm, respectively.  For tips within the same batch, 
the spring constant determined in our laboratory was found to be in the range 0.051 - 
0.069 N.m-1, and the tip radius 10 - 16 nm.  Among the tips evaluated, the spring 
constant was determined by measuring their resonant frequency22 using the 
NanoScope Image software, considering the dimensions, density, and elastic modulus 
as constant in the calculations.  The tip radii were measured using a TGT01 calibration 
silicon grating template (MikroMasch), and the Scanning Probe Image Processor (SPIP 
software, version 3.2.7.0, Image Metrology A/S) as described earlier.20 
 
3.2.2  Pretreatment of substrates and atomic force microscopy (AFM) tips 
Microscope cover glasses (22 x 22-2, from Fisher Scientific) were used as 
substrates.  For removing surface impurities, they were immersed in 5% (v/v) HCl 
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aqueous solution for 4 h, rinsed with DI-water, and immersed in DI-water overnight, 
followed by drying in oven.  They were then degreased in ethanol for 15 min using a 
sonication bath (VWR, P250D, set to 180 W), dried in air flow, and placed in freshly 
prepared piranha solution (70/30 v/v H2SO4/H2O2)
20 for 40 min.  The Si3N4 cantilevers 
were rinsed with ethanol, blown with a light stream of air, and immersed in freshly 
prepared piranha solution for 5 min.  The glass substrates and Si3N4 tips were 
subsequently rinsed with DI-water, ethanol, blown with a light stream of air, and dried in 
vacuum oven for 1 h before the surface chemical modification with silanes. 
 
3.2.3  Surface chemical modification of substrates and Si3N4 tips by solution 
deposition 
Dried glass substrates and Si3N4 tips were immersed in a 5 mM solution of 
C8TS, or COCTS, or COOCTS in toluene for 4 h at room temperature.  Compact and 
ordered monolayers of silane molecules on glass surfaces are known to be formed by 
solution deposition (after ca. 1.5 h).23  Similar success has been achieved on surfaces 
of Si3N4 tips (after ca. 1 h)
24.  The substrates and Si3N4 tips were washed vigorously in 
toluene after deposition, blown in a light stream of air, kept for 1 h in the vacuum oven, 
followed by storage in the desiccator overnight before the CFM experiments.  Our 
previous works20, 25 show that monolayers with excellent quality are formed using the 
earlier described protocol. 
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3.2.4  Chemical force microscopy (CFM) 
The adhesion force between the silane-modified Si3N4 tip and glass substrate 
was determined at room temperature using a PicoSPM LE AFM (Molecular 
Imaging/Agilent Technologies).  It is worth noticing that in our work, Fad is truly a 
cohesive force – forces are measured between tip and substrates modified with the 
same silane.12, 26   However, for consistency with the CFM literature,27-31 we will use the 
word adhesion instead.  All cantilever deflection-distance curves were obtained using a 
sealed liquid cell filled with a freshly prepared mixture of HPFP/ethanol (100/0, 90/10, 
70/30, 50/50, 30/70, 20/80, 10/90, 0/100 v/v).  HPFP is a liquid at ambient conditions 
that, because it has similar properties to HFAs, it has been extensively used as a model 
to propellants HFAs,7, 8, 14, 19, 20, 25  and is required in CFM measurements, as the 
experiments cannot be performed with propellants.  The cell was sealed by ring-shaped 
elastic on the bottom, and a ring-shaped film on the top.32  Prior the measurements, the 
cell was thoroughly washed with ethanol and rinsed with the respective HPFP/ethanol 
mixture.  To avoid deviations due to solvent evaporation, the whole HPFP/ethanol 
mixture was constantly replaced by a freshly prepared mixture in the liquid cell.  Fad 
measurements took place during the approach/retract cycles in nine different contact 
points, which were randomly distributed on the surface of the substrate 6000  6000 nm 
and with speed of 1 second per cycle.  At each contact point, 25 deflection-distance 
curves were recorded, and corrected by the slope of the curve.  Fad was calculated as 
the product between the cantilever deflection and the spring constant of the tip.20, 28  
Histograms of calculated Fad were fit to Gaussian distribution, from which the average 
Fad and deviation was obtained. 
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3.2.5 Modeling the adhesion force and molecular simulation 
The Fad between the chemically modified tip and substrate in liquid environment 
was calculated using the JKR theory29, 30 – Equation (1): 
tmsad WRF  .  .  .  
2
3
  (1) 
where R is the radius of curvature of the tip, and tmsW  is the work per unit of area 
required to separate the modified tip (t) and substrate (s) in the solvent medium (m).  
The JKR theory is based on the balance between interfacial and elastic distortion 
energies,29 on the assumption of perfect elastic interaction and frictionless interface, 
and on thermodynamic equilibrium.33  Changes in chain conformation of the sample 
create a disordered monolayer on the tip and substrate, which are only considered in 
models that account for plastic deformations.34 
Wtms was estimated based on individual interfacial free energies between the 
modified tip and the medium  tm , that between the substrate and the medium  sm , 
and that between the modified substrate and tip  st
15 – Equation (2):  
stsmtmtmsW     (2) 
In this work, considering that the modified tip and substrate have the same 
surface functional groups, then 0st , and tmsm  
30, and thus, Equation (2) 
becomes Equation (3): 
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12222   tmsmtmsW  (3) 
12  represents the interfacial free energy between the tail of the silane (1) (it contains 
the chemical moiety of interest – alkyl, ether, or ester) and the liquid medium (2) 
(HPFP/ethanol mixture).  HPFP is a liquid model for propellant HFAs.7, 8, 14, 19, 20, 25  12  
was calculated using the Girifalco-Good-Fowkes approach35 – Equation (4): 
    2/121
2/1
212112  2 2
ppdd
   (4) 
where 
1  and 2  are the total surface free energies of the silane tail, and that of the 
liquid medium, respectively, in equilibrium with the saturated vapor phase.  The upper 
scripts d and p represent, the dispersive and polar contributions of surface free energy, 
respectively. 
The total surface free energies  ti  for the C8 moiety, ethanol and HPFP were 
obtained from the literature as 21.6 (from n-octane),36  21.4,37  and 13.6 mN.m-1,8 
respectively.  For COC and COOC moieties, the total surface free energies were 
calculated using the Beerbower correlation38 – Equation (5): 
    3/1222 1 9.13    632.0 632.0 mhpdti V   (5) 
where  ’s are the Hansen Solubility Parameters:  d  is the dispersive, p  the polar, 
and h , the hydrogen bonding contributions [ (cal.mol
-3)1/2 ].  Those were calculated 
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using the expanded table of Beerbower’s group contribution.39  mV  represents the molar 
volume, estimated using Fedor’s group contribution.40 
For the C8 moiety and ethanol, the dispersive contribution of surface free energy 
 di  was taken from literature as 21.6 36 (same as ti  of n-octane, since 0pi 35 ) and 
18.8 mN.m-1 37 respectively.  For COC and COOC moieties, 
d
i  was calculated using 
Panzer correlation38 – Equation (6): 
dm
d
i V 
3/1
 0715.0  (6) 
The polar contribution of the surface free energy  pi  was estimated using the 
Fowkes approach41 – Equation (7): 
p
i
d
i
t
i    (7) 
No suitable experimental information or correlation was found to model the 
dispersive or polar contributions for HPFP.  These values were thus used as fitting 
parameters, which also served to shine light into the relative contributions of the 
dispersive/polar forces of HFAs in the solvation of the moieties containing alkyl, ether, 
and ester groups, as discussed later. 
  (total , dispersive and polar contributions) for the HPFP/ethanol mixture were 
calculated using a simple (ideal) mixing rule42 – Equation (8), where the parameter  
represents the volume fraction: 
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
m
i
ii  (8) 
The properties required in the calculation of the normalized adhesion force 
(Fad/R) using the JKR theory (along with the parameters obtained as discussed earlier) 
are listed in Table 3.1.  The total surface free energy calculated for COC and COOC 
moieties is comparable to the original silanes (22.7 and 25.7 mN.m-1, respectively).43, 44 
 
Table 3.1.  Molar volume, solubility parameters, and surface free energies for the chemistries used in this 
work.  These values were used in the calculation of Fad/R with the JRK theory. 
 
Chemistry 
 
Molar 
Volume 
(Vm, 
cm
3
.mol
-1
) 
 
 
Solubility Parameters 
(MPa
1/2
) 
 
 
Surface Free 
Energy (mN.m
-1
) 
 
Fad/R (mN.m
-1
) in 
pure HPFP 
 
d 
 
p h t 
(a) 
 
 
d 
 
 
 
p
 
 
 
t
 
 
CFM 
 
JKR 
 
C8 moiety 
COC moiety 
COOC moiety 
Ethanol 
HPFP 
 
- 
85.6 
99.8 
- 
- 
- 
15.1 
14.0 
- 
- 
- 
4.9 
4.9 
- 
- 
- 
4.7 
7.2 
- 
- 
- 
16.6 
16.5 
- 
-
 
 
21.6 
17.2 
15.5 
18.8 
8.4
(b)
 
 
0.0 
2.3 
3.9 
2.6 
5.2
(b)
 
 
21.6 
19.5 
19.4 
21.4 
13.6 
 
83.6 ± 32.1 
20.1 ± 2.7 
9.1 ± 1.9 
- 
- 
 
77.8 
20.0 
11.0 
- 
- 
 
(a) 2222
hpdt    
39
 
(b)
 It was used as a fitting parameter as no literature/correlation is available for its estimation. 
 
Molecular simulation was carried out using Gaussian 09.45  Full geometric 
optimization was performed at the semi-empirical PM6 level of theory.  PM6 was used 
as it has been shown to be a good choice for studying systems governed by hydrogen 
bonds,46 and it is computationally less expensive than more accurate models such as 
second order Møller Plesset (MP2), thus permitting the study of cluster systems as 
large as the one shown here.47 
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3.3  Results and Discussion 
CFM is a variation of AFM that utilizes functionalized tips and substrates in order 
to determine the cohesive forces (Fad) between chemical groups.
29  The chemical 
modification on the surfaces can be performed by self-assembled monolayers (SAMs) 
of covalently attached organosilanes.15, 24  SAMs of a large enough number of carbons 
in the tail group are expected to be highly oriented and ordered upon deposition, 
irrespective of the functional groups at the end of the monolayer.48  Fad is a direct 
measurement of the enthalpic penalty for creating interfaces between modified tip and 
solvent (and modified substrate and solvent as well) at the moment that the tip-
substrate contact is broken due to retraction of the cantilever.20  Small Fad  is obtained 
when the moieties on tip and substrate are well solvated; conversely, large Fad  are 
observed when the interaction between solvent and moieties is not as favorable.20  
Thus, Fad has been used to evaluate the solvation ability of non-polar and polar 
solvents,30 being a good predictor of solvation forces.3, 19, 20, 25 
In what follows, the experimental results of the normalized cohesive forces 
(Fad/R) from CFM measurements, and the modeling of those results using the JKR 
theory for alkyl (C8), ether (COC), and ester (COOC) moieties in the presence of 
different volume fractions of the cosolvent ethanol mixed with liquid HPFP are 
discussed.  The C8 moiety was selected as the baseline moiety, as it represents the tail 
groups of surfactants currently used in commercial pMDI formulations, e.g. oleic acid 
and sorbitan trioleate.12, 17  Alkyl-based surfactants, such as oleic acid and sorbitan 
trioleate have very low solubility in HFAs,17 and are poorly solvated by HFAs alone, 
being unable to stabilize drug suspensions in HFAs.7, 12, 20  The COC and COOC 
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moieties contain more polar groups, which provide possible sites to form strong polar 
interactions with the HFAs.15  The COC moiety is representative of compounds such as 
poly(ethylene glycol) (PEG) which is currently being used as an excipient in 
Symbicort®, a commercial HFA-based pMDI formulation.12  The COOC moiety is 
representative of biodegradable polymers such as poly(lactic acid) (PLA), which has 
been investigated as potential stabilizers in HFAs.3, 19, 25 
 
3.3.1 Solvation in HFAs without the presence of ethanol 
The Fad/R for C8/C8, COC/COC, and COOC/COOC in HPFP determined from 
the CFM measurements was 83.6 ± 32.1, 20.1 ± 2.7, and 9.1 ± 1.9 mN.m-1, respectively 
– the results are shown in Table 3.1.  The trend observed here is in agreement with that 
previously reported by our group.15, 20  These Fad results are relevant, as they provide a 
quantitative scale of solvation in HFAs, where the reference state – ideal solvation – is 
that of Fad/R  0 mN.m
-1.20  The results obtained here can thus be correlated with the 
ability of the semi-fluorinated solvents to solvate the candidate compounds containing 
alkyl, ether, and ester moieties.  The COOC moiety was found to be the most HFA-
philic, followed by the COC fragment.  The C8 moiety, the control group, was observed 
to be poorly solvated by HPFP, as expected.  These results suggest that the COOC 
moiety would be the best candidate in screening inter-particle forces in HFA 
suspension-based formulations. 
It is interesting to note that the JRK theory can be used to estimate the Fad/R, 
and equally as important, that the theory shows a trend similar to that observed in the 
CFM experiments – values are summarized in Table 3.1.  The favorable (and 
69 
 
 
 
enhanced) enthalpic interactions between HFA and COOC and COC fragments 
captured experimentally and with the JRK theory are expected due to the presence of 
the more polar oxygen-containing groups, which are capable of interact with the 
HPFP.12, 20, 25  The dipole moment of HPFP is very similar to that of HFA-227 and HFA-
134a,12 the two propellants approved for inhalation use.11, 21  At the same time, the 
significant dipole and also the presence of bulkier fluorine atoms, negatively impact the 
ability of semi-fluorinated propellants to solvate non-polar tails such as C8.20, 21, 25  The 
results obtained here are in line with previous ab-initio calculations,20, 25 which showed a 
more favorable binding energy (Eb) between HFA and fragments with increasing 
polarity. 
 
3.3.2 Solvation in HFAs in the presence of ethanol 
The Fad/R for the candidate tails measured in HPFP/ethanol mixtures was also 
determined.  Experimental and calculated (JKR) results are summarized in Figure 3.1 – 
the Fad/R decreases upon increasing the volume fraction of ethanol in the liquid mixture 
with HPFP.  The same trend is seen for all moieties.  These results suggest that ethanol 
indeed has the ability to enhance the solvent environment for all compounds containing 
alkyl, ether, and ester moieties investigated here, as detected by a reduction in the 
cohesive forces. 
At 15% (v/v) ethanol, which is in the upper range of volume fraction of ethanol 
used in commercial HFA-based pMDI formulations,49, 50 the Fad/R was reduced to 55 
mN.m-1 (34 %) for C8, 7.5 mN.m-1 for COC (63 %), and down to 3 mN.m-1 for COOC 
tails (67 %). 
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Figure 3.1.  Effect of the volume fraction of ethanol on the Fad/R of (a) alkyl (C8)- ; (b) ether (COC)- ;         
(c) ester (COOC)-based moieties. (  ) CFM measurements were at 298 K and in HPFP/ethanol mixtures; 
(  ) Fad/R calculated using the JKR theory, considering d  = 18.8, p  = 2.6, and t  = 21.4 mN.m
-1
 for 
ethanol; and ( - - - ) Fad/R calculated using the JKR theory, considering for ethanol: d  = 18.8, p  = 0.0, 
and t  = 18.8 mN.m
-1
.  Insets: Molecular structures of (a) C8TS; (b) COCTS; and (c) COOCTS. The 
moieties of interest are shown in brackets. 
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While the Fad/R numbers have not been quantitatively correlated with the ability 
of surfactants to stabilize particle-suspensions in HFAs, i.e., no threshold number has 
been attributed to a region of stability vs. a region of instability, a reduced cohesive 
force between drug particles due to the introduction of surfactants in HFAs has been 
demonstrated to correlated with enhanced particle dispersibility, and improved aerosol 
performance of the corresponding formulation.19, 51 
It can also be seen that the presence of ethanol has a much greater impact in the 
systems containing COC- and COOC-based moieties, than in that containing the C8 
groups.  It can be also seen that, even at high volume fractions of ethanol, the Fad/R, 
especially for C8, falls very far from that expected in case of ideal solvation            
(Fad/R  0 mN.m
-1).20  A volume fraction of ethanol of 48% is required in the C8/C8 
system in order to achieve the same level of solvation observed for the system with 
COC/COC and no ethanol, and 80% to reach Fad/R values for COOC/COOC in pure 
HPFP.  However, such high amounts of ethanol in pMDI formulations are not practical, 
since it has been shown that the presence of such high concentrations of non-volatile 
excipients mixed with HFA dramatically (and negatively) impacts the aerosol 
performance of both solution13, 49 and suspension formulations,1, 18 as the vapor 
pressure of the mixture is significantly reduced.7, 49 
The results presented here suggest, therefore, that in the range in which ethanol 
may find use in commercial HFA-based formulations (0 - 15% v/v),49, 50 its ability to 
enhance the solvation capacity of HFA is very limited for excipients containing alkyl 
(non-polar) fragments, such as is the case of most surfactants in FDA-approved pMDI 
formulations.12  It is interesting to put the results observed here in perspective with 
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particle-particle force interactions obtained in liquid HFPF in the presence of surfactant 
and ethanol.  The adhesive forces between salbutamol particles was shown to be 
suppressed upon the addition of 7% (v/v) ethanol in HPFP by about 87% when in 
presence of 1 mM oleic acid (surfactant with alkyl tails).19  However, that system still 
exhibited very fast flocculation of the formulation in HFA, indicating that such reductions 
in particle forces or Fad/R are not enough to enhance the solvation of alkyl tails to levels 
required for particle stabilization in propellant HFAs. 
 
3.3.3 Fad/R in presence of ethanol – analysis from CFM measurements and JKR 
theory 
In the JKR model, the interaction forces are only considered inside the contact 
region between tip and planar surface of the substrate, and therefore, this model is 
better applied in the case of soft samples with large adhesion, and tips with large radius 
of curvature.27  However, this theory yields satisfactory results for other systems as 
well.24, 27, 30  While limitations in the theory do exist, the JKR model is known to provide 
better overall agreement with Fad when compared to other theories, such as Derjaguin-
Muller-Toporov (DMT) and Hertz,33 and was thus employed in this work.  The Fad/R 
results determined from JKR theory are shown in Figure 3.1 (lines). 
Overall, the JRK results correlate well with those determined by CFM – compare 
solid line against the symbols in Figure 3.1a, 3.1b, and 3.1c, when the dispersive and 
polar contributions of surface free energy of HPFP were set to 61.8 and 38.2 %, 
respectively (Table 3.1).  The best agreement between theory and experiment was 
found for the ether moiety (Figure 3.1b).  For the COOC moiety, a minimum in the 
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calculated Fad/R was predicted at around 65% (v/v) ethanol in HPFP, representing a 
qualitatively different trend compared to that observed experimentally.  This may be at 
least in part explained based on the strong polar nature of the interactions between 
HPFP and ethanol, and that between the solvents and the ester group of the moiety in 
question, which may not be accurately captured by the theory or the simple mixing rules 
used in our calculations. 
The agreement between the Fad/R from the JKR theory and the CFM 
experiments as a function of the HPFP/ethanol ratio for the alkyl moiety, on the other 
hand, was observed to be inadequate – compare the solid line against symbols in 
Figure 3.1a.  One hypothesis for this behavior is that the very polar ethanol molecules, 
when in presence of non-polar moieties, such as the alkyl-based fragments evaluated in 
this work, will tend to enhance the polar interactions among themselves, so as to 
minimize the energy of the system.  According to this hypothesis, the non-polar part of 
the ethanol molecules (CH3-CH2-) will be the ones predominantly interacting with the 
alkyl tails; i.e., ethanol/C8 interactions in that case would resemble much more the 
interaction between two non-polar molecules, than between a highly polar and a non-
polar group.  Such behavior is not well captured by the theory in question, as the 
interfacial energy used in the calculation of Fad is highly affected by the distribution of 
polar and dispersive contributions of the solvent and tail groups – Equations (3) and (4). 
This hypothesis was tested via molecular simulations, and the result is presented 
in Figure 3.2a and 3.2b.  In this simulation, a central propane molecule (representing 
the non-polar alkyl group) is left to interact with a cluster of methanol molecules.  
Methanol was chosen instead of ethanol to prove the point in question in a more 
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obvious way (methanol is a more polar short molecule which magnifies the dipole-driven 
interactions), and in order to reduce the computational effort of the simulation.  Starting 
with a cluster of methanol molecules distributed around a central alkyl group – Figure 
3.2a – it can be observed that the polar molecules preferentially interact with each other 
– Figure 3.2b.  The methanol molecules form a cluster, and at the same time orient 
themselves in a way so as to have their polar hydroxyl groups pointing away from the 
non-polar alkyl groups.  Based on this observation, the Fad/R was recalculated using the 
JKR theory, except that now the nature of solvation was considered purely dispersive; 
i.e., the dispersive, polar, and total contributions of surface free energy of ethanol was 
set to 18.8, 0.0, and 18.8 mN.m-1, respectively.  The results from this calculation are 
shown in Figure 3.1a – dashed line.  It can be observed that the Fad/R calculated in this 
way agrees much better with the experimental values, thus suggesting that the 
dispersion forces of ethanol are indeed of great relevance to the solvation of the alkyl 
tails. 
This potential structuring effect of ethanol seen in the system discussed earlier 
seems to be related to that observed in previous works on the solubility of solutes in 
water/ethanol mixtures (ethanol was also being used as cosolvent).52-54  There is an 
enhancement of the hydrophilic interactions between the hydroxyl groups from ethanol, 
which work as promoters of hydrophobic interactions54, i.e., dispersive interactions 
between alkyl groups and non-polar segment from ethanol.  In fact, it has been reported 
that ethanol can form hydrophobic interactions with the exposed alkyl residues of 
proteins.53  A further increase in ethanol concentration makes the structuring effect on 
the solvent even more relevant,53 behavior that we have also in the Fad measurements 
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between C8/C8 tails, as evidenced by the more pronounced deviation between 
experimental and calculated Fad/R observed as the volume fraction of ethanol 
(cosolvent) mixed with HPFP (solvent) increased. 
 
3.4 Conclusions 
In this work we investigated the ability of cosolvent ethanol in HPFP/ethanol 
mixtures to enhance the solvation of compounds containing alkyl, ether, and ester 
moieties, which are of relevance to HFA-based pMDI formulations.  CFM was used to 
determine the Fad between surfaces containing the moieties of interest (alkyl, ether, and 
ester) in HPFP/ethanol liquid mixtures with varying volume fractions of ethanol.  HPFP 
was used as liquid model for HFAs in the CFM measurements.  The normalized 
adhesion force (Fad/R) in HPFP was thus used as a measure of the solvation forces. 
The CFM experimental results show that ethanol is indeed capable of enhancing 
the solvation of all fragments, and that the solvation increases as the volume fraction of 
ethanol increases.  However, for the alkyl moiety, volume fractions of ethanol much 
larger than those typically employed in commercial formulations (< 15%) are required to 
achieve a level of solvation comparable to that of the ether moiety in pure HPFP.  The 
effect of ethanol in the solvation of the ether fragment is much more pronounced (same 
for the ester fragment), thus suggesting the potential of ethanol to be applied in PEG-
based pMDIs.  The Fad/R was calculated using the JKR theory, which shows the 
potential for modeling the CFM experimental results.  Fad/R determined by JKR theory 
suggests a strong dispersive contribution to the solvation of the alkyl tails in 
HPFP/ethanol mixtures.  Thus, the results help us evaluate the potential and limitation 
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of predictive tools in understanding solvation in HFAs, such novel and challenging 
fluids.  Because ethanol is a commonly used cosolvent in HFA-based pMDI 
formulations, the results obtained in this work as a function of the chemistry of the 
moieties (alkyl, ether, and ester groups) is of relevance as they may help design HFA-
philic compounds, including surfactants and stabilizers, which may be used in the 
development of more efficient suspension-based pMDI formulations. 
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CHAPTER 4 
Propellant-based Inhalers for the Non-invasive Delivery of Genes via Oral 
Inhalation 
 
4.1   Introduction 
There is tremendous potential in targeting genes to the lungs.1-3  Asthma, cystic 
fibrosis, chronic obstructive pulmonary disease (COPD), emphysema, and lung cancer 
are just some of the many examples of pulmonary diseases that can be potentially 
treated by gene therapy.1, 2, 4-6  However, there are several challenges associated with 
the formulation and regional delivery of genes via oral inhalation (OI),1 the preferred 
mode of administration of therapeutics to the lungs. 
The mucus layer in the airways and the lung surfactant in the alveolar region 
represent important extracellular barriers to the delivery of genes to the respiratory 
tract.7, 8  As transfection with free DNA is not efficient, the choice of the gene carrier 
system is also of great relevance.9  For polymeric carriers, the polymer chemistry, and 
the physical properties of the polymer-DNA complexes (polyplexes), including their size, 
surface charge, and DNA loading greatly affect the transfection efficiency.10, 11  In 
addition, those parameters also influence the uptake and trafficking of the gene carriers 
and the release of DNA in the cellular environment, which are examples of intracellular 
barriers that need to be overcome.12  The choice of the aerosolization technique is also 
expected to influence the transfection efficiency as the dose and location where the 
polyplexes will be delivered depend on device characteristics and particle engineering.5, 
13, 14 
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The ideal scenario in terms of gene delivery to the lungs would be for both 
patients and health care providers to be able to choose from a host of different delivery 
devices, as patient compliance and device suitability depends on the patient and 
disease state/condition.  Nucleic acids can be potentially delivered to the lungs via 
nebulizers, dry powder inhalers (DPIs) or pressurized metered dose inhalers (pMDIs).15  
Nebulization has many advantages,5, 13, 15, 16 but it is less efficient and less convenient 
than portable devices.5  Therapeutically active molecules can also be delivered to the 
lungs by DPIs.  The delivery of such molecules using DPIs have several advantages, 
including the fact that DPIs are propellant-free, portable, simple use, have good shelf-
life, and reduced time of administration.17  Some studies have demonstrated the 
potential of liposomal gene powders,17 and also of gene powders prepared by 
supercritical CO2 using chitosan (CS) as non-viral carriers for use in DPIs.
18, 19  
However, there are also some disadvantages associated with the delivery of genes with 
DPIs, as for example potential problems in dose uniformity, dependency on patient’s 
inspiratory flow rate, and less protection from environmental effects.20 
Genes can also be delivered to the lungs using pMDIs.  However, pMDIs have 
received considerably less attention than DPIs and nebulizers.  The only work 
discussing gene delivery in hydrofluoroalkane (HFA)-based pMDIs consists in using 
surfactant-coated DNA particles prepared by reverse microemulsion.13  However, 
liposomes were needed during transfection to improve the in vitro transfection efficiency 
of the particles used in the formulation.  In spite of the limited amount of work on pMDIs, 
such devices offer a potentially more efficacious and convenient alternative than DPIs 
and nebulizers, especially for repeat administration,13 and serve as a complementary 
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strategy to other devices.  pMDIs are also simple to use, have high compliance, and are 
extensively used for drug delivery to the lungs.21, 22  Nevertheless, it has been shown to 
be difficult to stabilize particle dispersions in the low dielectric propellant HFA,21, 22 and 
this is an extra challenge compared to DPIs and nebulizers in terms of the preparation 
of gene carriers for lung delivery.  Particles for pMDI formulations need not only to be 
within the appropriate size range for deep deposition to the lungs,23 but they must also 
have an appropriate surface chemistry to be efficiently dispersed in the propellant 
HFAs, so as to prevent particle aggregation, which may negatively impact the aerosol 
characteristics of the pMDIs.21, 22, 24 
In this work we propose a propellant-based, portable formulation for the OI 
delivery of genes, which addresses some of the challenges mentioned earlier.  We 
discuss the effect of the characteristics of the chosen polymer carrier (chitosan, CS) on 
the properties of the polyplexes.  The aerosol characteristics of the pMDIs containing 
the engineered core-shell particles (polyplexes as core and a co-oligomer as shell) are 
also reported.  Finally, we demonstrate the ability of the engineered particles containing 
the polyplexes to transfect a model lung alveolar epithelium cells in vitro before and 
after exposure to the hydrofluoroalkane (HFA) propellant used in the pMDIs, and the 
long term stability of the particles in the propellant and their morphology after actuation.  
This work is relevant as pMDIs are the least expensive and most widely used portable 
OI devices for the delivery of therapeutics to the lungs, and due to the fact that new 
gene-based therapies are expected to continue to be developed to treat medically 
relevant respiratory diseases.  The relevance of this work also stems from the fact that 
most of the work related to OI delivery of genes to the lungs has focused on DPIs15, 18, 
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19, 25, 26 and nebulizers,15, 16, 27, 28 and only one other report in the literature has 
addressed the formulation and delivery of genes using HFA-based pMDIs.13 
 
4.2   Experimental Section 
4.2.1   Materials 
Chitosan (CS) 100 - 300 kDa with 80% degree of deacetylation (DDA), Activated 
Calf Thymus DNA (10-15 million Da; 18,940 bp), Ninhydrin reagent 2% solution, Water 
Molecular Biology Reagent (MBR, filtered, sterile, DNase, RNase and protease free), 
Lysozyme from chicken egg white (69,000 units per mg solid), 3,6-dimethyl-1,4-
dioxane-2,5-dione (lactide, LA), Tin(II) 2-ethylhexanoate (Stannous octoate, SnOct2, 
95%), 2,5-dihydroxybenzoic acid (DHB, 98%), and DNase I (552 Kunitz per mg solid) 
were purchased from Sigma-Aldrich.  Plasmid DNA (pDNA) gWIz-GFP (5,757 bp) was 
purchased from Aldevron.  PicoGreen® dsDNA reagent, Dulbecco's Modified Eagle 
Medium 1X high glucose (DMEM, with and without phenol red), TrypLE™ Express 
Stable Trypsin and Penicillin-Streptomycin were purchased from Invitrogen.  Serum 
Advantage FBS non-heat inactivated was purchased from Atlanta Biologicals.  
TransFastTM Transfection Reagent, MTS [(3-(4,5-dimethylthiazole-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] and PMS 
(phenazine methosulfate) were purchased from Promega.  Culture flasks (75 cm2, 
Cellstar), 24 and 96-well culture plate (Corning) were purchased from VWR.  2H, 3H-
perfluoropentane (HPFP, 98%) was purchased from DuPontTM TMC Ind. Inc.  
Hydrofluoroalkane 1,1,1,2,3,3,3-heptafluoropropane (HFA-227, pharma grade, 99.99%) 
was a gift from Solvay Fluor.  Actuators from Ventolin HFA® (Glaxo Smithkline) were 
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used in the cascade impaction studies.  Glacial acetic acid (100%), hydrogen peroxide 
(31.4%), hydrochloric acid (37.2%), acetonitrile (ACS grade, 99.9%), toluene (HPLC 
grade, 99.9%), sodium acetate anhydrous (99%) and phosphate buffered saline (PBS, 
10X solution) were purchased from Fisher Chemicals.  Sodium sulfate anhydrous (99%) 
and acetone (ACS grade 99.5%) were purchased from EMD Chemicals.  Chitosanase 
Streptomyces sp. N174 (10 units per 100µL) was purchased from Calbiochem EMD 
Biosciences.  Sodium hydroxide (99%) and ethyl acetate (99.5%) were purchased from 
Mallinckrodt Chemicals.  Ethanol (200 proof) was purchased from Decon Labs.  
Deionized water (DI-water, resistivity of 18.2 M.cm) was obtained from NANOpure® 
DIamondTM UV ultrapure water system (Barnstead International).  Deuterated dimethyl 
sulfoxide (DMSO-d6, 99.9%) was purchased from Cambridge Isotope Lab. Inc.  Silicon 
nitride V-shape contact mode cantilevers with integrated pyramidal tips were purchased 
from Budget Sensors. 
 
4.2.2   Depolymerization and characterization of chitosan (CS) for CS-DNA 
nanoparticles 
Large molecular weight (Mw) CS was depolymerized for the preparation of the 
polyplexes.29  Briefly, 1 g of CS was dissolved in 100 mL of DI-water with 2 mL glacial 
acetic acid, under heating (50C) and magnetic stirring (3 h).  Hydrogen peroxide (1 mL) 
was added to the solution, and the depolymerization proceeded at 50C.  The solution 
was allowed to cool down in a cold water bath, and the pH was adjusted to neutral using 
a 3M sodium hydroxide solution.  The depolymerized CS was collected as a precipitate 
by centrifugation (5,000 rpm - 2,800 xg), washed with DI-water and acetone, and dried 
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in air at room temperature.  The Mw of  depolymerized and as received CS was 
determined by viscometry.30  Samples with different CS concentrations were prepared 
in 0.2 M acetic acid / 0.1 M sodium acetate aqueous solution at pH 4.4, and filtered 
using 0.2 µm filter (non-sterile, Nylon-membrane, PP-housing from Cole-Parmer).  Their 
relative (rel) and specific (sp) viscosities were calculated based on the efflux times 
using an Ubbelohde viscometer (OC-C938, Cole-Parmer) at 30C as follows:31 
 
rel = (tsolution)  (tsolvent) 
sp = rel – 1 
 
The intrinsic viscosity [] was determined as the intersection point at zero 
concentration of the inherent (inh) and reduced (red) viscosities (graphic method) using 
five different CS concentrations, according to these equations31 below, where C is the 
concentration in g.mL-1. 
 
inh = (ln rel)  C 
red = sp  C 
 
The [] was also calculated using the Solomon-Ciutâ approximation32 which 
requires only one CS concentration: [] = { [ 2.sp – 2.ln(rel) ] 
1/2 }  C.  Due to the 
agreement between the [] values obtained from these two approaches in the initial 
studies, the Solomon-Ciutâ approximation was chosen for the remainder of the 
experiments.  The Mw was calculated based on Mark-Houwink-Kuhn-Sakurada 
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(MHKS)32 equation [] = k.Mwa with k = 8.02  10-3 mL.g-1 and a = 0.960.  The 
constants k and a are specific for each CS-solvent system, and they were estimated 
from the knowledge of the DDA, type of solvent, pH and temperature, using equations 
from the literature.30 
 
4.2.3 Preparation and characterization of CS-DNA nanoparticles (NPs) 
4.2.3.1  Preparation of polyplexes.  Complex coacervation was used to prepare CS-
DNA NPs.33  Briefly, CS (100 - 500 µg.mL-1 in 5mM sodium acetate buffer at pH 5.5, 
filtered with 0.2 µm filter), and DNA solutions (60 - 100 µg.mL-1 in 5mM sodium sulfate) 
were initially preheated to 55C in a water bath.  CS solution (100 µL) was gradually 
added to the DNA solution (100 µL) while vortexing at high speed for 45 s.  The CS-
DNA NPs suspension was kept at room temperature for 30 min before use, to assure 
the complete formation of the polyplexes.  The number of phosphate groups (P) in the 
DNA content, and the number of amine groups (N) in the CS content used during 
complexation was determined based on CS Mw and DDA, number of base pairs (bp) of 
the DNA, and concentrations of CS and DNA solutions.  The nominal N/P ratio was 
calculated using that information.34  CS-DNA NPs were collected as precipitate by 
centrifugation (14,000 rpm - 21,500 xg for 1.5 h), and the supernatant was used for 
determination of free DNA and CS contents, which allowed a more precise 
characterization of the N/P ratio (actual N/P ratio), and encapsulation efficiency.  The 
CS-DNA NPs were gently re-dispersed in 0.5 mL MBR-water using a probe sonicator 
(OmniRuptor 250) at 25 W for 5 s.  The NPs suspension was used for further 
characterization and other preparations.  The encapsulation efficiency of DNA and CS 
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was indirectly determined by measuring the difference between the total DNA and CS 
contents added during the complex coacervation, and the amount of non-entrapped 
DNA and CS remaining in the aqueous supernatant.35  The supernatant was analyzed 
using PicoGreen® Assay (for the non-entrapped DNA) in a Fluorescence/Spectrometer 
(Parkin Elmer LS50B), and Ninhydrin reagent36 (for the non-entrapped CS) in a UV-
Visible Spectrophotometer (Cary 50 Bio).  The amount of DNA and CS in the NPs was 
calculated according to linear calibration curves. 
 
4.2.3.2  Size and morphology.  Malvern ZetaSizer (Nano ZS) was used to evaluate the 
size and zeta potential of the CS-DNA NPs.  The samples were diluted 1:10 in DI-water, 
and the measurements were performed in quintuplicate, at 25C, using the refractive 
index, viscosity and dielectric constant of pure water.37  The Smoluchowski Model was 
used to determine the zeta potential.38  Scanning Electronic Microscopy (SEM, Hitachi 
S-2400, 25kV) and Atomic Force Microscopy (AFM, Pico LE, Molecular Imaging) were 
used to investigate the morphology of the polyplexes.  For SEM imaging, several drops 
of CS-DNA NPs suspension in water were placed on a cover glass slip, allowed to dry 
overnight, and sputter-coated with gold (Ernest Fullan) for 40 s.21  Image J software 
(version 1.42 q, National Institutes of Health, NIH) was used to estimate the size of the 
polyplexes from the SEM images.  The histogram of the measured NPs diameter (> 400 
particles) was fit to a Gaussian distribution, from which an average size and deviation 
was obtained.  For AFM imaging, 20 µL of the freshly prepared CS-DNA NPs 
suspension was incubated on a freshly cleaved mica surface for 5 min, so as to allow 
the binding of the polyplexes on the substrate.39  The excess of liquid was then removed 
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by washing with DI-water, the system was left to dry at room temperature under air flow, 
and the images were obtained using Si3Ni4 V-shape cantilever in contact mode.
39 
 
4.2.3.3  DNA encapsulation efﬁciency.  Chitosanase/lysozyme digestion was used to 
directly determine the DNA encapsulation efficiency in CS-DNA polyplexes.39, 40  These 
results were compared to the indirect DNA loading obtained from the determination of 
free DNA and CS contents in the supernatant after complexation as described earlier.  
CS is susceptible to chitosanase and lysozyme digestion – lysozyme degrades sites 
near the N-acetylated glucosamine, and chitosanase attacks the sequences of three 
consecutive deacetylated units.40  CS-DNA NPs (100 µL) were incubated at 37C for    
6 h with 80 µL chitosanase (0.625 U.mL-1) in 50/50 (v/v) 50 mM sodium acetate buffer at 
pH 5.5 / glycerol, and 20 µL lysozyme (1000 U.mL-1) in 50 mM sodium acetate buffer at 
pH 5.5,39, 40 followed by DNA quantification using PicoGreen® Assay. 
 
4.2.4 Synthesis and characterization of oligo(lactide)-grafted-CS (OLA-g-CS) co-
oligomer 
The preparation of water soluble, low Mw CS, followed by the synthesis of OLA-
g-CS co-oligomer was performed according to a modified method from literature.21  
Details about methods, results and discussion can be found in Appendix A. 
 
4.2.5 Preparation and characterization of CS-DNA core-shell particles 
4.2.5.1  Preparation of core-shell particles.  Emulsification diffusion was employed to 
prepare core-shell particles containing CS-DNA NPs.21  Briefly, 25 mg OLA-g-CS was 
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dissolved in 0.5 mL DI-water, and CS-DNA NPs (50 - 300µg.mL-1) were dispersed in 
another 0.5 mL of DI-water.  The OLA-g-CS solution and the dispersion containing the 
polyplexes were combined and emulsified in 19 mL of ethyl acetate using a sonication 
bath (VWR, P250D, set to 180 W) for 5 min at 15 - 20°C, producing water-in-oil (W/O) 
emulsion.  This emulsion was subsequently added to a large volume of ethyl acetate 
(180 mL).  Core-shell particles (OLA-g-CS as the shell, and CS-DNA NPs as the core) 
were thus formed, collected by centrifugation (5,000 rpm - 2,800 xg, 15min) and dried in 
air at room temperature. 
 
4.2.5.2  Size and morphology.  SEM (Hitachi S-2400) was used to evaluate the size 
and morphology of the core-shell particles.  A small amount of the particles was 
dispersed in HPFP using a sonication bath (VWR, P250D, set to 180 W, at 15 - 20°C) 
and several drops of the suspension were placed on a cover glass slip, allowed to dry, 
and sputter-coated with gold for 40 s (Ernest Fullan) before SEM imaging.  Image J was 
used to determine the size from SEM images (> 200 particles) using similar procedure 
as described earlier.  Dynamic Light Scattering (DLS) was also used to evaluate the 
size of CS-DNA core-shell particles.  Samples were prepared in HPFP, a model HFA 
that is liquid at ambient conditions.21  The measurements were performed in triplicate, at 
25C, using the refractive index, viscosity and dielectric constant of pure HFPF in the 
calculations.41  The morphology of the core-shell particles was also investigated by 
Transmission Electronic Microscopy (TEM, JEOL JEM-2010).  A drop of the particles 
dispersion in HPFP was placed on a 200-mesh copper grid and allowed to dry before 
TEM imaging. 
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4.2.5.3  DNA loading in core-shell particles.  Chitosanase/lysozyme digestion was 
also utilized to quantify the DNA loading in the core-shell particles, and on the stages of 
the Andersen Cascade Impactor (ACI, discussed next).  The procedure was similar to 
that described earlier for quantification of the amount of DNA encapsulated in the 
polyplexes.  Because the OLA-g-CS (the co-oligomer shell) is water soluble, the core-
shell particles quickly break down, forming a homogeneous aqueous solution of the co-
oligomer,21 with dispersed polyplexes.  The method then proceeded as described earlier 
for CS-DNA NPs, except that core-shell particles were incubated with the enzymes 
instead of the NPs alone. 
 
4.2.6 Preparation of pMDI formulations and evaluation of their physical stability 
An exact mass of core-shell particles containing CS-DNA NPs was weighed into 
pressure proof glass vials (8412-B, West Pharmaceutical Services), and crimp-sealed 
with a metering valve (63 µL, EPDM Spraymiser, 3M Inc.).  A known amount of HFA-
227 was added with the help of a manual syringe pump (HiP, 50-6-15), and a home-
built high pressure aerosol filler, to make 2 mg.mL-1 concentration of CS-DNA core-shell 
particles in the propellant HFA-227.  The dispersions were sonicated (VWR, P250D, set 
to 180 W, at 15 - 20°C) in order to break up any large aggregates.  The physical stability 
was investigated by visually monitoring the quality of the dispersion as function of time 
after mechanical energy input ceased. 
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4.2.7 Aerosol characteristics 
The aerosol properties of the CS-DNA core-shell particles and CS-DNA NPs 
alone in pMDI formulations were determined with an Andersen Cascade Impactor (ACI, 
CroPharm, Inc.) fitted with a USP induction port and operated at a flow rate of          
28.3 L.min-1, at 298 K and 45% relative humidity.21, 22  The pMDI formulations containing 
core-shell particles loaded with CS-DNA NPs were prepared as described in Section 
4.2.6.  pMDI formulations containing CS-DNA NPs alone were prepared as follows:  CS-
DNA NPs re-dispersed in 0.5 mL MBR-water were frozen in liquid N2 and lyophilized 
(Labconco Freeze Zone 1) at 0.05 mbar and -47C for 48 h.  The solid obtained was 
placed into a pressure proof glass vial (8412-B, West Pharmaceutical Services), and 
crimp-sealed with a metering valve (63 µL, EPDM Spraymiser, 3M Inc.).  A known 
amount of HFA-227 was subsequently added, so that the total amount of CS-DNA NPs 
was the same as in the formulations prepared with CS-DNA core-shell particles.  The 
dispersions were sonicated (VWR, P250D, set to 180 W, at 15 - 20°C) in order to break 
up any large aggregates.  Before each test, five shots were first fired to waste.  
Subsequently, twenty shots were released into the ACI, with an interval of 10 s between 
each actuation.22  Three independent canisters were tested for each formulation.  After 
each run, the ACI was disassembled and the actuator, induction port (IP) and the 
stages were rinsed thoroughly with 20 mL of DI-water.  The aqueous solution relative to 
each part of the ACI was frozen separately in liquid N2, and lyophilized (Labconco 
Freeze Zone 1, 0.05 mbar, -47C) for 48 h.  The powder collected was dissolved in   
150 µL of 50 mM sodium acetate buffer at pH 5.5, and incubated at 37C for 6 h with 80 
µL chitosanase (0.625 U.mL-1) in 50/50 (v/v) 50 mM sodium acetate buffer at pH 5.5 / 
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glycerol, and 20 µL lysozyme (1000 U.mL-1) in 50 mM sodium acetate buffer at pH 5.5.  
After the chitosanase/lysozyme digestion, the amount of free DNA was quantified by 
PicoGreen® Assay, and the DNA content in each stage of the device thus determined.  
The fine particle fraction (FPF), mass median aerodynamic diameter (MMAD), and 
geometric standard deviation (GSD) were calculated.  FPF is defined as the mass of 
DNA on the respirable stages of the impactor (from stage 3 to filter) over the total mass 
of the DNA released into the device (from IP to filter, excluding the amount remaining in 
the actuator).42  The cumulative DNA mass fraction into the device (stage 0 to filter) was 
calculated, and a graph of cut-off diameter of each stage (x axis, log 10 scale) versus 
the cumulative DNA mass fraction (y axis, probability scale) was plotted, and fitted 
linearly.  The MMAD was determined as the particle size at which the line crossed the 
50% mark, and GSD was defined as the ratio between the particle size at 84.1% mark 
and at 50% mark.43  The single % dose per actuation was calculated by dividing the 
total mass of the formulation found in the ACI (from actuator to filter) to the nominal 
expected dose emitted during each run (in this case twenty),22 which can be calculated 
based on the volume of the reservoir and the concentration of DNA loaded per volume 
of solvent. 
 
4.2.8 In vitro transfection 
A549 cells (human lung adenocarcinoma cell line, an in vitro model of Type II 
alveolar epithelium)44 were seeded in a 75 cm2 cell culture flask and subcultured until 
approximately 90% confluence.  The cell culture medium (DMEM supplemented with 
10% FBS and 1% antibiotics) was changed every two days.  The cells were seeded on 
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24-well culture plate at density of 5104 cells per well, and cultured in 0.5 mL DMEM 
supplemented with 10% FBS and 1% antibiotics for 24 h at 37C and 5% CO2 (Thermo 
Scientific Incubator, NAPCO 8000WJ).  The cells were rinsed with 1X PBS twice, and 
transfection was initiated by adding 0.2 mL of transfection mixture containing CS-DNA 
NPs alone or CS-DNA core-shell particles (both equivalent to 0.25 µg DNA per well) in 
DMEM at pH 6.9 (without phenol red, antibiotics and serum).  After 6 h of incubation, 
the cells were overlaid with 0.3 mL DMEM (without phenol red, supplemented with 10% 
FBS and 1% antibiotics) and incubated at 37C and 5% CO2.  Free DNA was used as 
negative control, and DNA complexed with TransFastTM Transfection Reagent was used 
as positive control.  The biological functionality of the reporter pDNA gWIz-GFP was 
investigated at 48 h post-transfection using a Fluorescence Microscope (Zeiss Imager 
Z1, Axio Cam MRm).  The experiments were performed at 48 h based on the protocol 
suggested by the supplier of the transfection agent used as positive control.45  All 
experiments were carried out in duplicate.  The effect of the propellant HFA-227 on the 
biological activity of the pDNA was also investigated.  CS-DNA NPs (alone and 
engineered as core-shell particles, both prepared as pMDI formulations at same pDNA 
concentration) were stored in HFA-227 at 298K and saturation pressure of the 
propellant.  After 6 weeks, the HFA-227 propellant was slowly released by 
depressurization (removal of the gas phase), and the particles were allowed to dry at 
room temperature, following dispersion of the particles in 0.6 mL MBR-water.  This 
solution was used in transfection experiments (equivalent to 0.25 µg DNA per well) in 
A549 cells, following similar protocol as explained earlier to determine the effect of 
storage under the compressed HFA environment. 
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4.2.9 In vitro cytotoxicity 
A549 cells were seeded on 96-well culture plate (5103 cells per well) and 
cultured in 100 µL DMEM supplemented with 10% FBS and 1% antibiotics for 24 h at 
37C and 5% CO2.  Cells were rinsed with 1X PBS twice, and it was added a culture 
medium containing CS-DNA NPs at varying concentrations of CS (5 - 100 µg.mL-1), or 
OLA-g-CS (0.5 - 13.5 mg.mL-1), or CS-DNA core-shell particles (5 - 100 µg.mL-1 CS 
from NPs, and 0.5 - 13.5 mg.mL-1 OLA-g-CS).  The concentration of CS-DNA NPs and 
OLA-g-CS co-oligomer used in the experiments fall within the ranged used in the 
transfection and the ACI studies.  The cells were incubated in these solutions for 15 h 
(overnight) at 37C and 5% CO2.  This time was chosen based on previous literature, 
which have shown that CS-based polyplexes46-49 and OLA-g-CS21 are not cytotoxic at 
least up to 24 h.  The cells were then rinsed with 1X PBS twice, and the medium 
containing the particles was replaced by 100 µL culture medium (particle free) and 20 
µL MTS/PMS cell proliferation assay.  The cells were allowed to incubate in this mixture 
for 4h at 37C and 5% CO2.  MTS is bioreduced into formazan (which is soluble in the 
culture medium) by dehydrogenase enzymes found in metabolically active cells into 
formazan, which is soluble in the culture medium.21  The absorbance of the formazan at 
490 nm was measured directly from the 96-well culture plate (Molecular Devices, 
Spectra Max 250).  This quantity is directly proportional to the number of living cells in 
the culture.  Cell viability (%) is defined as the ratio of the absorbance between the 
treated (with particles) and untreated cells (control). 
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4.2.10 Stability of CS-DNA polyplexes and integrity of gWIz GFP pDNA 
DNase I assay was performed in order to assess the protection of complexed 
gWIz GFP pDNA against nuclease degradation.  Freshly prepared CS-DNA NPs at N/P 
ratio of 7, equivalent to 5 g pDNA, were incubated with different concentrations of 
DNase I, model enzyme,50 at 37°C for 15 min.  The reaction was stopped by heat 
inactivation: 60°C for 15 min,51 in presence of 0.5 M EDTA, at 5 L per 1 U DNase.52  
CS-DNA NPs were collected by centrifugation (14,000 rpm - 21,500 xg for 1.5 h), and 
incubated with chitosanase/lysozyme at same conditions as described in Section 
4.2.3.3, for DNA release.  Samples were loaded in 1% (w/v) agarose gel (SeaKem® LE 
Agarose, Lonza) in TAE buffer 1X with 0.5 g.mL-1 ethidium bromide   (10 mg.mL-1 
solution, Promega).  Free pDNA, and CS-DNA NPs without exposure to DNase I were 
used as controls.  The electrophoresis was performed at 100 V (E0160-VWR Mini Gel 
Electrophoresis) for 45 min, the pDNA-dye migration was observed under UV irradiation 
(FOTO/Analyst® Investigator/Eclipse with UV Transilluminator, Fotodyne Inc.) and the 
images were recorded using the FOTO/Analyst® PC Image software (v.5). 
The integrity of the gWIz-GFP pDNA after complexation with CS, core-shell 
particles preparation, and storage in propellant HFA, was also analyzed by gel 
electrophoresis, following the protocol described earlier.  100 L samples of CS-DNA 
polyplexes alone at N/P ratio of 7, and CS-DNA polyplexes formulated as core-shell 
particles, which were freshly prepared and stored in HFA-227 at 298K and saturation 
pressure of the propellant, were incubated with chitosanase/lysozyme under same 
conditions as described in Section 4.2.3.3 for DNA release.  Free pDNA as received 
and the same particles without exposure to the enzymes were used as controls. 
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4.3 Results and Discussion 
4.3.1 Depolymerization and characterization of CS for preparation of CS-DNA 
NPs 
The Mw of CS has a strong influence on its physicochemical and biological 
properties.34  The Mw has been also shown to modulate the transfection efficiency in 
vitro33 and in vivo.18, 33, 37  The literature brings several examples of in vitro transfection 
studies with CS-DNA NPs using medium/high Mw CS (40 - 600 kDa),38, 40 and also low 
Mw CS (1 - 50 kDa).33, 53  Based on those previous works, CS with Mw varying between 
10 and 100 kDa,53 when considered in combination with other relevant parameters such 
as DDA, N/P ratio, pH and serum content of the culture medium, and cell type,34 seem 
to optimize in vitro gene expression of polyplexes between CS and DNA. 
Low Mw CS can be easily prepared by random depolymerization using hydrogen 
peroxide as free radical generator.29  The acidity of the solution and temperature cause 
decomposition of the hydrogen peroxide (H2O2  H
+ + HOO-), producing unstable 
perhydroxyl anions (HOO-), which decompose in powerful oxidants – the hydroxyl 
radicals (HO) – abstracting hydrogen from carbons (RH + HO  R + H2O).
54  These 
H-abstractions lead to cleavage of 1,4--D-glucoside bonds in CS chains, decreasing its 
Mw.29, 54  Parameters as the acidity and concentration of H2O2, temperature, and 
reaction time all affect the final Mw of CS, and can be used to control the 
depolymerization process.29, 54 
Before starting the CS depolymerization, the Mw for non-depolymerized CS was 
determined using viscometry.30, 31  The Mw was related to the intrinsic viscosity [] by 
the MHKS equation,32 and the [] was calculated by the graphical method,31 and using 
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the Solomon-Ciutâ approximation.32  Figure 4.1a shows how the [] for non-
depolymerized CS was determined using the graphical method. 
 
 
Figure 4.1.  (a) Plot for the determination of intrinsic viscosity [] of non-depolymerized CS (310 kDa, 
80% DDA) based on inherent and reduced viscosities;  (b) Exponential reduction in the Mw of CS (80% 
DDA) according to the depolymerization time. 
 
The results indicate that the [] of non-depolymerized CS with 80% DDA was 
1524 mL.g-1.  The [] calculated by Solomon-Ciutâ approximation was 1520 mL.g-1, in 
agreement with the graphical method.  From the [] results, the Mw of non-
depolymerized CS with 80% DDA (ca. 1464 amine and 366 acetyl units) was 
determined to be 310 kDa, in agreement with the results provided by the manufacturer.  
Because the [] obtained by the Solomon-Ciutâ approximation was in good agreement 
to the more laborious graphical method, this approximation was used for all other 
determinations.  Thus, in order to prepared CS with Mw between 10 and 100 kDa, large 
Mw CS (310 kDa, 80% DDA) was depolymerized using 2% CH3COOH and 1% H2O2 
(v/v) at 50C for 7, 15 and 60 min.  The Mw of depolymerized CS was found to be 49, 
42 and 31kDa, respectively, as shown in Figure 4.1b. 
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CS depolymerizes very quickly in the first few minutes of reaction, leveling off 
after only 11 min (Figure 4.1b).  Such exponential reduction of Mw is observed due to 
the rapid decrease in the solution’s viscosity.54  No significant change in the DDA of CS 
was expected under such relatively mild reaction conditions (low CH3COOH and H2O2 
concentrations, low temperature and short reaction times).31, 54  Indeed, the DDA of     
31 kDa CS, which is the one obtained using the longest depolymerization time, was 
determined by 1H-NMR to be 77% (141 amine and 41 acetyl units), which is very close 
to the non-depolymerized / as received CS.  Details about these results can be found in 
Appendix A.  In addition, we also show (discussion in the Appendix A) that even for 
stronger reaction conditions used in the depolymerization of CS for the OLA-g-CS co-
oligomer synthesis, the DDA does not change appreciably (also 77%).  The DDA is an 
important quantity as it relates to the overall positive charge density of CS, and it is thus 
expected to have an effect on the transfection efficiency.34, 55 
 
4.3.2 Preparation and characterization of CS-DNA NPs 
4.3.2.1  Preliminary screening.  In order to prepare CS-DNA polyplexes with small 
size (diameters around 200 nm or smaller), enhanced colloidal stability, and also good 
in vitro transfection efficiency in A549 cells, we performed a series of preliminary 
experiments that involved the preparation of polyplexes with varying CS Mw and N/P 
ratio.  The polyplexes were characterized according to their size and zeta potential (), 
and their ability to transfect A549 cells (good/poor).  Calf Thymus DNA (18,940 bp long) 
and a pDNA encoding for green fluorescent protein (gWIz-GFP; 5,757 bp long) were 
chosen as models for this screening step.  The use of two different DNAs (plasmid vs. 
linear, and with different number of bp) is relevant in terms of the applicability of the 
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proposed methodology for the delivery of a broad range of genes to the lungs, since it 
has been shown that efficient gene transfer can be achieved using large pDNA (up to 
20.2 kbp in size)56 and DNA in the linear form.57  A brief discussion on the effect of the 
different variables is provided next. 
The Mw of CS has a strong effect on the size of the polyplexes.58  Literature has 
shown that it is possible to obtain smaller polyplexes with lower Mw CS.58, 59  This can 
be attributed to the higher solubility and flexibility of the shorter CS chains in solution.59  
During the preliminary screening, our results indicated that the size of CS-DNA NPs 
decreased as the Mw CS decreased – e.g. the size of the polyplexes formed with Calf 
Thymus DNA, CS 80% DDA, and nominal N/P ratio of 6 decreased from 547 ± 92 nm to 
183 ± 51 nm when the CS Mw was reduced from 310 to 31 kDa. 
The size of the polyplexes is also influenced by the N/P ratio, and an increase in 
N/P ratio usually yields polyplexes with smaller diameters.40  During our preliminary 
screening using CS (31 kDa, 80% DDA) and gWIz-GFP DNA, a size reduction from  
229 ± 93 nm to 181 ± 62 nm was observed when the nominal N/P ratio increased from 5 
to 7.  The N/P ratio is also known to have a significant impact on in vitro transfection.  
N/P ratios that are too low typically yield physically unstable polyplexes, and poor in 
vitro transfection.34  More stable dispersions of polyplexes can be obtained at higher 
N/P ratios.40  Our preliminary results are in agreement with this trend.  Polyplexes (CS 
31 kDa, 80% DDA, gWIz-GFP DNA) showed poor in vitro transfection in A549 cells at 
nominal N/P ratio of 2 and 4.  These polyplexes had lower zeta potential                       
( = + 13 ± 1 mV at N/P ratio of 2; and  = + 16 ± 1 mV at N/P ratio of 4), and were 
physically unstable (aggregated) in aqueous medium even at short times, as observed 
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during the DLS measurements.  In vitro transfection improved when the nominal N/P 
ratio increased to 5 and 7, with  = + 23 ± 1 mV; and  = + 22 ± 6 mV, respectively.  
Collectively, these results indicate that the Mw and N/P ratio may be used as 
parameters to optimized in vitro transfection in A549 cells. 
 
4.3.2.2  CS-DNA NPs selected for further studies.  Polyplexes containing Calf 
Thymus and gWIz-GPF DNA, prepared with CS 31 kDa and 80% DDA, and possessing 
similar size and zeta potential to each other were selected for further studies.  The 
properties of these polyplexes are shown in Table 4.1.  Additional details about the 
properties of CS-DNA polyplexes obtained during the preliminary screening that lead to 
the selection above can be found in Appendix A. 
 
Table 4.1.  DNA and CS encapsulation efficiency (EE), particle size, and zeta potential of the CS-DNA 
NPs selected for further studies.  The characteristics of the CS (Mw and DDA), nominal and actual N/P 
ratio are also shown. 
 
 
CS 
Mw 
(kDa) 
 
CS 
DDA 
(%) 
Type of 
DNA 
Nominal 
N/P ratio 
DNA EE 
(%) 
CS EE 
(%) 
Actual 
N/P ratio 
Particle 
Size 
(nm) 
Zeta 
Potential 
(mV) 
 
31 
31 
 
80 
80 
Calf Thymus 
gWIz-GFP 
6 
7 
90 ± 8 
95 ± 3 
79 ± 19 
70 ± 8 
5 
5 
183 ± 51 
181 ± 62 
21 ± 4 
22 ± 6 
 
Results in mean ± s.d. for n = 5 (five independent polyplexes preparations, and s.d. = standard deviation). 
 
In order to better characterize the polyplexes, the encapsulation efficiency (EE) 
of DNA and CS was determined, and are presented in Table 4.1.  The results show that 
the DNA EE, calculated based on the amount of free DNA measured in the supernatant 
after complexation – the indirect method described in Section 4.2.3.1 – was 90% for 
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Calf Thymus and 95% for gWIz-GFP DNA.  The DNA EE determined after 
chitosanase/lysozyme digestion (direct method described in Section 4.2.3.3) was        
96 ± 5% for both types of DNA.  These results are in agreement with each other, 
indicating that almost all DNA was trapped within the NPs, and also serve to validate 
both methods for determining the DNA EE.  High DNA EE is typically reported in the 
literature.39, 40, 58  The CS EE, on the other hand, was much smaller (70 - 80%,        
Table 4.1).  Similar findings have been reported in the previous works.39, 40 
Based on the EE results, the N/P ratio of the polyplexes after complexation was 
(re)calculated.  The actual N/P ratio was determined to be 5 (Table 4.1).  Although 
these results indicate a decrease in the N/P ratio,  around + 21 mV suggests that the 
CS-DNA NPs have high enough charge density to provide good colloidal stability.53, 58  
Given the deviation in EE, especially for CS, it seems that a nominal N/P ratio is not 
sufficient information when discussing the effect of such variable on the transfection 
efficiency.  Instead, an actual N/P ratio, which takes into account the DNA and CS EE, 
seems to be more appropriate, along with experimental information on the  and 
stability of the polyplexes. 
In order to provide efficient gene transfer, polyplexes must have well-defined 
properties to overcome the intracellular barriers.55  The size of the polyplexes plays a 
key role in this process.  Since the uptake happens by endocytosis, some studies 
suggest that the size of NPs should be limited to diameters smaller than 150 nm.39, 60  
However, several reports demonstrate that polyplexes may efficiently transfect cells in 
vitro with NPs with a much broader size range.33, 48, 58, 61-63  It is clear, therefore, that 
apart from particle size, other biological and biophysical parameters play important role 
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in the transfection process.60  The results in Table 4.1 show that the size of CS-DNA 
NPs (Calf Thymus and gWIz-GFP DNA) obtained in this work was around 182 nm.  
Similar diameters have been reported in the literature.33, 58  It interesting to also note 
that, based on our results, the type and size of the DNA does not seem to exert a large 
influence on the size and/or  of the resulting polyplexes, as has been shown in other 
studies.40  The morphology and size of the selected CS-DNA NPs was further 
characterized by SEM and AFM, and the results are shown in Figure 4.2. 
 
 
Figure 4.2.  Histograms and Gaussian fits to the particle size distributions obtained from the SEM images 
of the CS-DNA NPs prepared with CS (31 kDa, 80% DDA) and (a) Calf Thymus DNA at nominal N/P ratio 
of 6; or (b) gWIz-GFP DNA at nominal N/P ratio of 7.  Insets: SEM and AFM images of the CS-DNA NPs. 
 
CS-DNA polyplexes exhibited somewhat spherical morphology, as reported in 
the literature.37, 39, 60  While spheroids, toroids and rods are the most common 
morphologies for polyplexes, other less defined shapes, such as rings and flower-like 
can be also observed.64  The size of the CS-DNA NPs estimated from the SEM using 
Image J images was 187 ± 51 nm for NPs containing Calf Thymus DNA at nominal N/P 
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ratio of 6, and 171 ± 41 nm for NPs containing gWIz-GFP DNA at nominal N/P ratio of 
7, showing excellent agreement with the DLS results presented in Table 4.1. 
 
4.3.3 Preparation and characterization of core-shell particles loaded with CS-
DNA NPs 
In order to efficiently deliver genes to the lungs using propellant-based OI 
formulations, several hindrances need to be overcome.  One of the foremost challenges 
that need to be addressed is pertaining to the aerodynamic size of the particles.  For 
optimal deep lung  deposition, the particle size needs to be between 1 and 5 µm,65 a 
range that falls far from the size of the DNA-polymer nanocomplexes being studied here 
(ca. 200 nm).   Secondly, the polyplexes need to be well dispersed in the propellant for 
optimum aerosol performance.21, 66  Because steric mechanisms are thought to 
dominate the stability of colloidal aggregates in the low dielectric HFAs, the relatively 
high surface charge of the polyplexes is thus expected to be another challenge in the 
formulation of the colloidal particles.67  We propose, therefore, to engineer core-shell 
particles with the polyplexes as the core, and the shell being employed to generate 
micron-sized particles that are structurally stable in the propellant (shell not soluble in 
HFA), and yet break down in aqueous solutions (shell soluble in water).  The shell is 
also designed so as to sterically-stabilize the dispersions in HFAs (the shell contains 
HFA-philic groups that reduce particle-particle interactions).  Core-shell particles 
containing CS-DNA NPs as core (with Calf Thymus or gWIz-GFP DNA), and OLA-g-CS 
co-oligomer as shell, were thus prepared by emulsification-diffusion. 
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Polyplexes were dispersed in aqueous solution containing the co-oligomer, which 
was subsequently emulsified into ethyl acetate.  The emulsification process was aided 
by the presence of the co-oligomer, which is active at the water/ethyl acetate interface.21  
The emulsion was diluted into an excess of the organic phase, and the water, which has 
high solubility in the organic phase, diffused from within the emulsion droplets, thus 
templating the micron-sized particles containing the polyplexes as core and the OLA-g-
CS co-oligomer as shell.  The oligo(LA) units grafted on the low Mw CS are relevant in 
the proposed formulation as they are well solvated by HFAs, and are capable of 
improving dispersion stability in the propellants used in pMDIs.24, 66, 67 
The DNA loading efficiency (% DNA that was entrapped from the initial amount 
added in the dispersion) into core-shell particles was measured (n = 5, five independent 
experiments) using PicoGreen® Assay after chitosanase/lysozyme digestion, and it was 
found to be very high: 73 ± 8% (gWIz-GFP DNA) and 90 ± 5% (Calf Thymus DNA), both 
w/w.  CS-DNA core-shell particles were characterized by SEM and TEM for size and 
morphology (Figure 4.3) before loading into pMDI formulations. 
The SEM images indicate that the core-shell particles have spherical 
morphology, as expected, since they were templated by emulsion droplets.  In addition, 
they were fairly polydisperse, with geometric diameters estimated to be 1.1 ± 0.8 µm 
and 0.8 ± 0.3 µm, for core-shell particles prepared with Calf Thymus and gWIz-GFP 
DNA, respectively.  In good agreement with the SEM results, DLS experiments revealed 
that the size of the core-shell particles dispersed in HPFP was 0.8 ± 0.2 µm (Calf 
Thymus DNA) and 1.4 ± 0.1 µm (gWIz-GFP DNA).  TEM images (insets in Figure 4.3) 
corroborate the presence of the polyplexes within the OLA-g-CS co-oligomer. 
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Figure 4.3.  Histograms and Gaussian fits to the particle size distributions obtained from the SEM images 
of the core-shell particles loaded with CS-DNA NPs prepared with CS (31 kDa, 80% DDA) and (a) Calf 
Thymus DNA at nominal N/P ratio of 6; or (b) gWIz-GFP DNA at nominal N/P ratio of 7.  Insets:  SEM and 
TEM images of the CS-DNA core-shell particles. 
 
4.3.4   Physical stability of the CS-DNA core-shell particles in propellant HFA 
Core-shell particles containing the CS-DNA NPs had their physical stability 
qualitatively evaluated in HFA-227 propellant through sedimentation rate experiments at 
298 K and saturation pressure of the propellant.  CS-DNA core-shell particles were 
weighed, placed into pressure proof glass vials, and crimp sealed.  A known volume of 
the propellant was then added to make 2 mg.mL-1, and the system dispersed with the 
aid of sonication bath.  The stability of the formulations was determined as the 
creaming/sedimentation rate as a function of the time after stopping the mechanical 
energy input.21, 22  During these experiments, digital images were taken, and the results 
are shown as insets in Figure 4.4. 
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Figure 4.4.  Aerodynamic characteristics of the CS-DNA NPs alone and engineered as core-shell 
particles.  Polyplexes prepared with CS (31 kDa, 80% DDA) and (a) gWIz-GFP DNA at nominal N/P ratio 
of 7; or (b) Calf Thymus DNA at nominal N/P ratio of 6.  pMDI formulations in HFA-227 at 298 K, and 
saturation pressure of the propellant.  CS-DNA core-shell particles at 2 mg.mL
-1
 of propellant, and DNA 
concentration ca. 4 µg.mL
-1
 (Calf Thymus) and ca. 6 µg.mL
-1
 (gWIz-GFP) for all formulations.  AC, IP and 
F refer to actuator, induction port and filter, respectively.  Insets: Core-shell particles loaded with CS-DNA 
polyplexes – dispersion stability of freshly prepared pMDI formulations (right), and SEM of particles 
actuated from pMDIs after one year of storage (left). 
 
The pMDI formulations of CS-DNA core-shell particles (containing gWIz-GFP 
DNA, inset in Figure 4.4a; or Calf Thymus DNA, inset in Figure 4.4b) showed excellent 
physical stability.  A small precipitated layer of the core-shell particles could be clearly 
observed after 2 h.  However, such precipitated layers could be easily redispersed by 
simply shaking the formulation, which indicates that the core-shell particles did not form 
irreversible aggregates.  Easily redispersible aggregates have also been found in pMDI 
formulations prepared with surfactant-coated pDNA particles in HFA-134a.13  However, 
those particles were suspended in the propellant in presence of ethanol, a co-solvent 
presumably necessary to enhance the solvation of the alkane groups that make the 
surfactant coat around the pDNA particles. 
These results demonstrate that the OLA-g-CS co-oligomer shell was able to 
enhance the physical stability of the CS-DNA NPs in HFA-227.  This improved stability 
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can be attributed to the ability of the HFA to solvate the oligo(LA) side chains of the co-
oligomer shell.24, 66, 67  These results are in sharp contrast to the poor stability of the 
formulations prepared with CS-DNA NPs alone (using either Calf Thymus or gWIz-GFP 
DNA).  Those formulations were observed not to be completely dispersible (large 
aggregates formed for NPs containing gWIz-GFP DNA), or settled immediately after 
sonication stopped (NPs prepared with Calf Thymus DNA).  This lack of physical 
stability is expected as particle-particle attractive interactions dominate over (any 
potential) electrostatic repulsions in the low dielectric HFAs, as no steric barrier is 
present when the particles are not coated by the HFA-philic shell.68, 69  CS-DNA core-
shell particles in HFA-227 after one year of storage at 298 K and saturation pressure of 
the propellant were actuated on the surface of a container, and the particles were re-
suspended in HPFP according to procedure described in Section 4.2.5.2, and imaged 
using SEM.  The results are shown as insets in Figure 4.4, and reveal that the core-
shell particles were stable upon storage and actuation, retaining their overall 
morphology and size compared to those freshly prepared – those not contacted with the 
propellant – SEM insets in Figure 4.3. 
 
4.3.5 Aerosol characteristics 
ACI was used to quantitatively characterize the aerosol properties of the pMDI 
formulations containing the polyplexes.  Such formulations were prepared using CS-
DNA NPs alone or polyplexes engineered as core-shell particles (same conditions as 
discussed in Section 4.3.4) in HFA-227 propellant.  During the cascade impaction tests, 
the particles are deposited on the different stages depending on their aerodynamic size.  
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The results shown in Table 4.2 thus serve as an in vitro metric for lung deposition 
efficiency.  The DNA content deposited on the ACI stages was determined using 
chitosanase/lysozyme digestion followed by PicoGreen® Assay as described earlier. 
 
Table 4.2.  Aerodynamic characteristics of the CS-DNA NPs alone and engineered as core-shell 
particles.  Polyplexes prepared with CS (31 kDa, 80% DDA), and pMDI formulations in HFA-227 at 298 K 
and saturation pressure of the propellant.  CS-DNA core-shell particles at 2 mg.mL
-1
 of propellant.  DNA 
concentration ca. 4 µg.mL
-1
 (Calf Thymus) and ca. 6 µg.mL
-1
 (gWIz-GFP) for all formulations. Results in 
µg DNA ± s.d. (s.d. = standard deviation) for n = 3 (three independent runs) and twenty actuations each. 
 
Stages 
 
CS-DNA NPs containing gWIz-GFP 
DNA at nominal N/P ratio of 7 
 
 
CS-DNA NPs containing Calf Thymus 
DNA at nominal N/P ratio of 6 
 
 
Polyplexes 
alone 
 
 
Polyplexes loaded in 
core-shell particles 
 
 
Polyplexes 
alone 
 
 
Polyplexes loaded in 
core-shell particles 
 
 
Actuator 
Induction Port 
Stage 0 (9.0-10.0 µm) 
Stage 1 (5.8-9.0 µm) 
Stage 2 (4.7-5.8 µm) 
Stage 3 (3.3-4.7 µm) 
Stage 4 (2.1-3.3 µm) 
Stage 5 (1.1-2.1 µm) 
Stage 6 (0.7-1.1 µm) 
Stage 7 (0.7-0.4 µm) 
Filter (0.0-0.4 µm) 
FPF (%) 
MMAD (µm) 
GSD 
 
 
0.2 ± 0.0 
1.0 ± 0.4 
0.4 ± 0.1 
0.1 ± 0.2 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
0.1 ± 0.1 
0.2 ± 0.1 
0.4 ± 0.2 
30.2 ± 2.6 
1.3 ± 0.3 
- * 
 
 
1.1 ± 0.4 
3.0 ± 2.6 
2.3 ± 2.5 
0.6 ± 0.4 
0.9 ± 0.5 
0.9 ± 0.7 
2.7 ± 2.4 
1.8 ± 1.3 
0.7 ± 0.2 
0.7 ± 0.1 
1.2 ± 0.2 
56.6 ± 10.6 
2.2 ± 0.8 
4.1 ± 0.3 
 
 
0.0 ± 0.1 
5.5 ± 2.9 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
1.0 ± 0.0 
17.7 ± 7.6 
- * 
- * 
 
 
1.4 ± 0.9 
0.8 ± 0.7 
1.1 ± 0.9 
0.8 ± 0.8 
1.0 ± 1.0 
0.8 ± 1.0 
0.8 ± 0.6 
1.2 ± 0.9 
0.8 ± 1.0 
0.6 ± 0.7 
1.2 ± 0.8 
63.0 ± 6.8 
2.0 ± 0.5 
4.7 ± 1.1 
 
 
* These values could not be calculated due to poor mass distribution on the ACI stages. 
 
The ACI results revealed a FPF of 57% for formulations prepared with CS-DNA 
core-shell particles using gWIz-GFP DNA, and a FPF of 63% for those with Calf 
Thymus DNA.  As expected, the FPF was lower for formulations prepared with 
polyplexes alone (no co-oligomer shell): 30% for those with gWIz-GFP DNA, and 18% 
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for those with Calf Thymus DNA.  FPF is a measure of the therapeutically beneficial 
portion of the inhaled mass of the formulation capable of reaching the lower respiratory 
tract,70 and thus indicate that the core-shell formulations are performing significantly 
better than those without the co-oligomer shell.  The somewhat high value of FPF (30%) 
for formulations prepared with polyplexes containing gWIz-GFP DNA may reflect the 
fact that the NPs had the opportunity to aggregate in clusters of larger diameters in the 
propellant, as observed during the physical stability experiments, thus attaining a more 
appropriate size range, closer to the expected optimum between 1 and 5 µm.23  The 
formation of such aggregates is undesirable, however, since it is uncontrollable, may 
affect the delivery dosage,71 and possibly their interactions with the lung epithelial 
cells.72  The results from Table 4.2, expressed as percentages, are shown in Figure 4.4. 
As seen in Figure 4.4, polyplexes alone were found to be entrapped mostly in the 
IP, stage 0 and filter, showing a very poor mass distribution along the other ACI stages, 
possibly due to widespread aggregation of the NPs in the propellant, because of the 
absence of a stabilizing shell.  On the other hand, pMDI formulations prepared with 
polyplexes engineered as core-shell particles showed a much better distribution of the 
DNA on the ACI stages, and also significantly less DNA entrapment in the IP.  In 
addition, the MMAD of the CS-DNA core-shell particles falls within the values suggested 
as appropriate for particle size distribution of aerosolized substances – 1 to 5 µm.23  The 
% DNA released per actuation was > 90% for CS-DNA polyplexes loaded in core-shell 
particles (for both types of DNA).  On the other hand, CS-DNA polyplexes formulated 
alone in pMDIs exhibited a % DNA released per actuation of ca. 30% for gWIz-GFP 
DNA, and ca. 80% for Calf Thymus DNA.  However, it is worth to mention here that this 
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somewhat high value for polyplexes alone (80%) is not related to the respirable stages 
(0 to filter), and mostly from the DNA entrapped in the IP, which is not part of the 
respirable fraction – Figure 4.4a. 
The results discussed earlier may be compared with those from pMDI 
formulations containing surfactant-coated pDNA particles prepared in HFA134a 
containing ethanol as co-solvent, and tested in an eight-stage ACI.13  Although the 
aerosol characteristics (FPF and MMAD) were not reported in that study, SEM images 
of the particulates deposited on the ACI stages revealed particles with variable 
diameters (< 10 µm with some agglomeration), but with a large fraction deposited on the 
stages four and five, suggesting that those particles were within the respirable size 
range.13 
In summary, the aerosol characteristics of the formulations containing CS-DNA 
NPs entrapped within the HFA-philic and biodegradable shell are significantly and 
statistically better (FPF tested with One-Way ANOVA, p-values < 0.05) than those 
observed for the polyplexes alone.  These results indicate that the co-oligomer shell 
helps reduce the forces between the polyplexes, thus improving the colloidal stability of 
the particles in the propellant, and ultimately the aerosol characteristics.  We have 
observed (and also confirmed by colloidal probe microscopy measurements) such 
screening effect in other systems stabilized by the LA-based polymers,24, 66, 67 and that 
physical stability in the propellant correlates well with the aerosol characteristics, that is, 
pMDI formulations showing good dispersion stability also show good aerosol 
characteristics. 
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4.3.6 In vitro transfection 
The transfection efficiency of the polyplexes alone and engineered as core-shell 
particles was qualitatively evaluated in vitro by detecting the expression of a green 
fluorescence protein in A549 cells, a type II alveolar epithelial cell line,73 using 
fluorescence microscope.  The results were compared with controls, both negative (free 
pDNA) and positive (TransFastTM).  The concentration of the reporter pDNA was kept 
constant for all systems, at 0.25 µg DNA per well.  The results are shown in Figure 4.5. 
 
 
Figure 4.5.  Fluorescence microscope images of A549 cells transfected in vitro with (a) free DNA 
(negative control); (b) CS-DNA NPs; (c) Core-shell particles loaded with CS-DNA NPs; (d) TransFast
TM
 
Transfection Reagent (positive control); (e) CS-DNA core-shell particles and (f) CS-DNA NPs after 6 
weeks of storage in HFA-227 at 298 K and saturation pressure of the propellant.  CS-DNA polyplexes 
prepared with CS (80% DDA, 31 kDa) and gWIz-GFP DNA at nominal N/P ratio of 7.  Dosage of 0.25 µg 
DNA per well.  All images at 10x magnification. 
 
CS-DNA NPs alone and those engineered as core-shell particles (Figure 4.5b 
and 4.5c) showed an intermediate level of in vitro transfection efficiency compared to 
negative and positive controls (Figure 4.5a and 4.5d).  The similarity of the results 
shown in Figure 4.5b and 4.5c indicates that the neither the co-oligomer shell nor the 
engineering steps for the preparation of the core-shell particles interfere in the 
(a) (b) (c)
(d) (e) (f)
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transfection process/biological activity of the pDNA.  It is also important to mention that 
DLS measurements of the CS-DNA core-shell particles in DMEM revealed that the size 
of the polyplexes does not change significantly (One-Way ANOVA, p-values < 0.05) in 
the presence of the co-oligomer (compared to the size before formation of core-shell 
particles).  It can be concluded, therefore, that the shell is performing its role of 
providing integrity to the particles while dispersed in the propellant, and at the same 
time breaking down in aqueous media, subsequently releasing the CS-DNA NPs to 
initiate the transfection process.  This water solubility of the co-oligomer shell is an 
important property that should help the NPs to rapidly disperse in the deep lung, 
avoiding potential macrophage uptake.23  Aqueous solubility should also aid in the 
removal of the co-oligomer from the lung tissue, thus minimizing any cytotoxic effects.74  
Combined, these results suggest that the selected CS (Mw, DDA), in combination with 
N/P ratio and other parameters discussed earlier, provide the appropriate 
characteristics for the polyplexes in the form of core-shell particles to overcome the 
intracellular barriers and successfully transfect the A549 cells in vitro.  Surfactant-
coated pDNA particles (5 µg pDNA per well) formulated in pMDIs have also been shown 
to transfect A549 cells in vitro.13  However, 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP, a cationic liposome dispersed in the culture medium) was required to aid in 
the transfection process,13 as free pDNA is not expected to show enhanced efficiency. 
Another result of great relevance is the fact that CS-DNA NPs (alone and 
engineered as core-shell particles) were able to successfully transfect A549 cells even 
after six weeks of storage in HFA-227, as shown in Figure 4.5e and 4.5f, indicating that 
the propellant does not have any effect on the biological functionality of the pDNA.  This 
115 
 
 
 
finding is in agreement with a previous report,13 which demonstrated that the in vitro 
transfection efficiency of surfactant-coated pDNA particles in A549 cells (with the help of 
DOTAP in the culture medium) is not altered after contacting pDNA particles with HFA-
134a propellant. 
 
4.3.7 In vitro cytotoxicity 
The evaluation of cell viability is a useful method to study the in vitro cytotoxicity 
of biomaterials.21  We tested the in vitro cytotoxicity of the polyplexes and co-oligomer 
on A549 cells using MTS assay, and the results are shown in Figure 4.6a, 4.6b and 
4.6c. 
 
 
Figure 4.6.  Cytotoxicity of (a) CS-DNA NPs; (b) OLA-g-CS co-oligomer; and (c) core-shell particles 
loaded with CS-DNA NPs.  Polyplexes prepared with CS (31kDa, 80% DDA) and gWIz-GFP DNA at 
nominal N/P ratio of 7.  All experiments carried out in A549 cell line. 
 
When assayed independently, neither CS-DNA polyplexes nor OLA-g-CS co-
oligomer reduce the cell viability of A549 cells within the concentration range 
investigated.  Even at high CS concentration (100 µg.mL-1), the cell viability was around 
100%.  The OLA-g-CS co-oligomer was also found to be non-toxic.  Cell viability was 
close to 100% up to extremely high concentration (13.5 mg.mL-1).  The results 
presented here are in agreement with previous studies that also have indicated CS and 
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CS-based polymers to be fairly non-toxic on lung cells at moderate to high 
concentrations.21, 75  This is indeed one of the main advantages in using CS for gene 
therapy applications.  This is indeed one of the main advantages in using CS for gene 
therapy applications. 
The results shown in Figure 4.6c indicate, however, that the viability of the lung 
alveolar epithelium cells can be impacted when they are exposed to CS-DNA NPs and 
co-oligomer at the same time, even at concentrations demonstrated to be non-toxic 
when each one is tested independently.  However, toxicity is only observed at extremely 
high concentrations of co-oligomer (6.5 and 13.5 mg.mL-1), which correspond to 361 
and 750 actuations from a 2 mg.mL-1 pMDI formulation, respectively, considering the 
ACI results shown earlier and that the particles emitted from a single actuation would be 
diluted in the lung alveolar fluid estimated to be 7 mL.76, 77  There results fare very well 
compared to the pMDI formulations containing surfactant-coated pDNA, where the 
viability of A549 cells was reduced to 60-70% upon contacting with equivalent dosage 
from 80 actuations.13  However, since those formulations were aerosolized directly on 
the cells, the cold-freon effect might have contributed to reduction in cell viability, as well 
as the presence of DOTAP in the cell culture medium.13 
 
4.3.8 Stability of CS-DNA polyplexes and integrity of gWIz GFP pDNA 
The protective efficacy of the pDNA against DNase I, upon complexation with the 
positively charged polymer (CS) was evaluated by gel electrophoresis.  CS-DNA 
polyplexes were incubated with different concentrations of DNase I, followed by release 
of the pDNA after digestion of CS by chitosanase/lysozyme.  The results are shown in 
Figure 4.7a.  The integrity of the pDNA after complexation with CS, core-shell particle 
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formation, and storage in HFA-227 propellant, was also analyzed by gel 
electrophoresis.  Particles in suspension were incubated with chitosanase/lysozyme for 
CS digestion, thus releasing the pDNA, whose structure was compared to free pDNA 
(control) as received.  The results are shown in Figure 4.7b. 
 
 
Figure 4.7.  (a) Gel electrophoresis for evaluation of the stability of complexed gWIz-GFP pDNA after 
exposure of the CS-DNA NPs to DNase I: free pDNA (control, lane 1); CS-DNA NPs freshly prepared 
before (lane 2) and after (lane 3) incubation with chitosanase/lysozyme; CS-DNA NPs + DNase I (1 U 
lane 4, 50 U lane 5, 0.5 U lane 6, 1 U lane 7, and 2 U lane 8 ) + chitosanase/lysozyme.  U means units 
DNase I per 1g pDNA.  (b) Gel electrophoresis for monitoring the integrity of gWIz-GFP pDNA after 
particle preparation and exposure to propellant HFA: free pDNA (control, lane 1); CS-DNA polyplexes 
freshly prepared before (lane 2) and after (lane 3) incubation with chitosanase/lysozyme; CS-DNA core-
shell particles freshly prepared before (lane 4) and after (lane 5) incubation with chitosanase/lysozyme; 
CS-DNA core-shell particles stored in HFA-227 at 298K and saturation pressure of the propellant for 12 
days before (lane 6) and after (lane 7) incubation with chitosanase/lysozyme. All CS-DNA polyplexes at 
N/P ratio of 7 – same as those used in all other studies. 
 
CS (31 kDa, 80% DDA) was able to successfully protect the gWIz-GFP pDNA 
against DNase I degradation up to 0.5 U enzyme per 1 g plasmid (Figure 4.7a).  The 
pDNA recovered from the polyplexes after treatment with DNase I (lanes 4, 5 and 6) 
showed essentially the same conformation to that not incubated with the endonuclease 
model (lane 3).  These results are comparable with those in the literature, which have 
shown that low Mw CS (22 kDa and 75% DDA)78 is able to provide protection to DNA 
against DNase I digestion at 0.5 U per 1 g DNA.  However, upon increasing the 
concentration of DNase I, the pDNA in the polyplexes was degraded, and only a small 
2 3 4 5 6 7 81 1 2 3 4 5 6 7
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portion of the open circular conformation (upper band, lanes 7 and 8) was recovered 
after CS digestion by chitosanase/lysozyme.  This is expected based on the relatively 
low Mw of CS.  It has been shown that even for polyplexes formed with high Mw CS 
(400 kDa, 85% DDA), protection can only be achieved to concentrations up to around   
1 U DNase I per 1 g DNA.79  Therefore, considering a range which DNase I assay is 
usually performed (up to 0.5 U per 1 g DNA) for polyplexes formed using low Mw CS 
(20-80 kDa)78, 80 the polyplexes studied here were able to provide an efficient protection 
for the GFP pDNA against nuclease degradation, and conform similarly to those 
reported in the literature. 
As seen in Figure 4.7b, polyplexes prepared with CS (31 kDa, 80% DDA, at N/P 
ratio of 7) effectively retarded the pDNA mobility (lane 2).  This result is in agreement 
with the literature, where the ability of CS to condense genetic material has been 
demonstrated.33  It can be also observed that the engineering of such polyplexes as 
core-shell particles did not affect the ability of CS to complex DNA (lane 4), and that 
storage of the polyplexes in propellant HFA (lane 6) did not impact the interaction 
between CS and DNA either.  The overall integrity of the active pDNA (combination of 
the supercoiled – lower band; and open circular – upper band) was largely retained 
during the studies, as can be concluded by comparing the bands from lanes 3, 5 and 7, 
with that from free pDNA (lane 1).  Reduction in the supercoiled form of the pDNA, upon 
complexation with CS, is mostly associated with the formation of the also active open 
circular form of the pDNA – see lane 3, and to a much lower extent with the increase in 
the non-active linear form (intermediate band).  No significant differences are to be 
expected in gene expression levels between supercoiled and open circular 
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conformations, while the linear pDNA is expected to be nearly 90% less efficient than 
supercoiled form.19  Such results are expected to be observed upon complexation of 
pDNA with CS.53  Further reduction in the supercoiled form into the open circular is 
observed upon formation of the core-shell structures (lane 5).  This is also to be 
expected upon further processing of the polyplexes.  Similar observations have been 
reported during the preparation of CS-DNA particles for DPIs under supercritical CO2 
processing.19  However, no further increase in the linear form is seen.  Most interesting, 
however, is to note that there are no further changes in the pDNA upon exposure of the 
core-shell structures containing the polyplexes to propellant HFA, in agreement with the 
in vitro transfection studies, and further suggesting the potential of the proposed 
platform for the delivery of polyplexes to the lungs. 
 
4.4 Conclusions 
In this work we demonstrated that DNA can be successfully formulated in pMDIs.  
Chitosan (CS)-DNA nanoparticles (NPs) were prepared by complex coacervation, using 
low Mw CS (31 kDa, 80% DDA).  The polyplexes showed high DNA encapsulation 
efficiency – greater than 90% (w/w), and appropriate size – average diameter less than 
200 nm.  Using emulsification-diffusion, the polyplexes were successfully encapsulated 
with high DNA loading efficiency within water soluble, biodegradable and HFA-philic co-
oligomer shell – up to 90% (w/w).  The chosen particle engineering strategy also 
allowed us to control the size range of the core-shell particles, which had an average 
diameter of 1 m, a key requirement for the generation of aerosols with enhanced deep 
lung deposition.  pMDI formulations of the core-shell particles prepared as dispersions 
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in HFA-227 propellant showed improved physical stability and excellent aerosol 
performance (MMAD = 2 m, and FPF of up to 63%), as measured by ACI.  In vitro 
studies revealed that the CS-DNA NPs engineered as core-shell particles were able to 
transfect A549 cells, even after several weeks of storage in the HFA-227, suggesting 
that the propellant does not have any effect on the biological functionality of the pDNA.  
In vitro cytotoxicity experiments showed that CS-DNA core-shell particles had no 
significant cytotoxic effect on A549 cells, even at very high concentrations.  All these 
results, when put in perspective, suggest that formulating polyplexes in core-shell 
particles is an efficient approach to deliver genes to the lungs using inexpensive and 
portable pMDIs to treat medically relevant pulmonary diseases, including asthma, 
COPD and cancer. 
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CHAPTER 5 
Dendrimer Nanocarriers and their Aerosol Formulations for siRNA Delivery to the 
Lung Epithelium 
 
5.1   Introduction 
RNA interference (RNAi) promotes silencing of gene expression in a post-
transcriptional manner,1 and its mechanism has been extensively discussed in 
literature.2, 3  The delivery of double-stranded small interfering RNA (ds-siRNA, typically 
consisting of 20 - 27 bp)4 which target the RNA-induced silencing complex (RISC) 
located into the cell cytoplasm is a very promising approach with great therapeutic 
potential to treat many diseases.1, 5  RNAi-based therapies have been studied as 
potential for treatment of several medically relevant pulmonary diseases, such as lung 
cancer,6, 7 cystic fibrosis,8, 9 asthma,10, 11 chronic obstructive pulmonary disease 
(COPD),10 respiratory syncytial virus (RSV),12 and severe acute respiratory syndrome 
(SARS) viral infection.13  However, the progress of siRNA delivery targeting locally the 
lung epithelium has been hampered largely by the lack of adequate nanocarriers 
capable to overcome the lung’s structure, extra and intracellular barriers present in the 
lung tissue, and formulation challenges related to the route of administration.1, 14, 15  
Therefore, the development of efficient nanocarries to deliver siRNA to the lungs and 
appropriate formulation strategies is very relevant. 
Poly(amidoamine) (PAMAM) dendrimers are dendritic polymers widely studied 
for biomedical applications.16  PAMAM dendrimers are highly branched polymers with 
low polydispersity, high functionality, and provide an ideal structure for construction of 
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effective drug carriers and gene transfer vehicles.16, 17  PAMAM dendrimers possess 
cationic primary amine groups (NH2) at their surface, which participate in the nucleic 
acid binding process forming nanoscale dendriplexes.  However, these promising 
vehicles have been less explored for the siRNA delivery to the lungs.18  Few reports in 
literature have investigated the in vitro knockdown efficiency of siRNA-4, 19 or antisense 
oligonucleotide- (AON)20 delivered to lung cells via dendriplexes, and up-to-date, there 
is no literature about the use of generation-four amine-terminated (G4NH2) PAMAM to 
deliver siRNA to lung cells.  Nonetheless, besides an adequate nanocarrier for siRNA, 
its route of administration to the lungs must be equally efficient. 
Oral inhalation (OI) is a very promising administration route for siRNA to the 
pulmonary epithelium, since it provides a direct and non-invasive mean of targeting 
different regions of the lungs.21  Pressurized metered dose inhalers (pMDIs) are the 
most widely used OI devices due to their portability, small size, long shelf life, reliability, 
ability of use even in patients with diseased lungs (propellant based and not respiratory 
driven) and low cost.22  However, to the best of our knowledge, no work has been 
reported on siRNA delivery to the lungs via pMDIs to date, and most of the in vivo 
studies use either intratracheal or intranasal routes.1, 14, 23  The most challenger barriers 
in formulating inhalable siRNAs in pMDIs are pertaining to (i) the aerodynamic size of 
the particles – for optimal deep lung deposition, the particle size needs to be between 
0.5 and 5 µm,57, 145, 146 and thus, nanocarriers > 500 nm trend to be exhaled due to their 
low inertia;24 and (ii) the quality of the dispersion – the particles must be very well 
dispersed in the propellant to provide good aerosol performance,25, 26 i.e., they need to 
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have an appropriate chemistry to be well-solvated by the propellant to prevent 
aggregation.26-28 
In this work we propose a portable propellant-based formulation for the OI 
delivery of siRNA, which addresses most of the challenges discussed above.  We report 
the preparation and characterization of siRNA-G4NH2 dendriplexes, and evaluate their 
in vitro gene knockdown efficiency in a model lung alveolar epithelium cells stably 
expressing enhanced green fluorescent protein (eGFP).  We propose different 
formulation strategies for the dendriplexes in pMDIs via encapsulation of those into 
microparticles formed from oligo(lactide)-grafted-chitosan (CSLA) co-oligomer or 
mannitol sugar alcohol, following evaluation of the aerosol performance.  This work is 
innovative since it discusses the gene knockdown provided by siRNA-G4NH2 
dendriplexes in human lung cancer cells, and addresses the formulation of siRNA in 
pMDIs, which have not been reported in literature yet.  Moreover, this work is relevant 
as pMDIs are the most widely used OI devices to deliver therapeutics to the lungs, and 
as new siRNA-based therapies to treat medically relevant pulmonary diseases are 
expected to continue in development. 
 
5.2 Experimental Section 
5.2.1 Materials 
Generation-four amine-terminated poly(amidoamine) dendrimer (PAMAM 
G4NH2, 14,215 g.mol-1, 64 NH2 surface groups) was purchased from Dendritech Inc., 
and provided in methanol (15.35 w/w).  Methanol was removed with the help of a rotary 
evaporator (Buchi R-200).  Double-stranded siRNA (ds-siRNA, sense: 5’- AAC UUC 
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AGG GUC AGC UUG C dTdT -3’; antisense:  5’- GCA AGC UGA CCC UGA AGU U 
dTdT -3’) was purchased from Bioneer Inc.  Double-stranded Dicer substrate siRNA 
(ds-DS-siRNA) targeting eGFP (sense: 5’- p ACC CUG AAG UUC AUC UGC ACC AC 
cg -3’; antisense: 5’- p CGG UGG UGC AGA UGA ACU UCA GGG UCA -3’) and a 
respective mismatch (Integrated DNA Technologies, IDT) were used in all gene 
knockdown experiments.  Capital letters represent ribonucleotides, underlined bases 
depict 2′-O-methylribonucleotides, lower case letters represent 2′-deoxyribonucleotides, 
“p” and “dTdT” depict an additional phosphate at the 5’-end, and thymine overhangs, 
respectively.  Deionized water (DI-water, resistivity of 18.2 MΩ.cm) was obtained from 
NANOpure® DIamond™ UV ultrapure water system (Barnstead International) and 
treated with DEPC (0.1% v/v) overnight, following autoclaving.  Diethylpyricarbonate 
(DEPC, high purity grade) and EDTA (0.5 M sterile solution, pH 8, DEPC treated) were 
purchased from Amresco.  A549 cells – human lung adenocarcinoma cell line, an in 
vitro model of Type II alveolar epithelium29 – were sourced from ATCC® (CCL-185TM, 
passage 82).  Gibco® Dulbecco's Modified Eagle Medium (DMEM, high glucose, 
GlutaMAX™, pyruvate), Gibco® Penicillin-Streptomycin Liquid (AB), Quant-iT™ 
PicoGreen ®, and Lipofectamine® 2000 Transfection Reagent were purchased from 
InvitrogenTM Life Technologies Corporation.  Fetal Bovine Serum Advantage (FBS, non-
heat inactivated, S11050) was purchased from Atlanta Biologicals Inc.  Trypsin EDTA 
1X (0.25% trypsin, 2.21 mM EDTA in HBSS) Corning® Cellgro® was purchased from 
Mediatech Inc.  CellTiter 96 ® AQueous Non-Radioactive Cell Proliferation Assay (MTS 
reagent powder) and TransFastTM Transfection Reagent were purchased from Promega 
Corporation.  Phenazine methosulfate (PMS, 95%) was purchased from MP 
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Biomedicals Inc.  eGFP lentiviral particles (LVP-340, 1107 IFU.mL-1, a puromycin gene 
under Rsv promoter allows the selection of transduced fluorescent positive cells) were 
purchased from GenTarget Inc.  Puromycin dihydrochloride (10 mg.mL-1) was 
purchased from Toku-E.  Cell culture ﬂasks Cellstar® (75 cm2), 24- and 96-well Costar® 
cell culture microplates (flat bottom, tissue culture treated, polystyrene, sterile) were 
purchased from Corning® Inc.  96-well microplate (black, flat bottom shape, 
polypropylene) was purchased from Greiner Bio One.  Ribonuclease A (RNase A, 
R5503, 43 U.mg-1 solid) from bovine pancreas, heparin sodium salt (H4784,              
194 U.mg-1) from porcine intestinal mucosa, D-mannitol (minimum 98%), chitosan (CS, 
100 - 300 kDa, 80% degree of deacetylation), 3,6-dimethyl-1,4-dioxane-2,5-dione 
(lactide, LA), Tin(II) 2-ethylhexanoate (Stannous octoate, SnOct2 , 95%) were 
purchased from Sigma-Aldrich.  RiboLock® RNase Inhibitor (RI, EO0381, 40 U.L-1) 
was purchased from Thermo Scientific.  SaeKem® LE Agarose was purchased from 
Lonza.  Ethidium bromide (98%, 10 mg.mL-1) was purchased from IBI Scientific.  Tris 
Base Ultrapure BioReagent (99.5%) was purchased from J.T.Baker.  Glacial acetic acid 
(100%), citric acid anhydrous (100%), phosphate buffered saline (PBS 10X solution), 
and microscope cover glasses (22  22 mm) were purchased from Thermo Fisher 
Scientific Inc.  Tris-HCl 1M pH 8, and TE 20X pH 7.4 buffers were purchased from 
Boston BioProducts.  Dibasic sodium phosphate anhydrous (99%) was purchased from 
EMD Chemicals Inc.  Ethyl acetate (99.5%) was purchased from Mallinckrodt 
Chemicals.  Propellant HFA-277 (Dymel 227 ea/P) was provided by DuPontTM.  2H, 3H-
perﬂuoropentane (HPFP, DuPontTM Vertrel® XF) was purchased from TMC Industries 
Inc.  Deuterated dimethyl sulfoxide (DMSO-d6, 99.9%) was purchased from Cambridge 
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Isotope Laboratories Inc.  Multi-75 silicon AFM probes for force modulation and light 
tapping (75 kHz, 3 N.m-1) were purchased from Budget Sensors.  Mica sheet was 
purchased from Ted Pella Inc. 
 
5.2.2 Preparation and characterization of siRNA-G4NH2 dendriplexes 
Dendriplexes were formed by mixing equal volumes (10 - 100 L) of (negatively 
charged) siRNA (50 - 150 g.mL-1 in RNase free DI-water) and (positively charged) 
PAMAM G4NH2 (150 - 3000 g.mL-1 in 20 mM Tris-HCl pH 7.4 buffer RNase free).19, 30  
siRNA solution was added dropwise into the G4NH2 solution under vortex at 3000 rpm 
(VWR Digital Vortex Mixer) for 1 min.  The siRNA-G4NH2 dispersions were kept at 
room temperature for at least 30 min before any further experiment to assure complete 
formation of the dendriplexes.30  The G4NH2 concentration was varied in order to 
prepare dendriplexes at different N/P ratios – the molar ratio between the primary amine 
groups (N) from G4NH2 and phosphate groups (P) from siRNA.31 
siRNA-G4NH2 dendriplexes dispersions (minimum of five independent batches, 
n = 5) were quantitatively analyzed using PicoGreen® assay32 in Synergy 2 Microplate 
Reader (BioTek, VT) for the uncomplexed siRNA content, which was calculated using a 
linear calibration curve (siRNA concentration vs. fluorescent units).  PicoGreen® is an 
ultrasensitive fluorescent nucleic acid stain used to quantify double-stranded DNA (ds-
DNA)32 and ds-siRNA in solution.33  The siRNA complexation efficiency (CE) was 
calculated based on the difference between the initial amount of siRNA added during 
the formation of the dendriplexes, and the non-entrapped free siRNA remaining in the 
dendriplex dispersion. 
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Light Scattering (LS, Malvern ZetaSizer Nano ZS) was used to evaluate size 
(diameter) and zeta potential () of the siRNA-G4NH2 dendriplexes.  Samples were 
diluted to 80 nM siRNA, and measurements were performed at 25C using refractive 
index, viscosity, and dielectric constant of the buffer (for size) or DI-water (for ).  
Dendriplexes were formed in RNase free DI-water for  , which was calculated using the 
Smoluchowski Model.31  A minimum of three independent batches (n = 3) were used to 
calculated an average size and . 
Scanning Electron Microscopy (SEM, Jeol/EO JSM-6510LV-LGS, 25 kV) and 
Atomic Force Microscopy (AFM, Pico SPM® LE Molecular Imaging) were used to 
investigate the morphology of the dendriplexes, which were formed in RNase free DI-
water.  For SEM imaging, several drops of the siRNA-G4NH2 dispersion were 
deposited on a microscope cover glass, dried overnight, and sputter-coated with gold 
(Ernest Fullan) under vacuum for 40 s.  The sizes of the dendriplexes were estimated 
from the SEM images using Image J 1.42q.34  The histogram of the measured 
diameters (> 400 particles) was fit to a Gaussian distribution, from which average and 
standard deviation were calculated.  For AFM imaging, 20 L of siRNA-G4NH2 
dendriplexes dispersion was deposited on a freshly cleaved mica sheet and incubated 
at room temperature for 5 min35 to allow the binding of the dendriplexes on the 
substrate.  The substrate was then washed with few drops of DI-water, and dried with 
gentle air flow.  AFM images were obtained using a Multi-75 silicon AFM probe in 
tapping mode.35 
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5.2.3 Gel retardation assay 
The capacity of G4NH2 to form complexes with siRNA was also examined by gel 
electrophoresis.  A known volume of the dendriplexes dispersions (equivalent to 300 ng 
siRNA) was loaded in the slots of casted non-denaturing agarose gel (1.5 % w/v in TAE 
1X pH 8.2 buffer) stained with ethidium bromide (0.5 g.mL-1).  The electrophoresis was 
performed at 60V (E0160-VWR Mini Gel Electrophoresis) for 40 min, and the siRNA-
dye migration was visualized under UV irradiation (FOTO/Analyst® Investigator/Eclipse 
with UV Transilluminator Fotodyne Inc.).  The images were recorded using the 
FOTO/Analyst® PC Image software (v.5). 
 
5.2.4 RNase protection assay 
Three RNase protection assays were performed as followed. (i) The 
determination of the minimal RNase A concentration needed to completely degrade 
bare siRNA is described in the Appendix B.  (ii) The effect of the N/P ratio on the 
protection efficiency against RNase A degradation.  Briefly, siRNA-G4NH2 dendriplexes 
at different N/P ratios were formed in buffer as described earlier, and 6 L dendriplex 
dispersions (equivalent to 250 ng siRNA) were incubated with 8 L RNase A in TE 1X 
pH 8 buffer (0.162 g RNase A per 1 g siRNA) for 6 h at 37C, following the addition of 
RiboLock® RNase inhibitor (RI, 1L = 40 U) and incubation for 30 min at 37C to stop 
degradation reaction.30  Dendriplexes were dissociated by adding 8 L heparin (455 U 
per 1 g siRNA) in TE 1X pH 8 buffer following incubation for 30 min at 37C.  Samples 
were frozen at -20C overnight, and the integrity of the siRNA was determined by gel 
electrophoresis at the same conditions applied for gel retardation assay.  (iii) The effect 
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of RNase concentration on the siRNA integrity at a fixed N/P ratio.  Briefly, siRNA-
G4NH2 dendriplexes at N/P 5 were incubated with increased concentrations of RNase 
(0.35, 0.7, 1.0, 1.5, and 3.5 g RNase A per 1 g siRNA) for 6 h at 37C, following the 
treatments with RI and heparin, as described earlier.  Appropriate controls (bare siRNA 
and dendriplexes +/- RNase A, and +/- heparin treatments) were included in all 
experiments.  Heparin decomplexation assay is described in Appendix B. 
 
5.2.5 In vitro release 
siRNA-G4NH2 dendriplexes at different N/P ratios were formed in buffer as 
described earlier.  A known volume of 0.1 M citrate/phosphate buffer (pH 5 or 7.4, to 
mimic intracellular endosomes/lysosomes and cytosol,36 respectively) was added to the 
dendriplexes dispersion (2.2 g siRNA) to make 2 mL, and samples were incubated in a 
water bath at 37C.  Aliquots of 50 L were taken out at each time point, placed in a 
black 96-well plate, and frozen at -20C.  The collected samples were quantitatively 
analyzed using PicoGreen® assay32 in Synergy 2 Microplate Reader (BioTek, VT) for 
the amount of siRNA released in each time point, which was calculated using a linear 
calibration curve (siRNA concentration vs. fluorescent units) and taking into account the 
amount of free and complexed siRNA removed out from the sample in each aliquot of 
50 L.  Experiments were performed in triplicates (n = 3). 
 
5.2.6 In vitro cytotoxicity 
A549 cells (passages 5 - 8 from the original passage provided by ATCC®) were 
seeded in a 75 cm2 cell culture ﬂask and subcultured until approximately 90% 
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conﬂuence.  The cell culture medium (DMEM supplemented with 10% FBS and 1% AB, 
v/v) was changed every two days.  Then, the cells were seeded in 96-well culture plate 
(5  103 cells per well) and cultured in 200 L culture medium for 24 h at 37C and 5% 
CO2 (Thermo Scientiﬁc Incubator, NAPCO 8000WJ).  For the cytotoxicity of bare 
PAMAM G4NH2, cells were rinsed with PBS 1X buffer, the medium was replaced by 
200 L of regular culture medium containing increased concentrations of G4NH2 
dendrimer (0 - 500 M), and the cells were kept in the incubator for 48 h at 37C and 
5% CO2.  For the cytotoxicity of dendriplexes, cells were rinsed with PBS 1X buffer, the 
medium was replaced by 100 L DMEM only containing increased concentrations of 
siRNA-G4NH2 dendriplexes at N/P 30 (0 - 25 M G4NH2, and 0 - 1.25M siRNA) 
formed in buffer as described earlier.  Cells were kept in the incubator for 6 h at 37C 
and 5% CO2.  They were then overlaid with 100 L of regular culture medium (the 
dendriplexes were kept in contact with the cells) and incubated for 72 h at 37C and 5% 
CO2.  The concentration ranges of G4NH2 and siRNA used in these cytotoxicity 
experiments were designed in such way that the concentrations of G4NH2 and siRNA 
applied in all gene knockdown and aerosol characterization fall within that.  Equally 
important, the incubation time in the cytotoxicity experiments falls within the usual time 
times (24 - 96 h) applied in gene knockdown experiments.37  The cell viability was 
assessed by MTS cell proliferation assay.38  Briefly, cells were rinsed with PBS 1X 
buffer, and 100 L DMEM only was added to the cells, followed by 20 L MTS/PMS 
solution.  Cells were incubated in this DMEM/MTS/PMS mixture for 4 h at 37C and 5% 
CO2.  MTS is bioreduced into formazan (which is soluble in the culture medium) by 
dehydrogenase enzymes found in metabolically active cells.38  Absorbance of formazan 
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at 490 nm was measured directly from the 96-well culture plate (Molecular Devices, 
Spectra Max 250) and is proportional to the number of living cells.  Thus, cell viability 
(%) was calculated as the ratio between the absorbance of treated (incubated with bare 
G4NH2 or dendriplexes) and untreated (G4NH2 and dendriplexes free) cells. 
 
5.2.7 In vitro gene knockdown 
In order to evaluate the knockdown efficiency achieved by siRNA-based 
dendriplexes, A549 cells stably expressing eGFP were developed as detailed in 
Appendix B.  After successfully establishing the eGFP A549 cell line, eGFP knockdown 
experiments were performed.  We tested both, the ds-DS-siRNA targeting eGFP – the 
positive sequence called siRNA(+), and the eGFP-mismatch ds-DS-siRNA, the 
scramble or negative sequence called siRNA(–).  Dendriplexes at different N/P ratios 
were formed between G4NH2 and siRNA(+) and siRNA(–) as described earlier.  
Commercial transfection reagents (Lipofectamine® 2000 and TransFastTM)37, 39 were 
used as positive controls, and free siRNA (+ and –) was used as a negative control.  All 
eGFP knockdown experiments were performed according to Lipofectamine® 2000 
protocol.37  Firstly, eGFP stable A549 cells (passages 10 - 20 from the original passage 
provided by ATCC®) were seeded in a 75 cm2 cell culture ﬂask and subcultured until 
approximately 90% conﬂuence.  The cell culture medium (DMEM supplemented with 
10% FBS and 2.5 g.mL-1 puromycin selective antibiotic) was changed every two days.  
Then, the cells were seeded in a 24-well culture plate (50,000 cells per well) and 
cultured in 500 L DMEM supplemented with 10% FBS (v/v, no antibiotics) for 24 h at 
37C and 5% CO2 (Thermo Scientiﬁc Incubator, NAPCO 8000WJ).  Cells were rinsed 
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with PBS 1X buffer, and 250 L transfection medium (DMEM containing siRNA(+) or 
siRNA(–) equivalent to 20 pmol per well, 80 nM siRNA) was added, and the transfection 
proceeded for 6 h at 37C and 5% CO2.  Then, the transfection medium was replaced 
by 500 L culture medium (DMEM + 10% FBS, no antibiotics) and the cells were 
returned to the incubator for 72 h at 37C and 5% CO2.  Cells were dispersed in 1 mL 
PBS 1X buffer, and the median fluorescence intensity (MFI) was measured by flow 
cytometry (FACS, HWCRC 615 – BD LSR II Analyzer in Microscopy) with data from 
10,000 to 20,000 cells.  Untreated non-eGFP and eGFP stable A549 cells (siRNA or 
dendriplexes free) were used as controls.  The MFI level of eGFP expression in 
untreated eGFP stable A549 cells was taken as 100%.  The % eGFP knockdown 
efficiency was calculated by correlating the eGFP expression of untreated eGFP stable 
A549 cells with that from transfected cells. 
The effect of the propellant HFA-227 on the biological activity of the siRNA was 
also investigated.  Briefly, a known amount of siRNA (+ and –) dissolved in RNase free 
DI-water was placed in a pressure proof glass vial, frozen at -20C overnight, and 
lyophilized (Labconco Freeze Zone 1) at -47°C and 0.055 mbar for 48 h.  The vial was 
closed with a pressure valve (HiP, 15-11AF1) and the propellant HFA-227 was filled into 
the vial with the help of a manual syringe pump (HiP, 50-6-15) and a home-built high-
pressure ﬁller.  The siRNA was stored in HFA-227 at 25C and saturation pressure of 
the propellant, simulating a pMDI formulation of bare siRNA.  After two months, the 
propellant HFA-227 was released by depressurization, and the siRNA was allowed to 
dry at room temperature, following its dissolution in a known volume of RNase A free 
DI-water, making a siRNA concentration of 10 nmol per 1 mL.  As control, an aliquot of 
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the lyophilized siRNA (+ and –) was kept in a freezer at -20C instead of being stored in 
pressurized, liquid HFA.  Gene knockdown experiments (as described earlier) were 
performed with these siRNA sequences (+ and –) to evaluate the effect of storage under 
a compressed HFA environment.  All transfection experiments (siRNA as received, 
stored in HFA and a freezer) were performed in a minimum of triplicates (n = 3). 
 
5.2.8 Preparation of CSLA microparticles loaded with dendriplexes.   
The biodegradable, water soluble, and HFA-philic CSLA co-oligomer was 
synthesized according to our previous work.40  CSLA was composed by short segments 
of lactide – oligo(LA) – grafted onto low Mw CS via ring-opening polymerization.40  
Details about its synthesis and characterization can be found in Appendix B.  
Emulsification diffusion40 was employed to prepare core-shell microparticles of CSLA 
loaded with siRNA-G4NH2 dendriplexes.  Briefly, 15 mg CSLA was dissolved in 800 L 
RNase free DI-water, and combined with 200 L dispersion of siRNA-G4NH2 at N/P 10.  
The mixture (equivalent to 5 - 10 g siRNA) was emulsified in 19 mL ethyl acetate using 
sonication bath (VWR, P250D, set to 180 W) for 5 min at 15 - 20C making a water-in-
oil (W/O) emulsion, which was quickly transferred to 180 mL ethyl acetate.  Core-shell 
microparticles loaded with siRNA-G4NH2 (CSLA as shell and dendriplexes as core) 
were thus formed, collected via centrifugation (5,000 rpm for 20 min) and dried in air-
flow at room temperature. 
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5.2.9 Preparation of mannitol microparticles loaded with dendriplexes 
siRNA-G4NH2 at N/P 10 were formed in buffer as described earlier, and 200 L of 
the dendriplex dispersion (equivalent to 10 g siRNA) was combined with 30 mg 
mannitol previously dissolved in 800 L RNase free DI-water.  The mixture was spray-
dried (BUCHI Mini Spray Dryer B-290) using the following parameters: atomizing air        
flow = 473 L.h-1, aspiration = 70%, pump ratio = 5%, nozzle cleaner = 0, inlet 
temperature = 45C, outlet temperature = 30 - 33C.  Nitrogen was the atomizing gas, 
and dry mannitol microparticles loaded with dendriplexes were accumulated in the 
collection vessel at the end of the glass cyclone. 
 
5.2.10 Characterization of CSLA and mannitol microparticles loaded with 
dendriplexes 
siRNA loading efficiency into microparticles was assessed by densitometry.  
Briefly, a known amount of particles was dissolved in 200 L TE 1X pH 8 buffer and 
incubated at room temperature overnight, so that the water-soluble mannitol or CSLA 
shell broke down.  Next, a known mass of heparin (equivalent to 455 U per 1 g siRNA, 
based on the estimation that all siRNA was loaded into the microparticles) was added to 
the mixture, which was vortexed until heparin dissolution.  The system was incubated 
for 30 min at 37C, so that the siRNA complexed with the G4NH2 was released (see 
heparin decomplexation assay in Appendix B).  Samples were frozen at -20C 
overnight, and gel electrophoresis was performed at conditions applied for gel 
retardation assay.  siRNA content encapsulated into microparticles was quantified by 
densitometry using Image J 1.42q34 based on the electrophoresis images.  
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Densitometry finds application in the quantification of proteins,8 DNA,41 and siRNA.42 
Details on this technique can be found in those publications.  Appropriate controls were 
employed – free siRNA mixed with heparin (positive control), and CSLA (or mannitol) 
mixed with heparin (no siRNA, negative control).  Four independent batches (n = 4) of 
microparticles loaded with dendriplexes were used to calculate the average of siRNA 
loading.  In addition, the integrity of the siRNA after dendriplexes formation and by 
encapsulation into CSLA or mannitol microparticles was also determined. 
The hydrodynamic diameter of the microparticles was assessed by LS.  Briefly, 
particles loaded with siRNA-G4NH2 at N/P 10 were dispersed in HPFP (2 mg per 1 mL) 
using a sonication bath, and measurements were performed at 25C using refractive 
index, viscosity, and dielectric constant of the HPFP, which is a model of propellant HFA 
that is liquid at ambient conditions.43  Next, HPFP was evaporated and 1 mL RNase free 
DI-water was added to the microparticles to break down the CSLA shell (or mannitol) 
and release the dendriplexes.  LS measurements were performed at 25C using 
refractive index, viscosity, and dielectric constant of the water, and thus, the 
hydrodynamic diameter of the dendriplexes was recorded, but at this time, in presence 
of the CSLA (or mannitol) dissolved in the aqueous medium. 
SEM was used to investigate the morphology of the microparticles, which were 
dispersed in HPFP using a sonication bath.  Several drops of the dispersion were 
deposited on a microscope cover glass, the HPFP was quickly evaporated by using air 
flow, and the glass was sputter-coated with gold (Ernest Fullan) under vacuum for 40 s, 
following acquisition of the images via SEM. 
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5.2.11 Preparation of the pMDI formulations and evaluation of their physical 
stability 
A known mass of microparticles (CSLA or mannitol) encapsulating siRNA-
G4NH2 dendriplexes (at N/P 10) was weighed into pressure proof glass vials (8412-B, 
West Pharmaceutical Services) and crimp-sealed (CroPharm, Inc) with a 63 μL 
metering valves (EPDM, 3M Drug Delivery Systems).  A known volume of propellant 
HFA-227 was added with the help of a manual syringe pump (HiP, 50-6-15) and a 
home-built high pressure ﬁller in order to make a 2 mg.mL-1 concentration.40  The 
particles were dispersed in the propellant using a sonication bath (VWR, P250D, set to 
180 W, 15 - 20°C).40  The physical stability was investigated via sedimentation rate 
experiment, i.e., by visually monitoring the quality of the dispersions as a function of 
time after stopping the mechanical energy from the sonication – digital images were 
taken according to the time.40  pMDI formulations of bare siRNA-G4NH2 dendriplexes at 
N/P 10 were attempted, as described in Appendix B.  The free dendriplexes were found 
not to disperse in the propellant. 
 
5.2.12 Aerosol characterization of the pMDI formulations 
An eight-stage Andersen Cascade Impactor (ACI, Copley Scientific) fitted with an 
USP induction port and operated with a flow rate of 28.3 L.min-1 at 25C and 75% 
relative humidity44 was used to evaluate the aerosol properties of the pMDI 
formulations, which were prepared as described earlier.  Prior each ACI test, the 
formulation was completely dispersed using a sonication bath for 10 - 15 min at 15 - 
20C, and five actuations were fired to waste.  Next, 50-65 actuations (depending on the 
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siRNA concentration in the formulation) were fired into the ACI, with an interval of 10 s 
between each actuation.40  The ACI was disassembled and had the actuator (AC), 
induction port (IP), and all stages rinsed with and kept in 20 mL RNase free DI-water for 
6 h in order to break down the water soluble CSLA shell (or mannitol) from the 
microparticles containing siRNA-G4NH2 dendriplexes.  Samples were frozen at -20C 
overnight, and lyophilized (Labconco Freeze Zone 1) at -47 °C and 0.055 mbar for 48 h.  
The collected powder was dissolved in 100 L TE 1X buffer pH 8 and incubated with a 
known mass of heparin (equivalent to 455 U per 1 g siRNA – see Appendix B) for      
30 min at 37C, in order to dissociate the siRNA from the PAMAM G4NH2.  Samples 
were frozen (-20C) overnight, loaded into the slots of non-denaturing agarose gel, 
following electrophoresis at conditions applied for gel retardation assay.  The siRNA 
content in each ACI stage was quantified by densitometry using Image J 1.42q34 based 
on the electrophoresis images and appropriate controls (presence or absence of siRNA, 
as described earlier).  The aerosol characteristics were thus calculated:  (i) fine particle 
fraction (FPF – the siRNA content on the respirable stages of the ACI (from stage 3 to 
ﬁlter) over the total siRNA content released into the impactor (from IP to ﬁlter) excluding 
the siRNA content remaining in the actuator);40  (ii) respirable fraction (RF – the siRNA 
content collected from stage 0 to filter over the total siRNA released into the impactor);27   
(iii) % siRNA recovered, and siRNA content in a single puff dose;  (iv) mass median 
aerodynamic diameter (MMAD); and (v) geometric standard deviation (GSD).  MMAD 
and GSD were calculated as described in the literature.40  ACI experiments were 
performed in duplicates (n = 2). 
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5.2.13 Statistical analysis 
One-Way ANOVA in OriginPro 8 SR0 v8.0724 (B724) software was used to 
perform all statistical analyses.  p values < 0.05 were considered statistically significant. 
 
5.3 Results and Discussion 
5.3.1 Preparation and characterization of siRNA-G4NH2 dendriplexes 
siRNA-G4NH2 dendriplexes at different N/P ratios were prepared and 
characterized with respect to their morphology, size and surface charge according to 
AFM, SEM and LS.  The results are summarized in Table 5.1.  Details of the 
characterization for one N/P ratio (N/P 20), including AFM and SEM micrographs, are 
shown in Figure 5.1. 
 
Table 5.1.  Size of siRNA-G4NH2 dendriplexes determined by LS and SEM as a function of the N/P ratio.  
Zeta potential () and siRNA complexation efficiency (CE) are also shown.  LS was performed with 
dendriplexes at 80 nM siRNA, and in 10 mM Tris-HCl pH 7.4 (for size) and pure water (for ).  Image J 
was used to estimate the size of the dendriplexes from the SEM images: histograms of the measured 
diameters (> 400 particles) were ﬁtted to Gaussian distributions, from which the average size and 
standard deviation was obtained. 
 
N/P ratio 
 
DLS 
 
SEM 
siRNA CE (%) 
Size (nm) PDI  (mV) Size (nm) 
 
5 
10 
20 
30 
 
267 ± 115 
246 ± 63 
262 ± 85 
254 ± 52 
0.4 ± 0.2 
0.4 ± 0.2 
0.6 ± 0.2 
0.5 ± 0.1 
+ 34 ± 9 
+ 36 ± 7 
+ 32 ± 4 
+ 33 ± 3 
285 ± 78 
285 ± 70 
207 ± 51 
257 ± 74 
97.3 ± 0.6 
96.2 ± 1.5 
97.2 ± 0.6 
97.5 ± 0.8 
 
It was observed that the hydrodynamic diameter of the dendriplexes did not vary 
substantially with the N/P ratio.  The average hydrodynamic diameter from all N/P ratios 
combined was ca. 257 nm.  This value is corroborated by SEM, with an average 
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diameter of 258 nm.  As seen in literature,35, 45, 46 the size of dendriplexes usually 
displays significant heterogeneities, as is the case for polyplexes prepared with other 
cationic polymers.  This heterogeneity has been attributed to the electrostatic and 
entropic nature of the complexation process.45 
 
 
 
Figure 5.1.  Size and morphology of siRNA-G4NH2 dendriplexes at N/P 20 as determined by LS (main 
distribution in the center), SEM (upper left inset), and AFM (lower left inset).  Histogram and Gaussian fit 
to the diameter distribution obtained from SEM images (> 400 particles) of the dendriplexes is also shown 
(upper right inset). 
 
The overall surface charge of the siRNA-G4NH2 dendriplexes did not show any 
specific trend as a function of the N/P ratio, with a magnitude of the order of 30 to 40, 
also in agreement with previous studies of dendriplexes with PAMAM dendrimers.46 
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5.3.2 Gel retardation assay of G4NH2 to siRNA 
The ability of G4NH2 to form complexes with siRNA as a function of the N/P ratio 
was investigated by gel electrophoresis (semi-quantitative) combined with PicoGreen® 
assay (quantitative).  The results are summarized in Table 5.1 and Figure 5.2. 
 
 
 
Figure 5.2.  siRNA complexation efficiency as a function of the N/P ratio, as quantified by PicoGreen® 
Assay of residual free siRNA in the dispersion after preparation of the dendriplexes.  Inset: Non-
denaturating agarose gel electrophoresis of the corresponding dendriplexes: N/P 0.2 (lane 2), 0.5 (lane 
3), 0.8 (lane 4), 1 (lane 5), 2 (lane 6), 3 (lane 7), 5 (lane 8), 10 (lane 9), 20 (lane 10), 30 (lane 11).  
Untreated siRNA control (300 ng) is shown in lane 1. 
 
The complexation efficiency (CE) of G4NH2 to siRNA is seen to be low (< 80%) 
at N/P < 1.  However, almost all siRNA was complexed with the at N/P ratios > 2 (siRNA 
CE > 95%).  These quantitative results assessed by PicoGreen® assay – measuring 
the uncomplexed siRNA remaining in solution after dendriplex formation – were 
confirmed by gel electrophoresis (inset in Figure 5.2).  The siRNA band is seen to 
disappear in the gel as the N/P ratio increases, indicating that the siRNA was largely 
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complexed with the PAMAM G4NH2 dendrimer, and thus, was unable to flow through 
the pores of the gel (compare lanes 2 - 11: siRNA-G4NH2 dendriplexes formed at N/P 
0.2 - 30, with lane 1: untreated siRNA control).  Therefore, these results reinforce that 
highly positively charged PAMAM G4NH2 is able to condense siRNA into NPs very 
efficiently, since very little uncomplexed siRNA was found to be free in the supernatant 
after the complexation (N/P > 2).  Similar findings have been reported in literature – 
starting at N/P 2 the relative fluorescence due to free siRNA in the medium after 
dendriplex formation was 30% (siRNA CE ca. 70%), as measured by ethidium bromide 
exclusion assay, and no band assigned to free siRNA is visualized in the non-
denaturing agarose gel after electrophoresis.47  In addition, higher siRNA CE (> 90%) 
have been reported for siRNA-based dendriplexes using cationic PAMAM at different 
generations (G4, G5, and G6) starting at N/P ratio 4, as quantified by densitometry 
using gel electrophoresis images.48 
 
5.3.3 Protection of siRNA by G4NH2 against RNase degradation 
siRNA is vulnerable to degradation by RNases,49 and one of the important 
potential advantages in using nanocarriers in siRNA therapeutic technologies is the 
ability to protect this frail cargo.  Thus, in order to evaluate the ability of PAMAM G4NH2 
to protect siRNA from RNase degradation, siRNA-G4NH2 dendriplexes were formed at 
several N/P ratios and incubated with the RNase A (the lowest concentration found to 
digest bare siRNA completely – 0.162 g RNase A per 1 g siRNA – as seen in 
Appendix B) for 6 h at 37C, following RNase inhibitor and heparin treatments, and gel 
electrophoresis so as to release and quantify the non-degraded siRNA.  The results are 
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shown in Figure 5.3.  PAMAM G4NH2 is seen to efficiently protect siRNA from RNase A 
degradation upon complexation.  For all tested N/P ratios, the siRNA released from the 
dendriplexes kept in contact with RNase A (lanes 3, 7, 11, and 15) was comparable to 
the siRNA released from dendriplexes which were not exposed to RNase A (lanes 5, 9, 
13, and 17, the positive controls). 
 
 
 
Figure 5.3.  RNase protection assay (non-denaturing agarose gel electrophoresis) of the siRNA-G4NH2 
dendriplexes as a function of the N/P ratio.  Dendriplexes incubated in the absence (-) or presence (+) of 
the treatments: RNase A (0.162 g per 1 g siRNA) for 6 h at 37 °C, followed by 1L (40 U) RiboLock® 
RNase inhibitor for 30 min at 37C to block RNase activity, and heparin (455 U per 1 g siRNA) for        
30 min at 37 °C to dissociate the siRNA from the dendrimer.  Aqueous medium:  TE buffer 1X pH 8.  
Untreated siRNA control (300 ng) before (lane 1) and after (lane 2) incubation with RNase A. 
 
In order to probe the protection efficiency provided by the PAMAM G4NH2 at 
increasing RNase A concentrations, siRNA-G4NH2 dendriplexes formed at N/P 5 were 
incubated with increased concentrations of RNase A (0.35, 0.7, 1.0, 1.5, and 3.5 g per 
1 g siRNA) for 6 h at 37C, following RNase inhibitor and heparin treatments, and gel 
electrophoresis.  The results are shown in Figure 5.4, and again indicate that the siRNA 
was sufficiently protected from RNase degradation upon complexation with G4NH2.  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
siRNA
G4NH2
RNase A
Heparin
Lane
+ + + + + + + + + + + + + + + + + +
- - + + + + + + + + + + + + + + + +
- + + + - - + + - - + + - - + + - -
- - + - + - + - + - + - + - + - + -
N/P 5 N/P 10 N/P 20 N/P 30
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Even at this relatively low N/P ratio (N/P 5) the siRNA was well protected when kept in 
contact with very high concentrations of RNase A (3.5 g per 1 g siRNA) – in Figure 
5.4, compare the siRNA from dendriplexes incubated in presence (lane 20) and 
absence (lane 22) of RNase A.  Literature results suggest that this protection ability 
should hold somewhat till even higher concentrations, as it was observed that 75% of 
the siRNA integrity is still maintained at RNase A concentrations 7-fold higher than the 
one studied here (at N/P 10).50  However, the experimental conditions laid out here 
were more severe than those reported in other works.51, 52   
 
 
 
Figure 5.4.  RNase protection assay (non-denaturing agarose gel electrophoresis) of the siRNA-G4NH2 
dendriplexes (N/P 5) as a function of the RNase A concentration.  Dendriplexes incubated in presence (+) 
or absence (-) of the treatments: RNase A (0.35, 0.7, 1.0, 1.5, and 3.5 g per 1 g siRNA, in lanes 4-7, 8-
11, 12-15, 16-19, 20-23, respectively) for 6 h at 37°C, followed by 1L (40 U) RiboLock® RNase inhibitor 
for 30 min at 37C to block RNase activity, and heparin (455 U per 1 g siRNA) for 30 min at 37 °C to 
dissociate the siRNA from the dendrimer.  Aqueous medium:  TE buffer 1X pH 8.  Untreated siRNA 
control (250 ng) in lane 1, after incubation with heparin (lane 2) and 0.35 g RNase A per 1 g siRNA 
(lane 3). 
 
5.3.4 In vitro release of siRNA from G4NH2 
The siRNA release from the dendriplexes was evaluated in vitro at 37C, in 
citrate/phosphate buffer at pH 5 and 7.4, in order to mimic endosomes/lysosomes and 
cytosol, respectively.36  The results are shown in Figure 5.5, and indicate that the siRNA 
in vitro release profile from dendriplexes (N/P 10, 20, and 30) is highly dependent upon 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
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the pH.  The release is much slower at acidic medium than at physiological pH.  At low 
pH (< 5) all primary and tertiary amines from G4NH2 are protonated53 and consequently 
the electrostatic interactions between the positively charged dendrimer and negatively 
charged siRNA increase, which results in stronger binding and lower siRNA released at 
low pH.  At physiological pH 7.4 the tertiary amines are deprotonated and only the 
primary amines are protonated53 which decreases the electrostatic interactions between 
siRNA and G4NH2, and as result, the release of the siRNA increases at higher pH. 
This degree of compactness observed at lower pH is also manifested on the fact 
that no burst release is observed at pH 5.0.  On the other hand, at physiological pH, a 
burst release was observed at 1 - 2 days, and it was ca. 3.5% or 5.5 pmol – based on 
the initial loading of siRNA into dendriplexes.  After 3 - 5 days, it was observed that 8 - 
10% siRNA was released from the dendriplexes, which corresponds to 13 - 16 pmol.  
The results in Figure 5.5 show that 48, 24, and 34% of the total siRNA complexed with 
G4NH2 is released from the dendriplexes at N/P 10, 20, and 30, respectively, after 20 
days in citrate/phosphate buffer pH 7.4 at 37C.  While no literature results are available 
for the in vitro release for siRNA from PAMAM-based dendriplexes, we can contrast the 
results obtained here with the release of oligonucleotides (ON) from PEI polyplexes.54  
At N/P 15 and 40 in PBS pH 7.4 and 37C, 55% of the ON was released after 20 days 
for those complexes, which is somewhat similar to the results obtained in our work. 
 
153 
 
 
 
 
 
Figure 5.5.  In vitro release of siRNA from dendriplexes in 0.1 M citrate/phosphate buffer (pH 5 and 7.4, 
mimicking intracellular endosomes/lysosomes and cytosol, respectively) at 37C.  siRNA-G4NH2 
dendriplexes differ by N/P ratio: N/P 10 (a), N/P 20 (b), and N/P 30 (c). 
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5.3.5  In vitro cytotoxicity of G4NH2 and siRNA-G4NH2 dendriplexes 
Cationic dendritic polymers, like polypropyleneimine (PPI), polylysine (PLL), and 
PAMAM may induce signiﬁcant in vitro cytotoxicity due to the high density of cationic 
groups on their surface.55  There are many reports discussing the effect of concentration 
and generation on the toxicity of dendrimers,17, 35, 55-57 which is a critical factor to be 
considered when evaluating the potential of dendrimers as nanocarriers for siRNA 
delivery.  In this work, in vitro cytotoxicity studies were performed with A549 cells by 
incubating them with bare G4NH2, and siRNA-G4NH2 dendriplexes at N/P 30, 
according to the MTS assay.38  The cell viability results are shown in Figure 5.6. 
 
 
 
Figure 5.6.  In vitro cytotoxicity of G4NH2 alone (a) and siRNA-G4NH2 dendriplexes at N/P 30 (b) in 
increased concentrations in A549 cell line.   = statistically different compared to untreated cells control; 
n.s.d. = no statistical difference among them (p value < 0.05, One-Way ANOVA). 
 
The results presented in Figure 5.6a indicate that the viability of A549 was > 85% 
when the cells were in contact with G4NH2 alone for 48 h at concentrations up to 5 M.  
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This result is in agreement with previous literature reporting that the viability of A549 
cells was > 80% for G4NH2 at low concentrations of 0.7 and 7 M, as evaluated by 
MTT assay after 72 h of incubation.58  Several other works report different cytotoxicity 
results for PAMAM G4NH2,47, 56, 57 and thus, the toxicity level of G4NH2 is dependent 
upon concentration, cell type, and incubation time.48  PAMAM dendrimers are known to 
be cytotoxic by causing membrane rupture, substantially related to the formation of 
cavities in the cellular membrane.48  Toxicity and other dendritic properties (interactions, 
mechanisms of cellular uptake, and intracellular fate) are most likely governed by the 
surface groups.59 
The toxic effects of siRNA-G4NH2 dendriplexes at N/P 30 (the highest N/P ratio 
applied in the gene knockdown experiments discussed next) to A549 were also 
investigated via MTS assay after 72 h contacting the dendriplexes with the cells.  The 
results in Figure 5.6b indicate that the cytotoxicity of the dendriplexes at N/P 30 was 
low, even at the highest concentration – viability of A549 cells was ca. 80% at 25 and 
1.25 M of G4NH2 and siRNA, respectively.  It has been reported in literature that J-774 
cells (macrophage-like cell line) showed 90 - 95% viability after 24 h incubation with 
siRNA-G4NH2 dendriplexes at N/P 10 (0.05 M siRNA) as measured by MTT assay.50  
Here in our work, at the same 0.05 M siRNA concentration, A549 cells showed ca. 
85% viability.  This result is interesting since the time of incubation and N/P ratio were 
both 3-fold higher than that reported in literature.50  Other work has reported that the 
viability of A549 was reduced to 45% when the cells were incubated with G5NH2/ON 
(0.16 M ON) dendriplexes at N/P 15 for 4 h, following measure by CellTiter-Blue®.20  
In our work, at similar 0.125 M siRNA concentration, the cell viability of A549 was ca. 
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80%.  These results are especially relevant and necessary in gene knockdown studies.  
When working in concentration regions of no toxicity, gene knockdown is not 
confounded with nonspecific toxicity.  At the harshest condition of the in vitro cytotoxicity 
studies, the cell viability of A549 was still ca. 80% after 72 h of incubation with siRNA-
G4NH2 dendriplexes at N/P 30 containing 25 and 1.25 M G4NH2 and siRNA, 
respectively.  In contrast, at the harshest condition of the in vitro gene knockdown 
experiments (discussed next), the A549 cells were incubated for 6 h only, with 
dendriplexes at N/P 30 containing 1.95 M and 80 nM G4NH2 and siRNA, respectively.  
At these latter G4NH2 and siRNA concentrations, the viability of A549 cells was at least 
ca. 90% (Figure 5.6b), and expected to be even higher at smaller N/P ratios.  In 
addition, cell debris was excluded during FACS analyses, and thus, the small fraction of 
dead cells due to toxicity (< 10% for the highest N/P ratio) is not expected to interfere in 
the FACS results. 
 
5.3.6  In vitro gene knockdown of siRNA-G4NH2 dendriplexes 
FACS of A549 cells stably expressing eGFP was used to investigate the gene 
silencing efficiency of siRNA-G4NH2 dendriplexes.  Lipofectamine® 2000 (LF) and 
TransFastTM (TF) were the commercial transfection reagents selected as positive 
controls.  TF is originally designed as a transfection reagent for DNA,39 but it has shown 
gene suppression ca. 60 - 90% in the in vitro delivery of siRNA(+).60  Bare siRNA was 
used as the negative control.  A549 cells that were not transduced (no eGFP) were 
used as reference.  Cellular debris due to dead or damaged dying cells was gated out 
during the FACS analyses to prevent any toxic effect of the nanocarriers to mask true 
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gene knockdown.  Transfection of eGFP stable A549 cells was performed with ds-DS-
siRNA targeting eGFP, the positive sequence siRNA(+), and an eGFP-mismatch, the 
scramble negative sequence siRNA(–).  The results are shown in Figure 5.7a, and 
indicate that the gene knockdown efficiency of G4NH2-siRNA(+) dendriplexes (average 
of 22 - 36%) was intermediate compared to LF (72%), TF (70%), and bare siRNA 
(2.8%).  No statistical difference was found when comparing gene knockdown as a 
function of the N/P ratio (One-Way ANOVA, p value < 0.05). 
 
 
 
Figure 5.7.  In vitro knockdown of eGFP expression in A549 cells stably expressing eGFP.  siRNA-
G4NH2 dendriplexes at N/P 5, 10, 20, and 30, were prepared with (a) siRNA as received from the 
supplier and (b) at N/P 20 with lyophilized siRNA stored in HFA-227 (HFA, at 25C and saturation 
pressure of the propellant) and in freezer at -20C (FRE, at 253 K) for 2 months.  Specificity of the 
knockdown (positive siRNA sequence, anti-eGFP) is maintained by comparison to effects with the 
negative siRNA sequence (scramble).  Lipofectamine® 2000 (LF) and TransFast
TM
 (TF) were the 
commercial transfection reagents used as controls, and bare siRNA was negative control.  G4NH2 
concentration at N/P 30 corresponds to 1.95 M, and siRNA concentration in all systems was 80 nM.  
 = statistically different compared to untreated eGFP A549 cells control;  = statistically different 
compared to eGFP A549 cells treated with bare siRNA; n.s.d. = no statistical difference among them (p 
value < 0.05, One-Way ANOVA). 
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While no gene knockdown have been reported for dendriplexes on A549 cells 
up-to-date, we try to contrast our results with the literature for other cell types.  For 
example, siRNA-G4NH2 dendriplexes at N/P 10 caused 12.5 and 22% inhibition of 
eGFP expression in J-774 (macrophage-like) and T98G (human glioblastoma) cell lines, 
respectively,50 and 10% eGFP knockdown in C-166 (mouse yolk sac embryo) cells.47  
Thus, the silencing efficiency obtained with siRNA-G4NH2 dendriplexes on eGFP 
expressing A549 cells seem to be improved.  
A reduction in eGFP expression in A549 cells was also observed when the 
scramble siRNA(–) was delivered using LF (34%), TF (19.5%), and G4NH2 (6 - 17%)  – 
Figure 5.7a.  It has been shown that LF-siRNA(–) complexes cause measurable and 
undesired gene silencing ca. 10 - 45% in several cell types.61-63  This unwanted eGFP 
suppression is most likely due to off-target effects64 which can be due to toxicity of the 
nanocarrier,61 but also depend on the similarity between the nucleotide sequence from 
the siRNA(–) and short motifs in messenger RNA (mRNA) and other unrelated genes 
not targeted during the transfection.64, 65  Off-target effects in RNAi are quite common 
and an issue of consideration when developing RNAi technologies,65 but may be hard to 
avoid,64 and are still not well understood.66 
Alterations in gene expression in vitro and in vivo have been problematic for 
several types of nanocarriers – e.g. linear and branched PEI,66, 67 PEG-PEI,66 PPI,49, 58 
diaminobutane (DAB),49, 58 and PAMAM.66, 67  In addition, siRNAs used as negative 
control for GFP target and deregulate endogenous genes with important roles in many 
pathways and in different cell lines, even though there are very small homologous 
region sequences between the siRNA(–) and the mRNA.64  However, the possible off-
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target effects should not annul the tremendous potential of RNAi in the development of 
siRNA-based therapies. 
 
5.3.7 In vitro gene knockdown of siRNA-G4NH2 dendriplexes exposed to 
propellant HFA 
In order to test whether the biological activity of the siRNA was preserved after 
the formulation in the pMDI (under HFA atmosphere), the gene knockdown activity of 
dendriplexes formed with siRNA that was lyophilized and stored under HFA-227 at 25C 
and saturation pressure of the propellant for two months, was compared to a control 
(lyophilized but stored at -20oC).  Gene knockdown experiments were performed on 
eGFP A549 cells with dendriplexes at N/P ratio of 20, and the results are shown in 
Figure 5.7b.  The results demonstrate that even after such harsh storage conditions in 
propellant HFA, the siRNA(+) was still biologically active to silence the eGFP expression 
in A549 cells – around 69% and 21% eGFP knockdown for TF and dendriplexes at N/P 
20, respectively – and low off-target effects were caused by the delivery of siRNA(–).  
Similar values of eGFP suppression were obtained with the control siRNA(+) that was 
not stored under HFA-227 – 68% and 21% for TF and N/P 20, respectively.  In addition, 
these results are readily comparable to those reported earlier (Figure 5.7a) for siRNA(+) 
as received – 70% eGFP knockdown for TF and 28% for N/P 20.  Collectively, these 
results indicate that the biological activity of the siRNA is kept even after long-term 
exposure in propellant HFA. 
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5.3.8  Preparation and characterization of microparticles loaded with 
dendriplexes 
There is one major obstacle in the regional delivery of the dendriplexes to the 
lungs when using OI devices.  While the dendriplexes are in the order of nanometers in 
size, the optimum aerosol size for deep lung deposition is in the micron range (between 
0.5 to 5 m).68, 69  Particles with an aerodynamic diameter < 0.5 m may be easily 
exhaled, while those > 5 m tend to be deposited in the mouth and throat, ending up in 
the digestive tract.  In the case of pMDIs, another hurdle that needs to be overcome is 
the physical stabilization of the microparticle dispersions (suspension) in the low 
dielectric propellant HFA.25, 26 
It is necessary, therefore, to develop particle engineering strategies capable of 
forming stable suspension of the dendriplexes in the form of microparticles.  We 
demonstrate in this work two such strategies.  One consists in encapsulating the 
dendriplexes within mannitol microparticles, via spray drying, and the other is the use of 
a CSLA co-oligomer shell formed during emulsification diffusion.  Mannitol was chosen 
as it is a generally recognized as a safe (GRAS) excipient widely used as bulking agent 
and non-active carrier in dry powder inhalers.70  Mannitol particles alone also have 
shown to have less adhesion/cohesion in propellant HFA, slower sedimentation rates, 
and superior aerosol performance than other sugars such as lactose.71  The CSLA co-
oligomer was chosen because it is water soluble, degradable and non-HFA soluble – 
the shell will not disintegrate in HFA but will break down when in contact with the fluid 
lining the lungs.  The ester groups from the oligo(LA) are HFA-philic,25, 28 and 
microparticles formed with CSLA shell have shown enhanced physical stability in 
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propellant HFAs.26, 27, 40  The size and morphology of the CSLA and mannitol 
microparticles containing siRNA-G4NH2 dendriplexes at N/P 10 were evaluated by LS 
and SEM.  The results are shown in Figure 5.8. 
 
 
 
Figure 5.8.  Size and morphology of mannitol (a) and CSLA (b) microparticles loaded with siRNA-G4NH2 
dendriplexes at N/P 10 as determined by LS (main distribution on right) and SEM (lower left inset).  
Particles were dispersed in HPFP (2 mg.mL
-1
) to perform LS, and after that, the HPFP was evaporated 
and 1 mL DI-water was added to dissolve the mannitol or CSLA shell, and LS was performed again, but 
at this time, the size of the dendriplexes released from the mannitol (or CSLA) was measured by LS 
(upper left inset).  Non-denaturing agarose gel electrophoresis (upper right inset) show the integrity of the 
siRNA after its release from mannitol (or CSLA) shell and G4NH2 dendrimer by incubation in aqueous 
heparin solution (455 U per 1 g siRNA) for 30 min at 37°C.  Untreated siRNA (250 ng) as positive control 
in lane 1; mixture of G4NH2, mannitol (or CSLA) and heparin (but no siRNA) as negative control in     
lane 2; siRNA-G4NH2 dendriplexes at N/P 10 loaded into mannitol (or CSLA) microparticles after 
incubation with aqueous heparin in lane 3. 
 
The hydrodynamic diameter of CSLA and mannitol microparticles measured by 
LS was found to be 2.0 ± 0.8 m and 4.6 ± 0.9 m, respectively – average and standard 
deviation calculated based on eight (n = 8) independent batches.  These results indicate 
that the dendriplexes-carrying microparticles are in the desired geometric diameter for 
appropriate deep lung deposition (> 5 - 6 m).71, 72  Additionally, the microparticles 
displayed a spherical morphology (SEM as inset in Figure 5.8), which is in agreement 
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with previous CSLA particles prepared via emulsification diffusion26, 40 and mannitol 
spray-dried particles.73 
It is worthwhile to mention that the size of the dendriplexes was measured by LS 
after contacting the microparticles with aqueous solution, and it was 236 ± 75 nm and 
192 ± 38 nm for CSLA and mannitol, respectively.  The size distribution of these 
dendriplexes is shown as inset in Figure 5.8 – average and standard deviation 
calculated based on five (n = 5) independent experiments.  Thus, the hydrodynamic 
diameter of the dendriplexes released from the shell are readily comparable to those 
(Table 5.1) before loading into CSLA or mannitol microparticles, and therefore, the 
process of forming the microparticles does not seem to induce any undesirable 
irreversible aggregation of the dendriplexes. 
The siRNA loading efficiency (% siRNA encapsulated from the initial content in 
dendriplexes) into CSLA and mannitol microparticles was measured via densitometry 
using Image J,34 based on the images obtained from gel electrophoresis using the 
protocol discussed in Section 5.2.10.  siRNA loading efficiency of 49.0 ± 8.4 % was 
found for CSLA (230 ± 20 ng siRNA per 1 mg CSLA particles), and 25.4 ± 4.0 % (229 ± 
47 ng siRNA per 1 mg mannitol particles) for mannitol.  The final yield was 65% and 
50% (w/w) after emulsification diffusion and spray drying, considering the initial content 
of CSLA and mannitol, respectively. 
The integrity of the siRNA after particle preparation was also evaluated using gel 
electrophoresis (inset in Figure 5.8).  The siRNA band after particle preparation was 
found to be very similar to the untreated siRNA control (compare lanes 1 and 3).  
However, the intensity of the band in lane 3 – which corresponds to the siRNA released 
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after breaking down the mannitol or CSLA shell and dissociation from G4NH2 
dendrimer – is weaker due to the reduced siRNA loading into the microparticles, as 
discussed above.  Collectively, these results demonstrate the feasibility of 
encapsulating siRNA-based dendriplexes into CSLA and mannitol microparticles via 
emulsification diffusion and spray drying processes, respectively.  The dendriplexes 
were successfully loaded into such microparticles (which showed appropriate size for 
further formulation in pMDIs), conserved their hydrodynamic diameter after particle 
processing and shell dissolution, and more importantly, the siRNA kept its integrity. 
 
5.3.9  Physical stability of microparticles loaded with dendriplexes in propellant 
HFA 
Sedimentation rate experiments of the microparticles containing dendriplexes at 
25C and saturation pressure of the propellant were performed in order to evaluate their 
physical stability in propellant HFA.  Microparticles were weighed into pressure proof 
glass vials, crimp sealed with 63 L metering valves, and a known volume of propellant 
HFA-227 was added to make 2 mg.mL-1.  The particles were dispersed with the aid of a 
sonication bath for 30 min at 15 - 20C.  Stability of the formulations was determined 
visually via sedimentation/flocculation rate as a function of the time after stopping the 
mechanical energy input from the sonication bath.  Digital images were taken, and the 
results are presented as insets in Figure 5.9. 
Dispersions of both CSLA and mannitol microparticles containing siRNA-G4NH2 
dendriplexes at N/P 10 in propellant HFA-227 showed excellent physical stability.  While 
some aggregation could be observed onto the walls of the canister and in the bulk 
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propellant, no strong flocculation or irreversible aggregation was observed (insets in 
Figure 5.9).  Aggregates formed due to sedimentation could be easily re-dispersed by 
simple manual agitation.  In the case of CSLA, the improved physical stability compared 
to dendriplexes alone, which are not dispersible in propellant HFA – Figure B5 in 
Appendix B, arises due to the enhanced solvation of the ester groups (LA chains) of 
CSLA by the propellant HFA.25, 28  In the case of the mannitol, the reasons for the 
enhanced stability are less clear, but we expect to have an improved density matching 
to HFA-277 since spherical spray-dried mannitol microparticles produce densities ca. 
1.47 - 1.51 g.cm-3 (depending on the spray drying conditions)74 and the density of HFA-
227 is 1.39 at 25C.43  Moreover, the fact that the cohesive forces for mannitol in HFA 
are relatively lower compared to other sugars71 indicates an enhanced solvation of that 
surface in the propellant, but this is relative to sugars and no comparison with CSLA has 
been shown. 
 
5.3.10 Aerosol performance of the pMDI formulations with the engineered 
microparticles 
An eight-stage ACI was used to characterize the aerosol properties of the HFA-
based formulations containing mannitol and CSLA engineered microparticles with 
siRNA-G4NH2 dendriplexes (N/P 10) loaded within their core.  As described earlier, free 
dendriplexes (negative control, with no mannitol or CSLA shell) did not disperse at all in 
propellant HFA-227 – the dendriplexes remained stuck onto the walls of the canister, as 
seen in Appendix B, and thus ACI tests could not even be performed.  The siRNA 
content for the pMDI formulations was quantified by incubation of the deposited mass of 
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each ACI stage with RNase free DI-water (which broke down the mannitol or CSLA 
shell, thus releasing the dendriplexes to the aqueous solution) followed by freezing, 
lyophilization, heparin decomplexation assay (which dissociates the siRNA from the 
G4NH2 – Appendix B), gel electrophoresis, and densitometry using the gel images, as 
described in the previous sections.  A summary of the results are shown in Table 5.2. 
 
Table 5.2.  Aerosol performance of pMDI formulations prepared with mannitol and CSLA microparticles 
loaded with siRNA-G4NH2 dendriplexes at N/P 10.  All formulations at 2 mg particles per 1 mL of HFA-
227 at 25C and saturation pressure of the propellant.  siRNA concentration of 290 - 550 ng.mL
-1
 in 
formulations prepared with dendriplexes-loaded into mannitol, and 420 - 505 ng.mL
-1
 in those prepared 
with CSLA.  Results in ng siRNA ± deviation for n = 2 (two independent canisters) and 50 - 65 actuations 
each, from AC to Filter. 
 
Stage 
siRNA-G4NH2 dendriplexes loaded into microparticles 
mannitol CSLA 
 
Actuator (AC) 
Induction Port (IP) 
Stage 0 (9.0 - 10.0 μm) 
Stage 1 (5.8 - 9.0 μm) 
Stage 2 (4.7 - 5.8 μm) 
Stage 3 (3.3 - 4.7 μm) 
Stage 4 (2.1 - 3.3 μm) 
Stage 5 (1.1 - 2.1 μm) 
Stage 6 (0.7 - 1.1 μm) 
Stage 7 (0.7 - 0.4 μm) 
Filter (0.0 - 0.4 μm) 
FPF (%) 
RF (%) 
Recovery (%) 
Single Puff Dose (ng) 
MMAD (m) 
GSD 
 
74.3 ± 27.6 
109.6 ± 87.4 
38.9 ± 0.4 
42.9 ± 14.1 
39.8 ± 22.2 
43.1 ± 2.2 
35.1 ± 8.6 
33.0 ± 6.9 
33.7 ± 5.6 
42.8 ± 12.9 
23.1 ± 32.6 
48.9 ± 5.7 
77.4 ± 9.9 
28.0 ± 10.5 
9.5 ± 3.2 
2.6 ± 0.5 
3.8 ± 0.4 
191.8 ± 13.7 
403.1 ± 61.2 
72.2 ± 17.5 
44.0 ± 47.6 
87.5 ± 0.0 
43.7 ± 28.9 
112.1 ± 33.3 
108.5 ± 5.2 
75.6 ± 52.8 
99.7 ± 46.9 
80.7 ± 17.6 
46.1 ± 2.5 
64.3 ± 4.0 
84.8 ± 0.1 
26.4 ± 0.7 
1.9 ± 0.7 
3.7 ± 0.1 
 
The FPF, an important aerosol characteristic that serves as a measure of the 
therapeutically beneficial portion of the inhaled mass of siRNA which would reach the 
lower respiratory tract,75 was determined from the ACI results.  The FPF for mannitol 
and CSLA microparticles was determined to be 49% and 46%, respectively, which is 
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excellent, falling within those of commercial HFA-based pMDIs (30 - 55% on average)26, 
76 even though no optimization of the pMDI formulations was attempted.  It is worth 
noticing that FPF for both formulations were not significantly different (One-Way 
ANOVA, p value < 0.05).  The RF – the siRNA content collected from stage 0 to filter 
over the total siRNA released into the impactor27 – was found to be a little higher for 
pMDIs formulated with mannitol microparticles (77%) than those with CSLA (64%), but 
again, without significant difference (One-Way ANOVA, p value < 0.05). 
The MMAD and GSD are properties that characterize the particles in the aerosol 
spray.  MMAD represents the aerodynamic diameter on a mass basis, and GSD is a 
measure of the spread of particle size around this median.77  As seen in Table 5.2, the 
MMAD and GSD of the mannitol and CSLA microparticles containing dendriplexes were 
not significantly different (One-Way ANOVA, p value < 0.05) from each other at 2.6 and 
1.9 m, and 3.8 and 3.7 m on average, respectively.  Since large particles with MMAD 
> 5 m tend to sediment in the oropharynx and upper airways, and particles with MMAD 
between 1 and 5 m tend to be deposited into bronchioles and deeper airways,15 the 
results presented here suggest that such microparticles from both strategies – mannitol 
and CSLA shell – would be able to deliver siRNA to the deep lungs.   
The considerable difference between both strategies came in the form of the total 
siRNA recovered and the siRNA content in a single puff dose, which were significantly 
different (One-Way ANOVA, p value < 0.05).  While the siRNA fraction recovered in the 
mannitol formulation was 28% only, 85% was recovered in the CSLA formulation.  The 
siRNA in a single puff dose from the mannitol formulation was only 9.5 ng, while that for 
CSLA formulation was 26 ng.  These results indicate that the strategy of encapsulating 
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siRNA-G4NH2 dendriplexes into CSLA microparticles using emulsification diffusion 
technique seems to have greater efficiency for delivering siRNA to the lungs. 
The results from Table 5.2 were expressed as percentages, and are shown in 
Figure 5.9. 
 
 
 
Figure 5.9.  Aerosol properties of the pMDI formulations prepared with siRNA-G4NH2 dendriplexes at 
N/P 10 loaded into (a) mannitol and (b) CSLA microparticles.  All formulations at 2 mg particles per 1 mL 
of HFA-227 at 25C, and saturation pressure of the propellant.  siRNA concentration of 290 - 550 ng.mL
-1
 
for pMDI formulations prepared with mannitol loaded with dendriplexes, and 420 - 505 ng.mL
-1
 for those 
prepared CSLA loaded with dendriplexes.  AC, IP, and F refer to actuator, induction port and ﬁlter, 
respectively.  Insets: Physical stability of freshly prepared pMDI formulations. 
 
Since there is no previous report in the literature discussing the formulation and 
aerosol characteristics of siRNA in pMDIs to date, the results shown here cannot be 
directly compared to other formulations, such as DPIs.73, 78  Collectively, our results 
presented and discussed here indicate that pMDI formulations from both microparticle 
engineering strategies proposed generate aerosols conducive to deep deposition of the 
siRNA to the lungs.  However, in terms of total siRNA recovered and the amount of 
siRNA actuated from the pMDI, the CSLA strategy showed a much greater efficiency. 
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5.4 Conclusions 
This study demonstrated that siRNA-based dendriplexes can be successfully 
formulated in pMDIs.  Dendriplexes were formed between siRNA and PAMAM G4NH2 
dendrimer, and showed very high siRNA complexation efficiency, and efficient 
protection against RNase degradation.  The in vitro release of siRNA from G4NH2 was 
found to be pH dependent, which can potentially help to keep the siRNA protected 
during intracellular traffic through endosomes and lysosomes, and facilitate its release 
in the cell cytosol.  At concentrations used to measure the in vitro gene knockdown 
efficiency, both dendrimer and dendriplexes were found to be non-toxic to lung cells.  
siRNA-G4NH2 dendriplexes demonstrated good eGFP knockdown efficiency, and more 
importantly, this efficiency was kept even after transfecting siRNA stored directly in 
propellant HFA, strongly indicating that the biological activity of the siRNA was 
successfully preserved under commercial/end user conditions.  Dendriplexes were 
loaded within non-active carriers – CSLA co-oligomer and mannitol sugar alcohol – and 
thus microparticles were formed with appropriate size for deep lung deposition when 
used in pMDIs.  The size of the dendriplexes and the siRNA integrity were kept after the 
particle preparation processes.  pMDI formulations prepared with CSLA and mannitol 
microparticles loaded with dendriplexes showed excellent physical stability and very 
good aerosol performance.  Therefore, all these results are very promising, and strongly 
indicate that formulating siRNA-based dendriplexes into appropriate non-active 
microparticles has great potential to efficiently deliver siRNA to the lung tissue using 
portable and inexpensive pMDIs.  Efforts to further optimize these proposed formulation 
strategies along with in vivo studies can help their development for knocking down 
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specific genes to treat medically relevant pulmonary diseases, including lung cancer, 
and cystic fibrosis, and asthma. 
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CHAPTER 6 
siRNA-Dendrimer Conjugates for the Lung Epithelium: Synthesis, 
Characterization, and Gene Silencing 
 
6.1   Introduction 
Since the discovery that RNA interference (RNAi) is operated by long double-
stranded RNA (ds-RNA) in a nematode,1 and that it can be mediated by small 
interfering RNA (siRNA) in mammalian cells,2 RNAi has become a potent tool in 
biological research, and an important therapeutic approach to treat genetic disorders.3  
RNAi promotes silencing of gene expression in a post-transcriptional manner,4 and its 
mechanism has been extensively discussed in the literature.3, 5-7  Specificity, potency, 
and versatility are the major advantages of RNAi.3  siRNAs are designed for high 
specific suppression of the target gene, and any type of gene can be targeted.  The 
synthesis of siRNA is simple and very straightforward in contrast to therapeutic proteins, 
for instance.  Compared to other types of gene therapies – e.g. DNA – siRNAs act in the 
cell cytoplasm thus avoiding an even greater barrier which is the nuclear envelope (in 
the case of DNA).  siRNAs are robust, potent, have low risk of cytotoxic effects, and are 
catalytic in nature.3  Therefore, RNAi offers great opportunity for the local and systemic 
treatment of  gene-causing and gene-promoting diseases such as cancer,8-14 diabetes,8 
and viral infections,9, 10 in different types of tissues and organs, such as skin,3, 15 lung,4, 
16-18 eye, nervous and digestive systems.3 
However, the progress of siRNA delivery systems has been hampered largely by 
the lack of efficient nanocarriers capable to overcome the many extra and intracellular 
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barriers that siRNA faces to reach its target (the cytosol).  Local extracellular barriers 
depend on the physiological structure of the target tissue.19  Phagocytosis and 
interaction with bloodstream components, degradation by serum nucleases, 
extravasation (the transport from the intravascular space within blood vessels into the 
tissue interstitium), transport across the interstitial space to the target cells, and 
diffusion through the extracellular matrix19, 20 are the extracellular barriers involved in 
systemic delivery of siRNA.  Cellular internalization, endolysosomal escape, 
degradation by nucleases during the cytoplasmic trafficking, release from the carrier into 
the cell cytosol, and assembly into the RNA-induced silencing complex (RISC) are the 
major intracellular barriers.21 
Since the administration of free siRNA usually fails to produce the desired 
therapeutic effect,19, 22 current research has focused on natural or synthetic carriers 
(viruses, lipids, peptides, and polymers) engineered to pack, protect, and deliver the 
siRNA to the target cell.22, 23  However, with regards to siRNA delivery systems based 
on the complexation with cationic polymers (polyplexes and dendriplexes, in the case of 
dendrimers) there are key disadvantages.  The sizes vary widely from as low as 50 nm 
to ca. 750 nm – the process of particle formation cannot be controlled (entropically 
driven) and thus the particle size distribution has high polydispersity and variable 
shapes24-26 which affect the cellular uptake.27  Moreover, the highly positive charges 
from the complexes can be cytotoxic due to non-specific interactions with the cellular 
components,28, 29 and moreover, cause aggregation in negatively charged fluids (e.g. 
serum, mucus, lung surfactant, and bronchoalveolar lavage – BAL).24, 28, 29  The 
positively charged complexes can be entrapped by the negatively charged fluid 
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components, and thus have reduced transport and cellular uptake.30  However, it has 
been demonstrated that charge is necessary, but not sufficient enough for cellular 
uptake.31  Additionally, in order to compact the siRNA into nanoparticles (NPs), high 
amount of the cationic polymer is required (nitrogen/phosphate ratio – N/P – between 5 
and 30) and due to this, the toxic effects may be significant.9, 32 
In order to address the issues discussed above, the direct conjugation of 
molecules (e.g. antibodies, peptides, and polymers) to siRNA has been proposed as an 
alternative which can improve in vivo pharmacokinetic behavior of the siRNA, enhance 
its biological half-life, and increase the delivery efficiency to the target cell population, 
while maintaining the gene silencing activity.33  Several reports have described the 
conjugation of siRNA with different compounds, e.g. HA,34 PLGA,35 PEG,36-43 PLL-PEG-
peptide,44 gold (Au)45, 46 and magnetic NPs,47 QD,48, 49 -tocopherol,50 poly(PEG 
acrylate),51 amphipathic poly(vinyl ether),52 and cell penetrating peptides.53-55  
Therefore, siRNA has a great versatility to be conjugated to several different molecules, 
and thus, the development of siRNA-based conjugates seems to be a viable strategy to 
overcome the extra and intracellular barriers present in the target tissue. 
PAMAM dendrimers are highly branched polymers with low polydispersity, high 
functionality, and provide an ideal structure for construction of effective drug carriers, 
gene transfer vehicles, and imaging of biological systems.56, 57  There has been a 
growing interest in the use of PAMAM with low generation (≤ G4) due to their low 
cytotoxicity at the needed concentrations in the delivery system.58  In terms of 
conjugation, PAMAM dendrimers are very attractive as polymeric nanocarriers (PNCs) 
due to their very small size (c.a. 4.5 nm), molecular uniformity, and abundance of 
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functional groups that allow for chemical modification and linkage of different 
molecules.9  Thus, PAMAM dendrimers are very promising PNCs for conjugation with 
siRNA.  However, besides the great potential of PAMAM, their application to direct 
conjugation with siRNA in order to develop siRNA-delivery systems has not been 
explored in literature to date. 
In this work we propose the use of generation-four amine-terminated PAMAM 
dendrimer (G4NH2) as PNC for conjugation with siRNA.  We report here a strategy for 
the conjugation that facilitates cytosol delivery, the characterization of the conjugates, 
and their in vitro gene knockdown efficiency.  G4NH2 and siRNA were conjugated via a 
reducible disulfide bond, and it is expected to be cleaved in the reductive cytosolic 
space, releasing the siRNA in the cytoplasm.33  The ability of G4NH2-siRNA conjugates 
to deliver siRNA to the lung epithelium was tested using in vitro gene knockdown 
experiments in A549 cells stably expressing eGFP.  This is the first report on siRNA-
dendrimer conjugates, and such siRNA-delivery system has potential for conjugation 
with target ligands, pH- and reducible-trigged molecules, and thus, the cell specificity 
and gene silencing efficiency can be improved.  Moreover, this work is relevant since it 
contributes for the development of siRNA-based therapies to treat medically relevant 
diseases. 
 
6.2 Experimental Section 
6.2.1 Materials 
Generation-four amine-terminated poly(amidoamine) dendrimer (PAMAM 
G4NH2) with 64 NH2 surface groups and 14,215 g.mol-1 (according to the supplier) was 
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purchased from Dendritech Inc.  G4NH2 was received in methanol (15.35 w/w), which 
was removed by rotary evaporation (Buchi R-200) prior to use.  N-succinimidyl 3-(2-
pyridyldithio) propionate crosslinker (SPDP) was purchased from ProteoChem Inc.  
Double-stranded Dicer substrate siRNA (ds-DS-siRNA with 25/27 bp) targeting eGFP 
(sense: 5’- p ACC CUG AAG UUC AUC UGC ACC AC cg -3’; antisense: 5’- p CGG 
UGG UGC AGA UGA ACU UCA GGG UCA -3’)59 was purchased from Dharmacon Inc. 
(Thermo Fisher Scientific Biosciences).  The 3’-end of the sense strand was modified 
with a thiol group (SH) and supplied in a protected form (SS) to prevent the formation of 
dimers.60  Capital letters in the sequence above represent ribonucleotides, underlined 
bases depict 2′-O-methylribonucleotides, lower case letters represent 2′-
deoxyribonucleotides, and “p” depicts an additional phosphate at the 5’-end.  An 
irrelevant ds-siRNA (19/21 bp) not targeting eGFP and having a thiol modification in the 
5’-end of the antisense strand was provided from Bioneer Inc.  Deionized water (DI-
water, resistivity of 18.2 MΩ.cm) was obtained from a NANOpure® DIamond™ UV 
ultrapure water system (Barnstead International), and treated with diethylpyricarbonate 
(DEPC, high purity grade) at 0.1% v/v overnight, following autoclaving.  DEPC and 
EDTA (0.5 M sterile solution, pH 8, DEPC-treated) were purchased from Amresco.  
A549 cell line (human lung adenocarcinoma cells, an in vitro model of Type II alveolar 
epithelium)61 was purchased from ATCC® (CCL-185TM, passage 82).  Gibco® 
Dulbecco's Modified Eagle Medium (DMEM, high glucose, GlutaMAXTM, pyruvate), 
Gibco® Penicillin-Streptomycin Liquid (AB), and Lipofectamine® 2000 Transfection 
Reagent were purchased from InvitrogenTM Life Technologies Corporation.  Fetal 
Bovine Serum Advantage (FBS, non-heat inactivated, S11050) was purchased from 
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Atlanta Biologicals Inc.  Puromycin dihydrochloride (10 mg.mL-1) was purchased from 
Toku-E.  Trypsin EDTA 1X (0.25% trypsin, 2.21 mM EDTA in HBSS) Corning® Cellgro® 
was purchased from Mediatech Inc.  TransFastTM Transfection Reagent was purchased 
from Promega Corporation.  Cell culture ﬂasks Cellstar® (75 cm2) and 24-well Costar® 
cell culture microplates (flat bottom, tissue culture treated, polystyrene, sterile) were 
purchased from Corning® Inc.  Dithiothreitol (DTT), fluorescein isothiocyanate (FITC), 
tris (2-carboxyethyl) phosphine hydrochloride solution (TCEP, Bond-Breaker®), sodium 
acetate anhydrous (99%), glacial acetic acid (100%), acetonitrile (HPLC grade, 99.9%), 
phosphate buffered saline (PBS 10X solution) were purchased from Thermo Fisher 
Scientific Inc.  Amicon® Ultra-15 and Ultra-0.5 Centrifugal Filters (3K and 30K MWCO, 
respectively) were purchased from EMD Millipore Co.  Dialysis membrane (1K MWCO 
Spectra/Por®) was purchased from Spectrum® Laboratories Inc.  Ellman’s Reagent – 
5,5'-dithio-bis-(2-nitrobenzoic acid) – was purchased from Alfa Aesar.  SaeKem® LE 
Agarose was purchased from Lonza.  Ethidium bromide (98%, 10 mg.mL-1) was 
purchased from IBI Scientific.  Tris Base ultrapure bioreagent (99.5%) was purchased 
from J.T.Baker.  Deuterium oxide (D2O, 99.9%) was purchased from Cambridge Isotope 
Laboratories Inc.  Monobasic sodium phosphate (monohydrate, 98-102%), dibasic 
sodium phosphate (anhydrous, 99%), and sodium chloride (99%) were purchased by 
EMD Chemicals Inc.  Sodium azide SigmaUltra, 2,5-dihydroxybenzoic acid (DHB, 98%), 
p-toluenesulfonic acid monohydrate (p-TSA, 98.5%) were purchased from Sigma 
Aldrich.  Dimethyl sulfoxide (DMSO, anhydrous, 99.7%, AcroSealTM) was purchased 
from Acros Organics.  Ethanol (200 proof) was purchased from Decon Labs. 
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6.2.2 Synthesis and characterization of G4NH2-PDP conjugates 
Figure 6.1(a) represents the reaction scheme between G4NH2 dendrimer and 
SPDP crosslinker.   
 
 
 
Figure 6.1.  Schematic illustrating the two-step preparation of G4NH2-siRNA conjugate.  (a) Synthesis of 
the G4NH2-PDP (3) via reaction between G4NH2 (1) and SPDP (2) crosslinker.  (b) Synthesis of G4NH2-
siRNA conjugate (5) via reaction between G4NH2-PDP (3) prepared in the first step and siRNA-SH 
immediately after thiol deprotection (4). 
 
A known amount of G4NH2 (1) was dissolved in 6 mL PBS:EDTA (100 mM 
sodium phosphate, 150 mM NaCl, 1 mM EDTA, 0.02 % sodium azide, pH 7.5 buffer),62 
and a known amount of SPDP (2) was dissolved in 2 mL anhydrous DMSO.  The 
G4NH2 solution was placed in ice-cold water, kept under agitation, and then the SPDP 
solution was added dropwise, and reacted for a total of 4 h.  The reaction proceeded at 
room temperature and under agitation for further 24 h.  The G4NH2-PDP conjugate (3) 
was concentrated using Amicon® Ultra-15 Centrifugal Filter (3K MWCO), followed by 
purification with RNase free DI-water to remove unreacted SPDP.  The purified G4NH2-
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PDP conjugate was frozen at -20C overnight and lyophilized (Labconco Freeze Zone 
1) at -47°C and 0.055 mbar for 48 h. 
The final product (G4NH2-PDP conjugate) was stored at -20C and 
characterized according to the Pyridine-2-Thione Assay62 to determine the level of 
SPDP modification on the G4NH2.  Briefly, the absorbance of the conjugate was 
measured in UV-Vis Spectrophotometer (JASCO V-630 with the SAH-769 One Drop 
Accessory) before and after reaction with DTT as reducing agent, which breaks the 
disulfide bond in the pyridyldithiol-activated dendrimer (G4NH2-PDP), and thus, enables 
the release of pyridine 2-thione, a molecule that is UV active at 343 nm. 
The molecular weight (Mw) of the pure G4NH2 and G4NH2-PDP conjugate was 
evaluated by MALDI-TOF (Bruker Ultraflex).  Briefly, the sample was dissolved in a 
mixture of DI-water and acetonitrile (50:50 v/v) and 1 µL was mixed with 1 µL of matrix 
solution (DHB, 30 mg.mL-1) on the target plate (MTP 384, Bruker) and allowed to dry at 
room temperature prior to MALDI-TOF analysis.  Proton Nuclear Magnetic Resonance 
(1H-NMR, Varian Mercury 400, D2O as solvent) was used to evaluate the chemical 
structure of the G4NH2 before and after conjugation of the SPDP crosslinker.  Light 
Scattering (LS, Malvern ZetaSizer Nano ZS) was used to measure size and surface 
charge (zeta potential, ) of the pure G4NH2 and G4NH2-PDP conjugate.  Samples 
were diluted to 1 mL using DI-water (5 - 50 M) and measurements were performed at 
25C using refractive index, viscosity, and dielectric constant of DI-water.   calculations 
were performed according to Smoluchowski Model. 
Fluorescent-labeled G4NH2-PDP conjugate was synthesized for the 
quantification of the number of siRNA molecules conjugated per dendrimer nanocarrier.  
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FITC was first conjugated to G4NH2, followed by the attachment of the SPDP on the 
dendrimer surface.  Briefly, a known amount of G4NH2 was dissolved in 15 mL 
anhydrous DMSO, and kept under agitation at room temperature.  A known amount of 
the catalist p-toluenesulfonic acid (p-TSA) was dissolved in 5 mL anhydrous DMSO, 
and added to the dendrimer solution.  Next, FITC was dissolved in 5 mL anhydrous 
DMSO, and added to the dendrimer solution as well.  The reaction proceeded under 
agitation, in the dark, and at room temperature for 48 h.  The product was dialyzed 
against DI-water (1K MWCO Spectra/Por® dialysis membrane) for 4 days, concentrated 
using Amicon® Ultra-15 Centrifugal Filter (3K MWCO), and purified with PBS:EDTA pH 
7.5 buffer62 supplemented with 1M NaCl followed by RNase free DI-water in order to 
remove pTSA and unreacted FITC.  The purified G4NH2-FITC conjugate was frozen at 
-20C overnight, lyophilized (Labconco Freeze Zone 1) at -47°C and 0.055 mbar for    
48 h, and characterized according to 1H-NMR and MALDI-TOF, as described earlier in 
this section.  Next, the G4NH2-FITC conjugate was reacted with SPDP according to the 
same methodology described earlier for pure G4NH2 and SPDP.  The G4NH2-FITC-
PDP conjugate was thus obtained, and characterized according to Pyridine-2-Thione 
Assay62, 1H-NMR, and LS, as detailed above. 
 
6.2.3 Synthesis and characterization of G4NH2-siRNA conjugates 
The reaction scheme for the conjugation of siRNA to the dendrimer nanocarrier is 
shown in Figure 6.1(b).  The 2-pyridyldithio group in the PDP molecule attached on 
G4NH2 reacts optimally with sulfhydryl groups (SH) at pH 7 - 8.62 
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However, prior the synthesis of the G4NH2-siRNA conjugates, the integrity of the 
siRNA-SH under the reaction conditions was evaluated via gel electrophoresis.  A 
known amount of the thiol-modified siRNA was deprotected according to protocol from 
the supplier,60 and the siRNA-SH was dissolved in 0.5 mL PBS:EDTA pH 7.5 buffer 
supplemented with 1M NaCl,62 kept under agitation and at room temperature for several 
days.  The reaction conditions were thus reproduced, but without the presence of PDP-
modified G4NH2 dendrimer.  Aliquots were sampled out from this simulated reaction 
according to specific time points and stored at -20C.  The samples were then loaded 
into the slots of a 2% (w/v) non-denaturing agarose gel prepared with TAE 1X buffer 
and stained with 0.5 g.mL-1 of ethidium bromide.  Untreated protected and deprotected 
siRNA were used as the controls.  The electrophoresis was performed at 60 V (E0160-
VWR Mini Gel Electrophoresis) for 40 min, and the siRNA-dye migration was observed 
under UV irradiation (FOTO/Analyst® Investigator/Eclipse with UV Transilluminator, 
Fotodyne Inc.).  The images were recorded using the FOTO/Analyst® PC Image 
software (v.5). 
The synthesis of G4NH2-siRNA conjugates was then performed according to 
reaction scheme in Figure 6.1(b).  A known amount of G4NH2-PDP was dissolved in 
0.5 mL PBS:EDTA 1M NaCl pH 7.5 buffer,62 kept under agitation and room temperature 
for 30 min.  Next, the air was purged from outside the flask using a light flow of nitrogen 
for 3 h.  The flow of nitrogen was then stopped, and the G4NH2-PDP solution was kept 
under agitation at room temperature in a sealed environment.  The thiol groups of a 
large excess of thiol-modified siRNA were deprotected according to the protocol.60  
Immediately after deprotection, the siRNA-SH (4) was dissolved in 0.5 mL PBS:EDTA 
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1M NaCl pH 7.5 buffer,62 added to the G4NH2-PDP (3) in solution, and the reaction 
proceeded under agitation, at room temperature for 4 - 5 days.  Prior the reaction, an 
aliquot of the siRNA-SH solution was used to quantify the amount of free sulfhydryl 
groups according to Ellman’s Assay63 to evaluate the thiol deprotection efficiency.44, 64  
The G4NH2-siRNA conjugate (5) was concentrated using Amicon® Ultra-0.5 Centrifugal 
Filter (30K MWCO), purified with several washes of PBS:EDTA 1M NaCl pH 7.5 buffer62 
and RNase free DI-water in order to remove unreacted siRNA-SH and G4NH2-PDP.  
The purified G4NH2-siRNA conjugates were stored at -20C. 
The siRNA content in the conjugate was quantified according to a UV linear 
calibration curve by measuring the siRNA absorbance at 260 nm.  To confirm the 
cleavage of the reducible disulfide bond between G4NH2 and siRNA, a known amount 
of G4NH2-siRNA conjugate (equivalent to 300 ng siRNA) was reacted with DTT 
(reducing agent) in PBS:EDTA pH 8.3 buffer, under vortex at 1500 rpm, room 
temperature for 3 h.  DTT was at the final concentration of 40 mM, which mimics the 
intracellular reducing environment65.  After the DTT reaction, the sample was stored at   
-20C overnight, and gel electrophoresis was performed as detailed earlier.  Free 
untreated siRNA and G4NH2-siRNA conjugate without exposure to DTT were used as 
controls.  The siRNA content conjugated on the G4NH2 was also quantified by 
densitometry using Image J 1.42q66 based on the electrophoresis images.35, 37, 67, 68 
The size and surface charge of the G4NH2-siRNA conjugates (equivalent to 1 - 5 
M siRNA) was evaluated by LS, as described in the previous section. 
Fluorescent-labeled G4NH2-siRNA conjugates were synthesized for the 
quantification of the number of siRNA molecules per dendrimer nanocarrier.  Briefly, the 
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G4NH2-FITC-PDP conjugate was reacted with siRNA-SH according to scheme shown 
in Figure 6.1(b), and thus the G4NH2-FITC-siRNA conjugates were prepared. The 
same methodology described earlier for the G4NH2-siRNA conjugates was used for 
reaction and characterization of the G4NH2-FITC-siRNA conjugates.  In addition, the 
G4NH2 content was quantified based on a UV linear calibration curve of G4NH2-FITC-
PDP by measuring the FITC absorbance at 502 nm, so that we could quantify the 
number of siRNA conjugated per dendrimer nanocarrier. 
 
6.2.4 In vitro gene knockdown 
In order to evaluate the gene knockdown efficiency in vitro of the G4NH2-siRNA 
conjugates, A549 cells stably expressing eGFP were developed as described in 
Appendix B.  After establishing the eGFP A549 cell line, eGFP knockdown experiments 
were performed using G4NH2 conjugated to ds-DS-siRNA targeting eGFP – the 
positive sequence siRNA(+) – and G4NH2 conjugated to an irrelevant ds-siRNA that 
does not target eGFP, the siRNA(–).  Thus, G4NH2-siRNA(+) and G4NH2-siRNA(–) 
conjugates were synthesized and characterized as described in the previous sections.  
Commercial transfection reagents (Lipofectamine® 2000 and TransFastTM)69, 70 were 
used as positive controls to deliver non-conjugated siRNA(+) and siRNA(–).  Free 
siRNA (+ and –) were used as a negative controls.  eGFP knockdown experiments were 
performed according to Lipofectamine® 2000 protocol.69  Firstly, eGFP A549 cells were 
seeded onto 75 cm2 cell culture ﬂasks and subcultured until approximately 90% 
conﬂuence.  The culture medium (DMEM with 10% FBS v/v and 2.5 g.mL-1 puromycin 
selective antibiotic) was changed every two days.  Then, eGFP expressing A549 cells 
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(passages 10 - 20 from the original passage provided by ATCC®) were seeded in a 24-
well culture plate (60,000 cells per well) and cultured in 500 L DMEM supplemented 
with 10% FBS (v/v, no antibiotics) for 24 h at 37C and 5% CO2 (Thermo Scientiﬁc 
Incubator, NAPCO 8000WJ).  Cells were rinsed with PBS 1X buffer, and 250 L 
transfection medium (DMEM containing siRNA (+ or –) equivalent to 20, 40, or 80 pmol 
per well – 80, 160, or 320 nM siRNA, respectively) was added to the wells, and the 
transfection proceeded for 6 h at 37C and 5% CO2.  The transfection medium was then 
replaced by 500 L culture medium (DMEM with 10% FBS only, no antibiotics) and the 
cells were returned to the incubator for 72 h at 37C and 5% CO2.  Cells were dispersed 
in 1 mL PBS 1X buffer, and the median fluorescence intensity (MFI) was measured by 
flow cytometer (FACS, HWCRC 615 - BD LSR II Analyzer).  Cellular debris due to dead 
or damaged dying cells was gated out during the FACS analyses to assure collection of 
data from 10,000 to 20,000 living cells.  Untreated non-eGFP and eGFP A549 cells 
were used as controls.  The level of eGFP expression in untreated eGFP expressing 
A549 cells was taken as 100% MFI.  The % eGFP knockdown efficiency was calculated 
by correlating the eGFP expression of the untreated eGFP A549 cells with that from 
transfected cells.  All transfection experiments were performed at a minimum of 
triplicates (n ≥ 3). 
 
6.3   Results and Discussion 
6.3.1 Synthesis and characterization of G4NH2-PDP conjugates 
G4NH2-PDP conjugates were prepared as shown in Figure 6.1(a).  The level of 
SPDP modification on the G4NH2 surface was quantitatively determined according to 
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the Pyridine-2-Thione Assay,62 and it was found to be ca. 15 PDP molecules per 
G4NH2.  1H-NMR spectrum of the G4NH2-PDP conjugate (Figure 6.2b) indicated the 
presence of protons corresponding to the aromatic ring of the thiopyridyl group71, 72 – 
7.059 ppm (1H, Ar), 7.588 ppm (1H, Ar), and 8.166 ppm (2H, Ar) – which evidence the 
successful linkage of the SPDP crosslinker to G4NH2.  Comparing the 1H-NMR spectra 
of the pure G4NH2 (Figure 6.2a) and G4NH2-PDP (Figure 6.2b) conjugate at the region 
6 - 9 ppm, the peaks assigned to PDP can be clearly observed.  Calculations based on 
the 1H-NMR spectrum of the G4NH2-PDP (Figure 6.2b) considering the integral 
intensities of the peaks at 8.166 ppm (2H from thiopyridyl group of the PDP) and 2.207 
ppm (248H from methylene next to the carbonyl group of the PAMAM G4NH2)73-76 
indicated 14 PDP molecules per G4NH2.  This result is in excellent agreement with that 
generated by UV-Vis spectroscopy method. 
MALDI-TOF spectrum of G4NH2-PDP conjugate revealed the Mw ca.        
17,817 g.mol-1 (upper right inset in Figure 6.2b) evidencing the conjugation of PDP 
when compared to the Mw of the pure G4NH2 (upper right inset in Figure 6.2a, Mw ca. 
14,090 g.mol-1).  Considering that each PDP molecule attached to the dendrimer 
surface adds the Mw ca. 213.3 g.mol-1 (upper left inset in Figure 6.2b) the number of 
PDP molecules linked to G4NH2 could be estimated to be 17, which is very consistent 
with previous results obtained from 1H-NMR and UV-Vis spectroscopy. 
LS measurements revealed that the  of the pure G4NH2 was +30.6 ± 8.1 mV, 
which falls in the range of previous  published in literature for PAMAM G4NH2.77, 78  
After the SPDP modification, the  of the G4NH2-PDP conjugates was determined to be 
+27.8 ± 7 mV, indicating only a slight reduction in .  Thus, the loss of protonable 
192 
 
 
 
primary amine groups on the dendrimer surface that happens upon the attachment of 
PDP molecules was balanced by the presence of pyridine groups in the PDP molecules, 
which may also undergo protonation.79-81  The hydrodynamic diameter of the pure 
G4NH2 was found to be 3.7 ± 0.3 nm (PDI = 0.3 ± 0.1), also in agreement with 
previously reported results,77, 82, 83 and no significant increase in size was detected in 
the G4NH2-PDP conjugates. 
 
 
 
Figure 6.2.  
1
H NMR characterization of (a) G4NH2, (b) G4NH2-PDP, (c) G4NH2-FITC, and (d) G4NH2-
FITC-PDP conjugates.  Insets:  molecular structures (upper left) and MALDI-TOF spectra (upper right). 
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The G4NH2-FITC conjugate was prepared for further reaction with SPDP 
crosslinker, in order to estimate the number of siRNA molecules per G4NH2.  FITC was 
conjugated to G4NH2 first, followed by the attachment of the SPDP crosslinker on the 
dendrimer surface.  1H-NMR of the G4NH2-FITC conjugate (Figure 6.2c) showed the 
presence of protons corresponding to the aromatic rings of the FITC molecule84 –   
6.399 ppm (6H, Ar) – indicating the successful attachment of FITC on the G4NH2 
surface.  Comparing the 1H-NMR spectra of the pure G4NH2 (Figure 6.2a) and G4NH2-
FITC conjugate (Figure 6.2c) at the region 6 - 7 ppm, the peak assigned to FITC can be 
clearly observed.  The Mw of the G4NH2-FITC conjugate was found to be ca.       
14,942 g.mol-1 according to MALDI-TOF (upper right inset in Figure 6.2c), which 
evidences a slight increase compared to the Mw of the pure G4NH2 (upper right inset in 
Figure 6.2a, Mw ca. 14,090 g.mol-1).  These results indicate the conjugation of ca. 2 
FITC molecules per G4NH2. 
The G4NH2-FITC conjugate was reacted with SPDP crosslinker.  
Characterization according to 1H NMR (Figure 6.2d) revealed protons that were 
assigned to the aromatic rings of the FITC molecule84 – 6.395 ppm (6H, Ar) – and 
protons corresponding to the aromatic ring of the thiopyridyl group of the PDP 
molecule71, 72 – 7.097 ppm (1H, Ar), 7.626 ppm (1H, Ar), and 8.206 ppm (2H, Ar).  This 
result indicates the successful conjugation of the SPDP crosslinker on the G4NH2-FITC 
conjugate.  Results from the Pyridine-2-Thione Assay62 (the UV method) along with 
calculations based on the 1H-NMR spectrum of the G4NH2-FITC-PDP conjugate 
(Figure 6.2d) indicated that such conjugate had similar number of PDP molecules linked 
on the dendrimer surface compared to the unlabeled previous one discussed above.  
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LS results revealed a  of +25.8 ± 1 mV for the G4NH2-FITC-PDP conjugates, which as 
expected, is very similar to the G4NH2-PDP conjugates. 
 
6.3.2 Synthesis and characterization of G4NH2-siRNA conjugates 
The integrity of the thiol deprotected siRNA-SH under reaction conditions 
(exposure to high salted buffer, stirring, and room temperature for several days) was 
qualitatively evaluated using gel electrophoresis.  The results are seen in Figure 6.3, 
and show that the bands corresponding to the siRNA-SH kept under reaction conditions 
up to 14 days (lanes 3 - 11) are readily comparable to those from untreated siRNA 
(lanes 1 - 2).  Since the reaction between siRNA-SH and G4NH2-PDP takes 4 - 5 days, 
these results indicate that the integrity of siRNA-SH after thiol deprotection is kept under 
the reaction conditions. 
 
 
Figure 6.3.  Non-denaturating agarose gel electrophoresis of siRNA-SH kept under reaction conditions 
(but no presence of PDP-modified G4NH2) for 6 h (lane 3), 1 day (lane 4), 4 days (lane 5), 5 days (lane 
6), 7 days (lane 7), 8 days (lane 8), 12 days (lane 9), 13 days (lane 10), and 14 days (lane 11).  Untreated 
siRNA before (lane 1) and immediately after (lane 2) thiol deprotection were used as controls.  All lanes 
were loaded with ca. 300 ng siRNA. 
 
G4NH2-siRNA conjugates were synthetized by the reaction between 
pyridyldithiol-activated dendrimer (G4NH2-PDP) and sulfhydryl-activated siRNA (siRNA-
1 2 3 4 5 6 7 8 9 10 11
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SH).  The result was the conjugation of siRNA onto G4NH2 via a crosslink containing a 
reducible disulfide bond, which may be cleaved in the cytosolic compartment (siRNA 
target site)33 by reducing molecules such as glutathione (GSH).85  The cytosol contains 
high concentration of GSH (2 - 10 mM) which can be 100 to 1000 times higher than that 
in the extracellular environment,86 thus making this a highly desirable targeted delivery 
strategy for siRNA, whose target site is the cell cytosol.  The cleavage happens via two 
thiol-disulfide exchange reactions.  Actually, the disulfide bond is expected to be 
transferred from the G4NH2-siRNA conjugate to two GSH molecules in two steps:87 (i) 
the thiolate (-S) of the GSH attacks the disulfide bond (-S-S-) (in this case from the 
G4NH2-siRNA conjugate), forming a mixed disulfide bond between the GSH and 
G4NH2 (or GSH and siRNA), which (ii) is attacked by another thiolate from the other 
GSH, releasing completely the G4NH2 and siRNA. 
The thiol deprotection efficiency of the siRNA prior its reaction with G4NH2-PDP 
(or G4NH2-FITC-PDP) was > 90% as measured by Ellman’s Assay.63  The reaction 
between siRNA-SH and G4NH2-PDP (or G4NH2-FITC-PDP) was carried out in high 
salt concentrated buffer to minimize the complexation between the positively charged 
PDP-modified dendrimer and the negatively charged siRNA-SH, which can hinder the 
desired reaction.  Purification of the G4NH2-siRNA and G4NH2-FITC-siRNA conjugates 
was performed using several washes of high salt concentrated buffer to remove all 
unreacted and complexed siRNA from the conjugates.37, 44, 45, 49 
The cleavage of the reducible disulfide bond between G4NH2 and siRNA was 
confirmed via agarose gel electrophoresis after reacting DTT and G4NH2-siRNA 
conjugate.  The results are shown in Figure 6.4, and indicated that the disulfide bond 
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between G4NH2 and siRNA can indeed be broken in a reducing environment similar to 
that of the cytosol. 
 
 
Figure 6.4.  Non-denaturating agarose gel electrophoresis of G4NH2-siRNA conjugate without (lane 2) 
and with (lane 3) DTT treatment.  Free and untreated siRNA control (300 ng) is shown in lane 1. 
 
The siRNA from the conjugate free of DTT (–DTT) is visualized as an upper band 
(lane 2) compared to that siRNA from the conjugate after DTT reaction (+DTT) which 
appears as a lower band (lane 3), and at the same level of the untreated free siRNA 
(control, lane 1).  The siRNA attached to the dendrimer travels at lower speed through 
the pores of the gel (lane 2) compared to the siRNA that was released from the 
dendrimer due to the cleavage of the disulfide bond by DTT (lane 3).  Similar behavior 
has been observed in the gel electrophoresis of siRNA conjugated to quantum dots 
(QD),48, 49 and can be attributed to the successful siRNA conjugation using a crosslink 
containing a reducible disulfide bond. 
The siRNA loading efficiency was found to be on average 45% (three batches 
G4NH2-siRNA conjugates), as calculated using the results from UV-Vis spectroscopy 
and densitometry, which showed excellent agreement (> 90%).  The characterization of 
G4NH2-FITC-siRNA conjugates indicated average loadings of 3 siRNA molecules 
1 2 3
siRNA
G4NH2-siRNA
DTT +--
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conjugated per G4NH2.  This result shows a good agreement with literature which 
report ca. 2 - 3 siRNA molecules per QD.48, 49  In contrast with siRNA delivery systems 
based on dendriplexes – nanoscale complexes formed between siRNA and 
dendrimers88 – the siRNA loading result obtained with the conjugates reveals a great 
opportunity to deliver siRNA using small amounts of nanocarrier (in this case PAMAM 
G4NH2), and thus, with lesser potential toxic effects, besides the smaller and better 
controlled size, as discussed below.  For example, siRNA-G4NH2 dendriplexes at N/P 
ratio of 10 – the typical N/P used in in vitro gene knockdown experiments78, 89 – 
approximately 8 G4NH2 molecules are needed for each siRNA.  Therefore, comparing 
both siRNA delivery strategies – dendriplexes vs. conjugation – the latter represents a 
24-fold decrease in mass loading of the nanocarrier (PAMAM G4NH2) for the same 
amount of siRNA.  This is an excellent result since the optimization of the G4NH2-
siRNA conjugates was not even attempted yet. 
Hydrodynamic diameter and  of G4NH2-siRNA conjugates were determined by 
LS, and found to be 10 ± 3 nm (PDI = 0.6 ± 0.2) and -16 ± 2 mV, respectively.  These 
results are in sharp contrast with the much larger, highly heterogeneous and difficult to 
control and predict sizes of siRNA-based dendriplexes83, 90 and polyplexes of ca. 50 - 
750 nm.91-93  The much smaller size of the G4NH2-siRNA conjugates reported here 
provides a great opportunity to modulate cellular responses,29 uptake,27, 94 intracellular 
trafficking,94 and interaction with extracellular fluids,30 since these properties are shown 
to be size-dependent on the nanocarriers, and thus, affect the gene suppression 
efficiency.27  In addition, these conjugates, in spite of the overall negative surface 
charge, are expected to be able to adhere to the cellular membranes, as it has been 
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demonstrated to other negatively charged conjugates,95 improve escape from 
macrophages, enhance blood circulation time, and accumulation in lung.95  The ability of 
these conjugates to be internalized with the cell, trafficked and released onto the cytosol 
is discussed in the next section when their gene knockdown ability is evaluated.   
It is worthwhile to mention here that the use of PAMAM dendrimers as 
nanocarriers for siRNA has unique advantages compared to other carrier systems such 
as dendriplexes and lipoplexes, as discussed earlier in the introduction.  Their small 
size, molecular uniformity, and high functionality that will enable further optimization of 
the nanocarriers as for example through the conjugation of internalization ligands, 
reducible- and pH-trigged molecules, imaging agents, and combination of therapeutics 
(small molecule and siRNA).9  Therefore, the use of PAMAM dendrimers offers a great 
potential for the development a “smart” siRNA delivery system. 
 
6.3.3 In vitro gene knockdown 
A549 cells stably expressing eGFP were used to investigate the gene silencing 
efficiency of G4NH2-siRNA conjugates.  The commercial transfection reagents 
Lipofectamine® 2000 (LF) and TransFastTM (TF) were used as positive controls, and 
free siRNA was the negative control.  siRNA concentrations in the conjugates were 80, 
160, and 320 nM.  The controls (free siRNA and siRNA complexed with LF and TF) 
were kept at 80 nM siRNA as base line, since LF and TF were very toxic and caused 
cell death during the experiments at higher siRNA concentrations.  Transfection was 
performed with siRNA(+) and siRNA(–) conjugated to G4NH2, complexed with LF or TF, 
and delivered without any carrier (free), and the results are summarized in Figure 6.5. 
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Figure 6.5.  In vitro knockdown of eGFP expression in A549 cells stably expressing eGFP.  G4NH2-
siRNA conjugates were equivalent to 80, 160, and 320 nM siRNA, as indicated in the plot.  
Lipofectamine® 2000 (LF), TransFast
TM
 (TF), and free siRNA were used as controls at 80 nM siRNA 
concentration.  Knockdown with positive siRNA sequence (anti-eGFP) is compared with the irrelevant 
siRNA sequence (negative).  G4NH2 concentration in the conjugate equivalent to 320 nM siRNA was 
0.06 M.   = statistically different compared to untreated eGFP A549 cells control;  = statistically 
different compared to eGFP A549 cells treated with free siRNA; p value < 0.05, One-Way ANOVA. 
 
The silence of eGFP expression in A549 cells achieved by the G4NH2-siRNA(+) 
conjugates (11, 28, and 53% for 80, 160, and 320 nM siRNA, respectively) was found to 
be intermediate to LF and TF (both ca. 75%) and free siRNA (-3.5%).  The nanocarriers 
provided a much higher and statistically significantly knockdown of eGFP compared to 
free siRNA(+) used as negative control (One-Way ANOVA, p value < 0.05).  However, a 
reduction in eGFP expression was also observed when the irrelevant siRNA(–) was 
delivered using the conjugates (5, 21, and 20% for 80, 160, and 320 nM siRNA, 
respectively) and as free (1.5%). 
This unwanted eGFP suppression is most likely due to off-target effects – the 
down regulation of specific genes caused by the siRNA(–) due to unintended 
interactions between silencing molecules and cellular components.96  In RNAi, off-target 
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effects can be due to toxicity of the nanocarrier,97 but also depend on the similarity 
between the nucleotide sequence from the siRNA and short motifs in the messenger 
RNA (mRNA) and other unrelated genes not targeted.96, 98  It has been demonstrated 
that siRNAs can alter the mRNA levels of off-target genes in addition to the targeted 
gene.99  Off-target effects in RNAi are quite common,98 hard to avoid,96 and still not well 
understood,100 but important to address siRNA therapeutics moving into the clinic. 
While no previous dendrimer-siRNA conjugates are available in the literature, the 
results obtained here can be contrasted with the reports on other siRNA conjugates.  
Disulfide-linked siRNA-QD conjugates (10 nM siRNA) were found to achieved 70% 
eGFP knockdown in HeLa cells when delivered together with Lipofectamine® 2000,49 
which is similar to the knockdown found here with Lipofectamine® 2000 and siRNA(+).  
In other works, disulfide-linked siRNA-QD conjugates (60 - 80 nM siRNA)48 and siRNA-
Au conjugates45 (90 nM siRNA) were able to silence ca. 90% the luciferase expression 
in HeLa cells, but such conjugates were delivered directly to the cell cytosol via 
electroporation to avoid membrane interactions,48 and via complexation with poly(-
amino ester),45 respectively.  siRNA-Au conjugates alone (100 nM siRNA) provided ca. 
50% reduction in luciferase expression in HeLa cells.46  This result is similar to the one 
achieved with our G4NH2-siRNA(+) conjugates at 320 nM siRNA.  Nevertheless, it is 
worthwhile to mention that the cell line and experimental conditions, which were 
different in both systems, play a role in the gene knockdown process and thus, it is hard 
to establish a direct comparison. 
It is interesting to observe the clear dose response in knockdown with the 
G4NH2-siRNA conjugates.  As the siRNA concentration of the conjugates increased 
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(from 80 to 160 and 320 nM), the eGFP knockdown efficiency improved (from 11 to 28 
and 53% with siRNA(+) in Figure 6.5).  Typical siRNA concentrations applied in gene 
knockdown experiments using siRNA-carrier systems is usually around 80 - 100 nM,45, 
46, 48, 49 with the maximum concentration often limited due to the toxicity of the 
carrier/complexing agent, as is the case for TF and LF.  In our work siRNA 
concentrations >> 100 nM could be applied because the high mass loading of siRNA 
conjugated onto the carrier, and the fact that the corresponding G4NH2 content in the 
conjugate during the transfection has been shown to be non-toxic to A549 cells (in vitro 
cytotoxicity results in the Chapter 5).  The 320 nM siRNA was not limited due to toxicity 
of the conjugate but simply an arbitrary maximum concentration selected for this study.  
G4NH2-siRNA conjugates at the highest siRNA concentration of 320 nM during 
transfection is equivalent to 0.06 M G4NH2, which falls within the range of G4NH2 
concentration where the viability of the A549 cells was not statistically different from the 
untreated cells as control (in vitro cytotoxicity results in the Chapter 5).  Based on cell 
viability studies and 3 siRNA molecules conjugated per dendrimer, we expect to be able 
to increase the concentration of siRNA up to 2.5 M without sacrificing cell viability.  
Based on the linearity between siRNA concentration and knockdown response, this 
would correspond to a knockdown > 90%, i.e., which seems even better than the 
commercial transfection reagents. 
The eGFP knockdown results obtained with G4NH2-siRNA conjugates are 
considerably better than those previously observed with siRNA-G4NH2(+) dendriplexes 
ca. 22 - 36%, as discussed in Chapter 5.  It is worthwhile to mention that the delivery of 
higher siRNA content via dendriplexes was limited due to the toxicity of G4NH2 caused 
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by its higher amount needed to achieve the desired N/P ratio.  Therefore, the results 
discussed here indicate that siRNA-delivery systems based on G4NH2-siRNA 
conjugates are very promising, and such systems can be optimized to increase the 
siRNA loading and via conjugation of other ligands (e.g. PEG and target ligands)  in 
order to improve gene knockdown efficiency with less off-target effects.  The poetical 
benefits of the conjugates in terms of size and ability to tailor their surface chemistry is 
expected to be even more evidenced when targeting tissues such as the upper airways 
where extracellular barriers (in that case mucus layer) represent a significant hindrance 
for the transport of encapsulated/complexed siRNA as they limit diffusion of larger 
particles and highly charged systems.30, 101, 102  The conjugates-based nanocarriers, 
therefore, offer great opportunities in targeting mucus-dependent diseases, e.g. gastric 
and lung – such as asthma, cystic fibrosis, COPD, and others.103, 104 
 
6.4 Conclusions 
In this work we demonstrate the successful conjugation of siRNA on PAMAM 
G4NH2 dendrimer via a reducible disulfide crosslink which can be broke down in the 
cellular cytosol, the site of action for the therapeutic siRNA.  G4NH2-siRNA conjugates 
were synthesized, characterized, and the disulfide bond between siRNA and G4NH2 
was shown to be cleaved by a reducing agent at typical concentration found in the cell 
cytoplasm.  The in vitro gene knockdown efficiency in A549 lung cell line stable 
expressing eGFP was found to be significantly improved relative to the free siRNA 
(negative control), and better when compared to siRNA-G4NH2 dendriplexes.  In 
addition, and more importantly, the eGFP silencing effect of the G4NH2-siRNA 
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conjugates was found to be siRNA-concentration dependent, and very high 
concentration of the conjugates could be employed due to their high mass loading of 
siRNA and low toxicity, different from many other carrier systems and the positive 
controls used in this work.  The G4NH2-siRNA conjugates proposed here provide a 
great potential for the development of an efficient and safe siRNA delivery platform, 
which can be further optimized via conjugation of specific ligands and therapeutics (e.g. 
small molecules) for targeting a wide range of local and systemic diseases. 
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CHAPTER 7 
Conclusions and Future Directions 
 
Although widely recognized as a very promising non-invasive administration 
route of therapeutics to and through the lungs, oral inhalation (OI) has still not been 
extensively explored for the delivery of nucleic acids as therapeutics.  Portable OI 
inhalers – such as pMDIs – are inexpensive, easy to use, and thus very popular to treat 
medically relevant pulmonary diseases, e.g. asthma and COPD, and have great 
potential for the treatment of other lung disorders, e.g. cystic fibrosis and lung cancer.  
However, due to the challenges in formulating therapeutics in HFA-based portable 
inhalers – (i) to achieve the appropriate aerodynamic size for deposition in the deep 
lungs, (ii) to find a suitable surface chemistry to be solvated by propellant HFA, and 
thus, generate stable and efficient dispersions, and (iii) lack of knowledge on the 
interactions between chemistries used in excipients (e.g. surfactants) in the HFA/co-
solvent mixture – the use of pMDIs to deliver DNA and siRNA locally to the lungs is still 
in its infancy.  Besides formulation challenges, the progress of OI for the delivery of 
DNA and siRNA to the lungs has been hampered largely by the lack of efficient 
nanocarriers capable of overcoming the lung structure, the extra and intracellular 
barriers present in the lung tissue to reach the site of action – the nucleus (DNA) and 
the cytoplasm (siRNA). 
Polymeric nanocarriers (PNCs) have great potential to improve OI delivery of 
nucleic acids.  However, most of the studies apply PNCs to form complexes with DNA 
or siRNA – polyplexes (cationic polymers in general) and dendriplexes (for dendrimers).  
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In spite of the advantages achieved by complexation, the disadvantages – the wide 
variation of the sizes, high polydispersity, variable shapes, possibility of interactions and 
entrapment in negatively charged extracellular fluids, and cytotoxicity issues – have 
suggested that alternative routes for DNA/siRNA delivery may be more appropriate, 
such as the conjugation of nucleic acids (instead of complexation) with nano-sized PNC 
using pH- and reducible-dependent crosslinks.  The decoration of the PNC with target 
and internalization ligands, molecules to reduce toxicity and off-target effects, improve 
endolysosomal escape, and the release of the attached cargo in the targeted site of 
action, are the basic strategies to the development of “smart” nano-sized DNA- or 
siRNA-conjugates delivery systems, and more research in this area is needed to 
improve their design and application up to the level of clinical trials. 
The main conclusions drawn from our studies and suggested future directions 
are discussed here: 
 
(i) We were the first research group to evaluate quantitatively and systematically 
the enhancement in solvation capacity of propellant HFA upon addition of co-solvent 
ethanol.  Fad is widely recognized as a good predictor of solvation forces.  CFM was the 
experimental approach used to determine the Fad between surfaces containing the 
moieties of interest (alkyl, ether, and ester – all relevant to HFA-based pMDI 
formulations) in HPFP/ethanol liquid mixtures with varying volume fractions of ethanol.  
HPFP was the liquid at ambient conditions to mimic propallent HFA.  CFM results 
indicated that ethanol is indeed capable of enhancing the solvation of all fragments, and 
that the solvation increases as the volume fraction of ethanol increases.  However, for 
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the alkyl moiety, volume fractions of ethanol much larger than those typically employed 
in commercial MDI formulations (< 15%) are required to achieve a level of solvation 
comparable to that of the ether moiety in pure HPFP.  The effect of ethanol in the 
solvation of the ether fragment is much more pronounced (same for the ester fragment), 
thus indicating the potential of ethanol to be applied in PEG-based pMDIs.  The CFM 
experimental results were modeled using the JKR theory, which suggested a strong 
dispersive contribution of the alkyl tails to the solvation in HPFP/ethanol mixtures. 
However, the reference state of ideal solvation – Fad/R  0 mN.m
-1 – was not 
achieved for any system, and high volume fraction of ethanol in HPFP was needed to 
bring the Fad/R  1 mN.m
-1 – the lowest value obtained – 90, 70, and 50% for alkyl, 
ether, and ester moieties, respectively.  Since these ethanol contents are extremely 
elevated to be applied in commercial HFA-based formulations (10% approved by FDA 
via respiratory (inhalation), aerosol, metered dosage form) suggested future work is this 
area includes the application of CFM and molecular simulations to search other HFA-
philic chemistries able to reach the ideal solvation state, but keeping the ethanol 
concentration within the range approved by FDA. 
Hydrofluoroolefins (HFOs) have emerged as the non-ozone depleting and low 
global warming potential (GWP) alternatives to HFAs, and thus the transition from 
propellant HFAs to HFOs to be used in medical aerosols is not so far to start happening 
in the US market.  Therefore, the use of CFM in combination with molecular simulations 
for the development of HFO-philic chemistries in presence/absence of co-solvent 
ethanol is of great relevance.  In addition, the design and application of an apparatus 
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which makes able to measure Fad under pressure – in situ – using HFA (or HFO) 
instead of other liquid mimicking the propellant, is also suggested as future work. 
 
(ii) We were the first research group to develop formulations of DNA-based 
polyplexes and siRNA-based dendriplexes in HFA-based pMDIs to deliver nucleic acids 
to the lungs.  CS-DNA polyplexes were prepared using low Mw CS, and high DNA 
complexation efficiency along with size < 200 nm were achieved.  Emulsification 
diffusion was applied to load the CS-DNA polyplexes into a biodegradable, water 
soluble, HFA-philic co-oligomer.  Thus, micron-sized core-shell particles (polyplexes as 
core, and co-oligomer as shell) were obtained and characterized as within the 
appropriate geometric diameter required for formulation in pMDIs.  CS-DNA core-shell 
particles were then dispersed in propellant HFA, and such pMDI formulations showed 
excellent physical stability (no flocculation even after many hours stopped the 
mechanical energy input) and very good aerosol properties (MMAD ca. 2 M and FPF 
ca. 63%).  More importantly, CS-DNA polyplexes alone and formulated as core-shell 
particles (even after exposure to propellant HFA) were found to transfect and deliver 
DNA to alveolar lung epithelial cells in vitro.  Collectively, all the results indicated that 
formulating polyplexes in core-shell particles is an efficient approach to deliver nucleic 
acids to the lungs using inexpensive and portable pMDIs with potential to treat medically 
relevant pulmonary diseases, including asthma, COPD, cystic fibrosis, and cancer. 
Since RNAi-based therapies have been proposed for the treatment of several 
genetic, chronic, and infectious lung disorders, essentially due to the advantages of 
siRNA over DNA, dendriplexes formed between PAMAM G4NH2 dendrimer and siRNA 
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were evaluated.  siRNA-G4NH2 dendriplexes showed high siRNA complexation 
efficiency, size ca. 250 nm, positive surface charge, efficient protection against RNase 
degradation.  The in vitro release of siRNA from G4NH2 dendrimer was sustainable and 
pH-dependent.  PAMAM dendrimers are very promising siRNA delivery vehicles, but 
their application to deliver siRNA to the lungs has not been well explored, and thus, we 
were the first group to demonstrate the use of siRNA-G4NH2 dendriplexes to 
knockdown gene expression in alveolar lung epithelial cells in vitro.  More importantly, it 
was found that dendriplexes prepared with siRNA stored in propellant HFA were able to 
provide the same level of gene suppression than those formed with untreated siRNA. 
The core-shell particles formulation strategy – successfully applied for CS-DNA 
polyplexes – was also employed for siRNA-G4NH2 dendriplexes.  Since the method of 
loading NPs using spray drying is very common to prepare dry powders – but the 
application of such microparticles has not been explored in pMDIs – the encapsulation 
of siRNA-G4NH2 dendriplexes in spray-dried mannitol sugar alcohol particles was also 
evaluated.  In conclusion, both strategies provided good siRNA loading, and particles in 
the appropriate size for deep lung deposition when applied in an aerosol.  In addition, it 
was found that the particle engineering process (core-shell emulsification diffusion or 
mannitol spray drying) did not affect the integrity of DNA or siRNA, and gel 
electrophoresis showed that the nucleic acid is essentially the same before and after the 
load into micron-sized particles.  pMDI formulations prepared using core-shell and 
mannitol particles loaded with siRNA-G4NH2 dendriplexes showed excellent physical 
stability and very good aerosol performance, which were equivalent to those from 
commercial pMDI formulations of therapeutic drugs. 
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Therefore, all these results are very promising, and strongly indicated that the 
formulation of DNA- and siRNA-delivery systems into appropriate non-active particles 
has great potential to deliver nucleic acids locally to the lung tissue using portable and 
inexpensive pMDIs. 
Suggested future work is this area includes the optimization of siRNA-based 
dendriplexes to knock down the gene expression in vitro in airway lung epithelial cells, 
which are more difficult to transfect most likely due to the mucus layer.  Colocalization 
studies using dendriplexes formed with fluorescent-labeled siRNA and dendrimer would 
be also relevant in order to explore the intracellular trafficking of the dendriplexes, free 
dendrimer and siRNA after its release from the PNC.  In vivo studies would be also of 
great importance. 
With regard to formulation strategies in portable OI devices, the use of porous 
particles for the delivery of siRNA-PNCs using pMDIs has the potential to be explored 
as future work.  Initial studies could be based on blending (in HFA atmosphere) siRNA-
PNCs with a porous non-active carrier (e.g. lactose or mannitol) as micron-sized 
particles.  The presence of PEG conjugated to the PNC is expected to help the 
dispersion stability, since it has been shown that the ether moieties in the PEG display 
HFA-philicity.  In addition, the formulation of siRNA-PNCs in DPIs is also very relevant 
as future work in this area. 
 
(iii) We were the first research group to propose and evaluate PAMAM dendrimer 
as PNC for conjugation with siRNA.  G4NH2-siRNA conjugates were designed to have 
a reducible disulfide crosslink, which cleaves in the cell cytoplasm by reducing agents 
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and releases the siRNA to its site of action.  These conjugates were synthesized, 
characterized, and without any further optimization, they were able to knock down the 
expression of eGFP in alveolar lung epithelial cells in vitro.  The eGFP knockdown 
efficiency was significantly different from that obtained with free siRNA treatment.  More 
importantly, the eGFP silencing effect of the G4NH2-siRNA conjugates was found to be 
siRNA-concentration dependent, while keeping the G4NH2 content at low levels which 
are demonstrated to be not toxic to the cells.  Therefore, siRNA-dendrimer conjugates 
are of great relevance in the development of safe and efficient siRNA-delivery systems, 
not only locally to the lungs, but they have potential to be expanded to other tissues and 
routes of administration. 
Suggested future work is this area includes the optimization of G4NH2-siRNA 
conjugates via linkage of other molecules.  (i) PEG, which has been shown to impart 
several advantageous traits to conjugates including faster diffusion and less 
aggregation in mucus and lung surfactant, improved aqueous solubility, decreased 
opsonization, and reduced cytotoxicity.  (ii) Since PEGylation can prevent 
endolysosomal escape, the crosslink between G4NH2 and PEG could have a molecule 
capable of enhancing the buffering capacity, such as aryl hydrazone (AH).  AH labile 
linker is hydrolyzed under acidic conditions (pH 5), and thus it is expected to release the 
PEG, exposing the amine groups from the dendrimer.  (iii) In order to address the issue 
that PEG reduces cellular uptake, internalization ligands (such as folic acid and lauroyl) 
could potentially be conjugated to the end of the PEG chain, being thus more exposed 
to receptors on the cell surface.  (iv) A fluorescent dye (such as Cyanine-3, Cy-3) 
should be linked to the G4NH2 surface, in order to facilitate the detection of the 
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conjugates in in vitro and in vivo experiments.  This suggested optimization requires 
systematic studies with regard the density, Mw, and molar ratio among the molecules to 
be attached on the G4NH2-siRNA conjugates.  Measures should include, but not limited 
to, in vitro and in vivo gene knockdown efficiency, cellular uptake, and colocalization 
experiments.  The preparation of G4NH2-siRNA conjugates with fluorescent- or radio-
labeled G4NH2 and siRNA would be thus important to elucidate cellular internalization 
mechanisms, intracellular trafficking pathways, and colocalization with cell organelles.   
With regard to in vivo studies, pharmacokinetics, biodistribution, and toxicity 
would be the routine experiments.  In addition, visualization in live animals or in isolated 
organs and tissues should also be considered in future work.  The use of diseased 
animal models would be very relevant to evaluate the stability, safety, and efficiency of 
the siRNA-delivered systems proposed in this dissertation.  For example, implantation 
of tumour cells into wild type or nude mice (xenograft) has been widely used as model 
for cancer in lung, breast, prostate, colon, ovarian, and liver.  Genetically engineered 
mouse models (transgenic) have been proposed to study gene therapy in brain cancer 
and skin disorders, and thus should also be planned for future work. 
Therefore, all the results discussed in this dissertation, along with the proposed 
future work, contribute significantly in the development of DNA- and siRNA-delivery 
systems and in their formulation in portable OI devices, with great potential to efficiently 
deliver nucleic acids to the lungs to treat medically relevant pulmonary disorders, such 
as COPD, asthma, virus infections, cystic fibrosis, and lung cancer. 
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APPENDIX A 
Supporting Information for Chapter 4 
 
A.1 Preparation of water soluble, low Mw CS 
Low Mw CS was obtained according to a modified version of a method previously 
described literature.1  Briefly, 4 g of CS (100 - 300 kDa, 80% DDA) were dissolved in 
200 mL DI-water with 1 mL concentrated hydrochloric acid, under heating (65 - 70C) 
and magnetic stirring (3 h).  Hydrogen peroxide (5 mL) was added, and CS was 
depolymerized at 65 - 70C for 12 h.  At the end of the reaction, the solution was 
allowed to cool down, and the pH was adjusted to 8 with a 3 M sodium hydroxide 
solution.  The water soluble, low Mw CS was separated by centrifugation (15 min at 
5,000 rpm - 2,800 xg) since the low Mw CS remains in the supernatant, and the 
insoluble large Mw CS precipitates.  The supernatant was diluted 1:1 (v/v) using DI-
water, and it was nanoprecipitated (200 mL, slow drip, approximately one drop each     
3 s) into a large volume of ethanol (900 mL) under stirring.  The low Mw CS is water 
soluble but insoluble in the ethanol/water mixture.  The final product was precipitated by 
centrifugation (5,000 rpm - 2,800 xg), washed repeatedly with ethanol and acetone, and 
dried in air at room temperature.  The nanoprecipitation step is required as CS is not 
soluble in the grafting reaction medium (toluene), and a dispersion of uniform and small 
nanoparticles is expected to aid in the grafting reaction described below. 
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A.2 Synthesis of OLA-g-CS co-oligomer 
It was performed according to a modified method described in the literature.1  
Briefly, 0.8 g of water soluble low Mw CS obtained as described earlier was dispersed in 
50 mL of toluene with the help of a sonication bath (VWR, P250D, set to 180 W).  
Subsequently, 4.3 g of recrystallized LA was added in the CS dispersion, and the 
system was heated in an oil bath to 90 - 95C under stirring.  Nitrogen was purged for   
30 min.  Stannous octoate catalyst was added (40 mg in 5 mL toluene) and the reaction 
carried out at 90 - 95C under nitrogen atmosphere for 24 h.  The total mass of CS, LA 
and stannous octoate added to the system was calculated based on a 1:100:1/5 molar 
ratio, respectively.  The product was precipitated by centrifugation (5,000 rpm -       
2,800 xg) and washed with toluene.  The precipitate was added to 50 mL toluene and 
the reaction repeated.  An additional mass of 4.3 g of LA, and 40 mg of catalyst were 
added to the system, and the reaction continued at 90 - 95C under nitrogen 
atmosphere for 50 - 60 h.  The final product was separated in two fractions (precipitate 
and supernatant) by centrifugation (2,600 rpm - 760 xg, 5min).  The OLA-g-CS in the 
supernatant (the final product) was then precipitated by centrifugation (10,000 rpm – 
11,200 xg), repeatedly washed with toluene and acetone, and dried in air at room 
temperature overnight. 
 
A.3 Characterization of low Mw CS and OLA-g-CS 
The Mw of the CS and OLA-g-CS co-oligomers was evaluated by MALDI-TOF 
(Bruker Ultraflex).2  A known amount of the sample (2 mg) was dissolved in 1 mL of 
80:20 (v/v) DI-water:acetonitrile solution.  The sample solution (1 µL) was mixed with    
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1 µL of matrix solution (DHB, 15 mg.mL-1) on the target plate (MTP 384, Bruker), and 
allowed to dry at room temperature prior to MALDI-TOF analysis.  Proton Nuclear 
Magnetic Resonance (1H-NMR, Varian Mercury 400) and Fourier Transform Infrared 
Spectrometry (FTIR, Bruker Tensor 27) were used to obtain the chemical structure of 
the CS and OLA-g-CS co-oligomers.1, 3  The sample (10 mg) was dissolved in 0.8 mL of 
DMSO-d6 for 1H-NMR analyses, and for the FTIR, 5 mg was mixed with 200 - 500 mg 
of potassium bromide, and pressed to a pellet. 
 
A.4 Characterization of low Mw CS and OLA-g-CS 
Recrystallized LA was reacted with CS in toluene in the presence of stannous 
octoate catalyst as described above.1, 3  Because the amine and hydroxyl groups of CS 
work as initiators during the reaction, the ring opening polymerization of LA results in 
grafts onto the CS backbone.1  The chemical structure of the low Mw CS and OLA-g-CS 
co-oligomer were characterized by 1H-NMR, FTIR and MALDI-TOF.  The results are 
shown in Figure A1. 
The 1H-NMR spectrum of the CS (Figure A1a) indicates a singlet at 3.1 ppm    
(H-2), multiplets at 3.3 - 3.7 ppm (H-3, H-4, H-5, H-6), and a singlet at 4.3 ppm (H-1) 
corresponding to the ring methenyl protons.3, 4  The singlet at 2.1 ppm is related to the 
methyl protons present in the N-acetyl-D-glucosamine units (-CH3, H-7).
5  To verify 
whether the chemical structure of the low Mw CS changed due to potential deamination 
during the depolymerization process,6 the degree of deacetylation (DDA) was calculated 
using the 1H-NMR spectrum and the following equation below, where ICH3 refers to the 
integral intensity of the peak from the methyl group of the N-acetyl-D-glucosamine units 
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(H-7) and IH2-H6 is the summation of integral intensities of the H2, H3, H4, H5 and H6 
peaks.7   
 
DDA = { [ 1 – [ (1/3 ICH3)  (1/6 IH2-H6) ] }  100 
 
The DDA of the CS was calculated to be 77% (ca. 1 acetyl and 5 amine units), 
suggesting that the molecular structure of the CS was not impacted due to deamination 
during depolymerization, given that the DDA before (80% reported by the supplier) and 
after were very similar. 
The Mw of the water soluble CS was evaluated by MALDI-TOF, and the 
spectrum is shown in Figure A1c.  Two predominant degrees of polymerization (DP) are 
clearly observed.  The peak-to-peak mass difference is 162.1 g.mol-1, in close 
agreement with the mass of one D-glucosamine unit (161.1 g.mol-1).8  Considering the 
DDA, the average molar mass between acetylated and deacetylated units, and the two 
dominant peaks, the spectrum in Figure A1c reveals that the CS is mainly composed of 
five and six repeat units (Mw 939 Da).  Small deviations observed by comparing the 
measured and theoretical masses can be attributed to fragmentation, which 
corresponds to cleavage of bonds in oligosaccharides during the analysis,8 despite the 
incorporation of a matrix.9  However, such deviations did not have significant effect on 
the DP obtained.  The MALDI-TOF spectrum of the OLA-g-CS co-oligomer shown in 
Figure A1c, indicates a larger molar mass compared to the CS, as expected.  However, 
due to sample fragmentation,8 especially because the easy degradation of the LA 
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chains,10 1H-NMR is preferred for the characterization of the size and density of the LA 
grafts.1, 3 
 
 
 
 
Figure A1.  (a) 
1
H-NMR; (b) FTIR; and (c) MALDI-TOF spectra for low Mw CS and OLA-g-CS. 
 
Compared with the CS, the 1H-NMR spectrum of the OLA-g-CS (Figure A1a) 
shows peaks at 4.2 and 5.2 ppm, which are assigned to the terminal methenyl protons 
of the oligo(LA), and its repeating units in the chain, respectively.  The peaks at 1.3 and       
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1.4 ppm are attributed to the methyl protons of the oligo(LA) moiety located at the 
terminal groups and the backbone.3  Structural changes in the low Mw CS brought by 
oligo(LA) grafting can be also seen in the FTIR spectra (Figure A1b).  Compared to the 
FTIR spectrum of the CS, the OLA-g-CS has a new absorption peak at 1757 cm-1, 
attributed to the carbonyl group of the LA repeat units.1, 3  The methyl asymmetric 
deformation of oligo(LA) is found at 1456 cm-1.3  The peak at 1189 cm-1 is assigned to 
the symmetric C-O-C stretching modes of the ester group, and the C-CH3 stretching 
vibrations appear at 1055 cm-1.3  The peaks at 1656 cm-1 and 1555 cm-1 can be 
attributed to C=O stretching vibrations (amide I) and N-H deformation coupled with C-N 
stretching vibrations (amide II) of the secondary amide11 formed between CS and 
oligo(LA), respectively.  Therefore, the results collectively indicate that oligo(LA) was 
successfully grafted onto the water soluble low Mw CS. 
Calculations based on the 1H-NMR spectrum of OLA-g-CS (Figure A1a), 
considering the integral intensities of the peaks at 4.3 ppm (from CS) and 5.2, 1.4,     
1.3 ppm from oligo(LA),1 indicated that there are ca. three oligo(LA) chains grafted on 
each CS backbone, and each oligo(LA) chain is composed of eight LA repeat units.  
Thus, the Mw of the OLA-g-CS co-oligomer was calculated to be 1729.6 g.mol-1.  Also 
using the 1H-NMR spectrum of OLA-g-CS, the grafting percentage based on the 
number of reactive groups (amine and hydroxyl) was 21.4%.  This result is in good 
agreement with the grafting percentage calculated by the gravimetric method,3  (grafting 
% = [(mass of OLA-g-CS) – (mass of CS) / (mass of CS)]  100), found to be 23.2%. 
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A.5 Characterization of the DDA of 31 kDa CS used in the preparation of the 
polyplexes 
To evaluate whether the chemical structure of the 31 kDa Mw CS was altered 
due to potential deamination during the depolymerization process, 1H-NMR was used to 
determine the DDA using the same methodology as detailed earlier.  The DDA was 
calculated to be 77%.  This result indicates that the molecular structure of CS was not 
changed due to deamination during depolymerization, based on the comparison with 
the DDA of CS as received (80% reported by the supplier). 
 
A.6 Characterization of CS-DNA polyplexes during preliminary screening 
In order to prepare CS-DNA polyplexes with small size (diameters around       
200 nm or smaller), enhanced colloidal stability, and also good in vitro transfection 
efficiency in A549 cells, we performed a series of preliminary experiments that involved 
the preparation of polyplexes with varying CS Mw (80% DDA) and N/P ratio.  The 
polyplexes were characterized according to DNA encapsulation efficiency (EE), size 
and polydispersity (PDI), zeta potential (), and the ability of in vitro transfection 
(good/poor).  The results are shown in Table A1. 
Polyplexes containing Calf Thymus and gWIz-GPF DNA, prepared with CS       
31 kDa and 80% DDA at N/P ratio of 6, showed high DNA EE (> 90%), similar size      
(ca. 180 nm) and  ca. + 21 mV, and thus were selected for further studies.  Based on 
the results from this preliminary screening (Table A1), such improved properties were 
obtained through reduction in Mw of CS, and optimization of N/P ratio. 
  
229 
 
 
 
Table A1.  Physicochemical properties of CS-DNA polyplexes according to Mw of CS (80% DDA) and 
nominal N/P ratio. 
 
 
CS Mw 
(kDa) 
 
Type of 
DNA 
Nominal 
N/P ratio 
DNA EE 
(%) 
Particle 
Size (nm) 
PDI of 
Size 
Zeta 
Potential 
() (mV) 
In vitro 
Transfection 
in A549 cells 
 
310 
 
49 
 
31 
 
31 
31 
31 
31 
31 
 
Calf Thymus 
 
gWIz-GFP 
 
Calf Thymus 
 
gWIz-GFP 
gWIz-GFP 
gWIz-GFP 
gWIz-GFP 
gWIz-GFP 
6 
 
6 
 
6 
 
2 
4 
5 
6 
7 
88 ± 7 
 
95 ± 1 
 
90 ± 8 
 
97 ± 1 
94 ± 2 
95 ± 1 
97 ± 5 
95 ± 3 
595 ± 85 
 
666 ± 21 
 
183 ± 51 
 
111 ± 71 
167 ± 146 
229 ± 93 
268 ± 51 
181 ± 62 
0.3 
 
0.6 
 
0.4 
 
0.9 
0.9 
0.8 
0.3 
0.5 
- 
 
+ 27 ± 1 
 
+ 21 ± 4 
 
+ 13 ± 1 
+ 16 ± 1 
+ 23 ± 1 
+ 31 ± 6 
+ 22 ± 6 
 
N.A. 
 
Poor 
 
N.A. 
 
Poor 
Poor 
Poor 
Good 
Good 
 
N.A. = not applicable 
PDI = polydispersity index 
 
The Mw of CS has an effect on the size of polyplexes,12, 13 and the size plays a 
role in the transfection process.  It is expected that high Mw CS has enhanced binding 
affinity to DNA, and condenses the genetic material more efficiently than low Mw CS, 
producing polyplexes with smaller sizes.12  However, several works12-20 have reported 
the formation of CS-DNA polyplexes with small size using low Mw CS.  This can be 
attributed to the higher solubility and flexibility of the short CS chains in solution, i.e., low 
Mw CS is more soluble than high Mw CS, and thus, low Mw CS becomes better 
hydrated by the aqueous solvent.12, 15, 21, 22  During our preliminary screening, at N/P 
ratio of 6 and for both types of DNA, polyplexes with smaller sizes were prepared when 
the Mw of CS was reduced from 310 to 31kDa, as seen in Table A1. 
The N/P ratio is another important property of the CS-DNA polyplexes which has 
effect on in vitro transfection efficiency.14, 23, 24  At a low N/P ratio, physically unstable 
polyplexes were obtained, and that resulted in poor in vitro transfection.  However, 
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stable complexes obtained at higher N/P ratio may also show reduced in vitro 
transfection,14, 23, 24 probably due to the fact that highly positive charged polyplexes may 
be toxic to the cells and/or establish non-specific interactions with the cells.25  In our 
preliminary screening, CS-DNA polyplexes exhibited poor in vitro transfection at N/P 
ratio of 2, 4, and 5, probably due to lower surface charge (ca. + 13 - 16 mV at N/P ratio 
of 2 and 4), or increased size of the NPs (large standard deviation and PDI at N/P ratio 
of 2, 4, and 5).  The in vitro transfection was improved when the polyplexes were 
formulated at N/P ratio of 6 and 7.  At these N/P ratios, CS-DNA polyplexes showed 
reduced size, and lower PDI. 
Based on the results from our preliminary screening, which were in agreement 
with trends reported in the literature for CS-DNA polyplexes, there is an optimal range 
for the N/P ratio (which is specific to the type of CS used – Mw and DDA), that 
influences size and surface charge of the polyplexes, and in vitro transfection as well.  
We chose CS-DNA polyplexes which demonstrated appropriate size and transfection, 
and had similar properties (size and ) for both Calf Thymus DNA and pDNA. 
 
A.7 References 
1. Wu, L.; Bharatwaj, B.; Panyam, J.; da Rocha, S.  Core-shell particles for the dispersion of small 
polar drugs and biomolecules in hydrofluoroalkane propellants. Pharm. Res. 2008, 25, (2), 289-
301. 
2. Cabrera, J. C.; Van Cutsem, P.  Preparation of chitooligosaccharides with degree of 
polymerization higher than 6 by acid or enzymatic degradation of chitosan. Biochem. Eng. J. 
2005, 25, (2), 165-172. 
231 
 
 
 
3. Luckachan, G. E.; Pillai, C. K. S.  Chitosan/oligo L-lactide graft copolymers: Effect of hydrophobic 
side chains on the physico-chemical properties and biodegradability. Carbohydr. Polym. 2006, 
64, (2), 254-266. 
4. Wu, Y.; Zheng, Y.; Yang, W.; Wang, C.; Hu, J.; Fu, S.  Synthesis and characterization of a novel 
amphiphilic chitosan-polylactide graft copolymer. Carbohydr. Polym. 2005, 59, (2), 165-171. 
5. Tian, F.; Liu, Y.; Hu, K.; Zhao, B.  Study of the depolymerization behavior of chitosan by hydrogen 
peroxide. Carbohydr. Polym. 2004, 57, (1), 31-37. 
6. Qin, C. Q.; Du, Y. M.; Xiao, L.  Effect of hydrogen peroxide treatment on the molecular weight and 
structure of chitosan. Polym. Degrad. Stab. 2002, 76, 211-218. 
7. Tan, S. C.; Khor, E.; Tan, T. K.; Wong, S. M.  The degree of deacetylation of chitosan: 
Advocating the first derivative UV-spectrophotometry method of determination. Talanta 1998, 45, 
(4), 713-719. 
8. Trombotto, S.; Ladavière, C.; Delolme, F. d. r.; Domard, A.  Chemical preparation and structural 
characterization of a homogeneous series of chitin/chitosan oligomers. Biomacromolecules 2008, 
9, (7), 1731-1738. 
9. Cohen, L. H.; Gusev, A. I.  Small molecule analysis by MALDI mass spectrometry. Anal. Bioanal. 
Chem. 2002, 373, 571-586. 
10. Lee, H.; Lee, W.; Chang, T.; Choi, S.; Lee, D.; Ji, H.; Nonidez, W. K.; Mays, J. W.  
Characterization of poly(ethyleneoxide)-block-poly(L-lactide) by HPLC and MALDI-TOF mass 
spectrometry. Macromolecules 1999, 32, 4143-4146. 
11. Socrates, G., Infrared and Raman characteristic group frequencies - Tables and charts. 3rd ed.; 
John Wiley & Sons, LTD: Chichester, 2001; p 347p. 
12. MacLaughlin, F. C.; Mumper, R. J.; Wang, J.; Tagliaferri, J. M.; Gill, I.; Hinchcliffe, M.; Rolland, A. 
P.  Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid 
delivery. J. Controlled Release 1998, 56, (1-3), 259-272. 
13. Huang, M.; Fong, C.-W.; Khor, E.; Lim, L.-Y.  Transfection efficiency of chitosan vectors: Effect of 
polymer molecular weight and degree of deacetylation. J. Controlled Release 2005, 106, (3), 391-
406. 
232 
 
 
 
14. Lavertu, M.; Méthot, S.; Tran-Khanh, N.; Buschmann, M. D.  High efficiency gene transfer using 
chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of 
deacetylation. Biomaterials 2006, 27, (27), 4815-4824. 
15. Liu, W.; Sun, S.; Cao, Z.; Zhang, X.; Yao, K.; Lu, W. W.; Luk, K. D. K.  An investigation on the 
physicochemical properties of chitosan/DNA polyelectrolyte complexes. Biomaterials 2005, 26, 
(15), 2705-2711. 
16. Bozkir, A.; Saka, O. M.  Chitosan nanoparticles for plasmid DNA delivery: Effect of chitosan 
molecular structure on formulation and release characteristics. Drug Deliv. 2004, 11, 107-112. 
17. Köping-Höggard, M.; Varum, K. M.; Issa, M.; Danielsen, S.; Christensen, B. E.; Stokke, B. T.; 
Artursson, P.  Improved chitosan-mediated gene delivery based on easily dissociated chitosan 
polyplexes of highly defined chitosan oligomers. Gene Ther. 2004, 11, (19), 1441-1452. 
18. Gao, S.; Chen, J.; Xu, X.; Ding, Z.; Yang, Y.-H.; Hua, Z.; Zhang, J.  Galactosylated low molecular 
weight chitosan as DNA carrier for hepatocyte-targeting. Int. J. Pharm. 2003, 255, (1-2), 57-68. 
19. De Smedt, S. C.; Demeester, J.; Hennink, W. E.  Cationic polymer based gene delivery systems. 
Pharm. Res. 2000, 17, (2), 113-126. 
20. Strand, S. P.; Lelu, S.; Reitan, N. K.; de Lange Davies, C.; Artursson, P.; Vårum, K. M.  Molecular 
design of chitosan gene delivery systems with an optimized balance between polyplex stability 
and polyplex unpacking. Biomaterials 2010, 31, (5), 975-987. 
21. Wang, W.; McConaghy, A. M.; Tetley, L.; Uchegbu, I. F.  Controls on polymer molecular weight 
may be used to control the size of palmitoyl glycol chitosan polymeric vesicles. Langmuir 2001, 
17, (3), 631-636. 
22. Mao, S.; Bakowsky, U.; Jintapattanakit, A.; Kissel, T.  Self-assembled polyelectrolyte 
nanocomplexes between chitosan derivatives and insulin. J. Pharm. Sci. 2006, 95, (5), 1035-
1048. 
23. Kim, T.-H.; Jiang, H.-L.; Jere, D.; Park, I.-K.; Cho, M.-H.; Nah, J.-W.; Choi, Y.-J.; Akaike, T.; Cho, 
C.-S.  Chemical modification of chitosan as a gene carrier in vitro and in vivo. Prog. Polym. Sci. 
2007, 32, (7), 726-753. 
233 
 
 
 
24. Ishii, T.; Okahata, Y.; Sato, T.  Mechanism of cell transfection with plasmid/chitosan complexes. 
Biochim. Biophys. Acta 2001, 1514, (1), 51-64. 
25. Yoksan, R.; Akashi, M.  Low molecular weight chitosan-g-L-phenylalanine: Preparation, 
characterization, and complex formation with DNA. Carbohydr. Polym. 2009, 75, (1), 95-103. 
 
 
234 
 
 
 
APPENDIX B 
Supporting Information for Chapter 5 
 
B.1 siRNA Degradation by RNase A 
In order to determine the minimum RNase A concentration to degrade siRNA 
completely, siRNA (300 ng) was incubated with different amounts of RNase A in TE 1X 
pH 8 buffer (0.02, 0.07, 0.162, 0.348, 0.7, and 3.3 g RNase A per 1 g siRNA) for     
45 min at 37C, in presence or absence of RiboLock® RNase Inhibitor (RI, 1L = 40U).  
The concentration of 0.35 g RNase A per 1 g siRNA has been reported in literature to 
be sufficient to degrade a large fraction of siRNA in polyplexes,1, 2 and based on that, 
the amount of RNase A was varied in this experiment.  Next, samples were frozen at     
-20C overnight, and loaded in the slots of a casted non-denaturing agarose gel (1.5 % 
w/v in TAE 1X pH 8.2 buffer) stained with ethidium bromide (0.5 g.mL-1).  The 
electrophoresis was performed at 60V (E0160-VWR Mini Gel Electrophoresis) for        
40 min, and the siRNA-dye migration was visualized under UV irradiation 
(FOTO/Analyst® Investigator/Eclipse with UV Transilluminator Fotodyne Inc.) and the 
images were recorded using the FOTO/Analyst® PC Image software (v.5).  The result is 
shown in Figure B1, and clearly indicates that free siRNA (not protected by RNase 
inhibitor) was completely degraded by RNAse A starting at concentration 0.162 g 
RNase A per 1 g siRNA, since no siRNA band was observed in lane 6 compared to 
lane 7 and lane 1. 
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Figure B1.  RNase degradation assay (non-denaturing agarose gel electrophoresis) of the free siRNA as 
a function of the RNase A concentration.  siRNA (300 ng) was incubated with increased concentrations of 
RNase A (0.02, 0.07, 0.162, 0.348, 0.7, and 3.3 g per 1 g siRNA, in lanes 2-3, 4-5, 6-7, 8-9, 10-11,   
12-13, respectively) for 45 min at 37C, in presence (+) or absence (-) of 1 L (40 units) RiboLock® 
RNase inhibitor.  Untreated siRNA control is in lane 1. 
 
B.2 Heparin Decomplexation Assay 
Heparin is known as a model polyanion competing agent with nucleic acids for 
electrostatic interactions with polycations,3 and it has been used to dissociate siRNA 
from several polycationic carriers.3-9  Thus, heparin was used in this work to dissociate 
siRNA from PAMAM G4NH2 dendrimer.  In order to determine the most favorable 
condition of heparin treatment to release the highest siRNA content from the dendrimer, 
siRNA-G4NH2 at N/P 10 were formed in 10 mM Tris-HCl pH 7.4 buffer,10 as described 
in the Experimental Section of the Chapter 5, incubated with heparin in TE 1X pH 8 
buffer at 37C for different time points, and frozen at -20C overnight.  The final heparin 
concentration was 5 mg.mL-1 corresponding to 455 U per 1 g siRNA calculated based 
on 1000 U per 1 mL.4  The final siRNA concentration after dilution of the dendriplexes to 
1 mL was 80 nM.  siRNA-G4NH2 dendriplexes incubated in presence or absence of 
heparin (minimum of three independent batches, n = 3) were quantitatively analyzed 
1 2 3 4 5 6 7 8 9 10 11 12 13
siRNA
RNase A
RiboLock®
Lane
+ + + + + + + + + + + + +
- + + + + + + + + + + + +
- + - + - + - + - + - + -
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using PicoGreen® assay11 in Synergy 2 Microplate Reader (BioTek, VT) for the siRNA 
content released, which was calculated using a linear calibration curve (siRNA 
concentration vs. fluorescent units).  Thus, siRNA released from the dendriplexes due to 
heparin treatment was determined based on the difference between the siRNA content 
truly complexed with G4NH2 (siRNA CE was applied in the calculations) and the free 
siRNA released and remaining in the dendriplexes dispersion.  Appropriate control 
(PAMAM G4NH2 in presence of heparin, but no siRNA) was used as blank.   The 
results are shown in Figure B2, and indicate that the siRNA is released from G4NH2 
dendrimer due to treatment of the dendriplexes with heparin.  The incubation time of   
30 min released the highest siRNA content – 80% on average, and narrower standard 
deviation – out of the total siRNA complexed with G4NH2, and thus, it was chosen as 
standard time for all further heparin decomplexation assay experiments. 
 
 
 
Figure B2.  Heparin decomplexation assay of siRNA-G4NH2 dendriplexes at N/P 10.  Dendriplexes were 
incubated with heparin (455 U per 1 g siRNA) at 37C for different time points, and the % siRNA 
released from PAMAM G4NH2 due to the heparin treatment was determined via PicoGreen® assay. 
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B.3 Development of eGFP Expressing A549 Cell Line 
A549 cells were genetically modified to constitutively express eGFP (enhanced 
green fluorescence protein) according to GenTarget protocol.12  Briefly, A549 cells 
(passage 5 from the original passage provided by ATCC®) were seeded in 24-well 
culture plate (25,000 cells per well) and cultured in 500 L DMEM supplemented with 
10% FBS and 1% AB (v/v) for 24 h at 37C and 5% CO2 (Thermo Scientiﬁc Incubator, 
NAPCO 8000WJ).  Cells were rinsed with PBS 1X buffer, and fresh culture medium 
(DMEM with 10% FBS and 1% AB, v/v) was added to them, following 50 L per well of 
eGFP lentiviral particles.  Cells were kept in incubator for 72 h at 37C and 5% CO2, 
and after that, they were rinsed with PBS 1X buffer, and the selective medium was 
added to them (DMEM with 10% FBS and 2.5 g.mL-1 puromycin selective antibiotic, 
which concentration was previously determined by a kill curve).  Cells were cultured 
under this selective condition for 4 weeks,13 so that only eGFP positive transduced cells 
survived.  Then, eGFP positive cells were sorted using flow cytometry (FACS, HWCRC 
615 Cell Sorter) and visualized under inverted fluorescent microscope (Nikon Diaphot 
300).  Cells were cultured in DMEM with 10% FBS (v/v) and 2.5 g.mL-1 puromycin for  
2 weeks at 37C and 5% CO2 before starting the in vitro gene knockdown experiments.  
The result is shown in Figure B3, and clearly demonstrates that the A549 cell line stably 
expressing eGFP was successfully established, since 99.7% of the transduced cells 
were found to express green fluorescence. 
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Figure B3.  Histogram plots obtained from FACS of (a) A549 cells before and (b) after transduction using 
eGFP lentiviral particles.  Insets: Dot plots from FACS, phase contrast and fluorescent images of A549 
cells before and after eGFP transduction, respectively. 
 
B.4 Characterization of CSLA Co-oligomer 
Briefly, CSLA co-oligomer was synthesized by reacting low Mw CS (previously 
prepared by depolymerization of large Mw CS) with LA via ring opening 
polymerization.14  See Appendix A for details about the methodologies.  Thus, short 
lactide chains – oligo(LA) – were grafted onto CS backbone.14  Proton Nuclear Magnetic 
Resonance (1H-NMR, Varian Mercury 400) was used to obtain the chemical structure of 
the synthesized CSLA co-oligomer – density and length of the LA grafts, and Mw of the 
CSLA.  Sample was prepared by dissolving 10 mg of CSLA in 0.8 mL of DMSO-d6.  
The 1H-NMR spectrum of the CSLA co-oligomer (Figure B4) shows peaks at 4.061 and 
5.186 ppm, which are assigned to the terminal methenyl protons of the oligo(LA), and its 
repeating units in the LA chain, respectively.  The peaks at 1.3 and 1.442 ppm are 
attributed to the methyl protons of the oligo(LA) moiety located at the terminal groups 
and the chain.15  Calculations based on the 1H-NMR spectrum of CSLA (Figure B4), 
(a) (b)
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considering the integral intensities of the peaks at 4.196 ppm (from CS backbone, 
correlated to 6.4H according to Mw determination via MALDI-TOF, Bruker Ultraflex) and 
5.186, 1.442, 1.3 ppm from oligo(LA),16 indicated that there were ca. 7.4 oligo(LA) 
chains grafted on each CS backbone, and each oligo(LA) chain was composed of ca. 
5.1 LA repeat units.  Thus, the Mw of the resulting CSLA co-oligomer was estimated to 
be ca. 3,650 g.mol-1.  Mw is a physical property which can be directly measured by 
MALDI-TOF.17  However, due to sample fragmentation,18 especially because the easy 
degradation of the LA segments of the CSLA,19 1H-NMR is preferred for the 
characterization of the size and density of the LA grafts.15, 16  The grafting percentage 
(% grafting) calculated via 1H-NMR based on the total possible number of reactive 
groups (amine and hydroxyl) onto CS was 38.9%, and the one calculated via 
gravimetric method15 – equation below – was found to be 25.3%. 
 
           (
                       
          
)      
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Figure B4.  
1
H-NMR spectrum of CSLA co-oligomer. 
 
B.5 pMDI Formulation of Free siRNA-G4NH2 Dendriplexes 
Aiming to have a negative control for comparison of physical stability and aerosol 
performance, siRNA-G4NH2 dendriplexes alone were attempted to be formulated in 
pMDI.  Dendriplexes at N/P 10 were prepared in RNase-free DI-water, the aqueous 
dispersion (siRNA and PAMAM G4NH2 at the same amount as loaded into CSLA and 
mannitol microparticles) was placed into the pressure proof glass vial, which was frozen 
at -20C overnight and lyophilized.  The canister was crimp sealed with a 63 L 
metering valve, and a known volume of propellant HFA-227 was filled into it so that the 
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siRNA concentration was the same for pMDI formulations containing dendriplexes 
loaded into CSLA or mannitol microparticles. 
Then, the pMDI formulation was placed into sonication bath (30 min at 15 - 20C) 
to disperse the dendriplexes in the propellant.  The result is shown in Figure B5.  The 
dendriplexes were observed getting stuck on the wall of the glass vial, and even after 
sonication for a long time, they did not disperse in the propellant.  Thus, it was not 
possible to have pMDI formulations of free siRNA-G4NH2 dendriplexes for further 
comparison with those prepared with CSLA and mannitol particles.  Therefore, this 
result presents the difficulty of formulating siRNA-based dendriplexes alone in 
propellant HFA, and strongly suggests that an appropriate micro-carrier is needed for 
the job – such as CSLA and mannitol microparticles proposed in the Chapter 5. 
 
 
 
Figure B5.  Free siRNA-G4NH2 dendriplexes at N/P 10 did not disperse in propellant HFA-227 and were 
observed to be stuck (yellow arrows) on the wall of the canister. 
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ABSTRACT 
POLYMERIC NANOCARRIERS AND THEIR ORAL INHALATION FORMULATIONS 
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Gene therapy has attracted attention in the fields of medicine, pharmacy, and 
bionanotechnology due to the potential for treating a large number of medically relevant 
diseases.  Oral inhalation (OI) is a promising route for the administration of therapeutics, 
including small molecules and biomacromolecules, such as nucleotides, peptides, and 
proteins, to (locally) and through (systemically) the lungs.  The use of OI is especially 
attractive for the delivery of nucleic acids as it provides a direct and non-invasive route 
for targeting the lungs.  Pressurized metered-dose inhalers (pMDIs), are the most 
commonly used OI in treatment of lung diseases and are thus promising OI devices to 
be used for the delivery of nucleic acids to the lungs.  However, progress in the 
development of pMDI formulations for the delivery of DNA and siRNA to the lungs has 
been hampered largely by the lack of efficient nanocarriers capable of overcoming the 
lung structure, the extra and intracellular barriers present in the lung tissue, and 
formulation challenges – aerodynamic particle size, surface chemistry of the particles, 
and solvation forces in propellant/co-solvent mixture.  In light of the challenges and 
opportunities described above, we propose in this work: (i) a quantitatively and 
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systematically evaluation of the enhancement in solvation capacity of propellant 
hydrofluoroalkane (HFA) upon addition of co-solvent ethanol; (ii) the development of 
efficient HFA-based pMDIs to deliver nucleic acids to the lungs; (iii) the design of 
siRNA-poly(amidoamine) (PAMAM) dendrimer conjugates.  We demonstrate that both 
DNA and siRNA can be efficiently formulated in HFA-based pMDIs upon the 
development of novel particle engineering strategies to overcome issues associated 
with their size and physical stability in the propellant.  We also demonstrate that the 
polymer-based nanocarriers are capable of enhancing gene expression (DNA) and 
knockdown (siRNA) in alveolar lung epithelial cells, and they do not lose their biological 
activity when formulated in the propellant HFA.  In conclusion, the results reported in 
this dissertation contribute significantly in the development of DNA- and siRNA-delivery 
systems and in their formulation in portable OI devices, with great potential to efficiently 
deliver nucleic acids to the lungs to treat medically relevant pulmonary disorders, such 
as COPD, asthma, virus infections, cystic fibrosis, and lung cancer. 
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